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ABSTRACT  
   
Globally, addiction to stimulants such as methamphetamine (METH) remains a 
significant public health problem. Despite decades of research, no approved anti-relapse 
medications for METH or any illicit stimulant exist, and current treatment approaches 
suffer from high relapse rates. Recently, synthetic cathinones have also emerged as 
popular abused stimulants, leading to numerous incidences of toxicity and death.  
However, contrary to traditional illicit stimulants, very little is known about their 
addiction potential.  Given the high relapse rates and lack of approved medications for 
METH addiction, chapters 2 and 3 of this dissertation assessed three different glutamate 
receptor ligands as potential anti-relapse medications following METH intravenous self-
administration (IVSA) in rats. In chapters 4 through 7, using both IVSA and intracranial 
self-stimulation (ICSS) procedures, experiments assessed abuse liability of the popular 
synthetic cathinones 3,4-Methylenedioxypyrovalerone (MDPV) , methylone, α-
pyrrolidinovalerophenone (α-PVP) and 4-methylethylcathinone (4-MEC). Results from 
these seminal studies suggest that these drugs possess similar abuse potential to 
traditional illicit stimulants such as METH, cocaine, and 3,4-
methylenedioxymethamphetamine (MDMA). Finally, studies outlined in chapter 8 
assessed the potential neurotoxic or adverse cognitive effects of METH and MDPV 
following IVSA procedures for the purpose of identifying potential novel 
pharmacotherapeutic targets. However, results of these final studies did not reveal 
neurotoxic or adverse cognitive effects when using similar IVSA procedural parameters 
that were sufficient for establishing addiction potential, suggesting that these parameters 
do not allow for sufficient drug intake to produce similar neurotoxicity or cognitive 
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deficits reported in humans. Thus, these models may be inadequate for fully modeling the 
adverse neural and psychological consequences of stimulant addiction. Together, these 
studies support the notion for continued research into the abuse liability and toxicity of 
METH and synthetic cathinones and suggest that refinements to traditional IVSA models 
are needed for both more effective assessment of potential cognitive and neural deficits 
induced by these drugs and screening of potentially clinically efficacious 
pharmacotherapeutics.    
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CHAPTER 1 
GENERAL INTRODUCTION 
The Costs of Drug Addiction 
Drug addiction is a chronically relapsing disorder principally characterized by the 
uncontrollable drive to obtain and failure to limit the use of drugs despite adverse, often 
severe, consequences. In addition, there is a concomitant loss of interest in engagement in 
other activities such as work, school, dependent care, and social gatherings, to name a 
few (Kalivas, Volkow, & Seamans, 2005; Koob, Sanna, & Bloom, 1998). Addiction casts 
a wide net of consequences, adversely affecting not just the health and well-being of 
individual users, but devastating families, straining healthcare resources, significantly 
damaging environments, and imparting a significant economic and medical burden to 
society as a whole (Ericson, 2001). Globally, the use of addictive drugs is responsible for 
nearly 10% of the total disease burden (Harwood & Bouchery, 2004). When factoring in 
the influence of treating drug-related health problems, crime, loss of productivity due to 
disability and withdrawal from the workforce, and premature death, the economic burden 
of drug addiction to the US is estimated to exceed half a trillion dollars annually 
(Substance Abuse and Mental Health Services Administration, 2011). In 2011, 21.6 
million persons in the U.S. aged 12 or older met criteria for substance dependence or 
abuse. However, only 2.3 million received treatment, with the other 19.3 million 
declining help largely because of the costs and inconvenience of treatment (Substance 
Abuse and Mental Health Services Administration, 2011). Currently, the prevailing 
treatment approaches consist of traditional cognitive-behavioral therapies, self-help and 
social support programs, adjunctive treatment with approved medications (when 
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applicable), and/or some combination thereof. However, only a small number of 
approved addiction pharmacotherapeutics exist, and only for nicotine, opioid, and alcohol 
addiction (Sofuoglu, DeVito, Waters, & Carroll, 2013). For addiction to 
psychostimulants such as cocaine, methamphetamine, and newer “legal high” designer 
stimulants, there are currently no approved medications (Sofuoglu, 2010). To make 
matters worse, even with the best treatment interventions, most individuals (up to 90% 
for some drugs) will relapse within 12 months of discontinuing drug use (Brandon, 
Vidrine, & Litvin, 2007; Hendershot, Witkiewitz, George, & Marlatt, 2011). Given these 
severe consequences to users, families and society, the large number of individuals 
declining much needed treatment, and high rates of relapse even with treatment, there is a 
significant demand for more effective treatment strategies designed to limit abuse and 
decrease the probability of relapse. Thus, there is a tremendous need for research aimed 
at finding new pharmacotherapeutic targets, developing more effective anti-relapse 
medications, employing more effective behavioral treatment strategies, or some 
combination of these approaches.  
Methamphetamine 
Methamphetamine (METH) is a highly addictive psychostimulant with potent 
effects on the central nervous system (Shrem & Halkitis, 2008) that can lead to severe 
adverse neurological and physical effects (Darke, Kaye, McKetin, & Duflou, 2008; Scott 
et al., 2007). According to the most recent World Drug Report published by the United 
Nations Office on Drugs and Crime, the use of amphetamine-type stimulants (ATS), 
which includes amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and 
METH, has reached epidemic levels globally and continues to increase in most regions of 
  3 
the world (United Nations, 2013). METH accounts for both the majority (71%) of all 
ATS use, and is primarily responsible for the continued global increase in use, since 
general amphetamine use has held steady and the global use of MDMA (i.e. “ecstasy”) is 
in decline (United Nations, 2013). Furthermore, global increases are primarily driven by 
crystalline METH (i.e. crystal METH).  In the United States, this increased use of METH 
has translated into an increase in individuals seeking treatment for primary METH 
addiction (Maxwell & Brecht, 2011).  However, even with treatment, approximately 70-
90% of METH users will relapse within three years (McKetin et al., 2012). In addition to 
the adverse physical and psychological effects on individual users, METH use also 
imparts a significant economic burden to societies.  When factoring in the costs of 
treatments, excessive health care utilization costs, lost productivity, crime, child 
endangerment, and consequences of METH manufacture, the annual cost to the U.S. is 
estimated to be around 23.5 billion dollars (Dobkin & Nicosia, 2009; Nicosia, 2009).  
Given the severe consequences of METH use to both society and individual users, the 
continued increase in global use, the high rates of relapse even with treatment, and lack 
of any approved anti-relapse medications, there is a tremendous need for basic research 
focused on developing more effective pharmacotherapeutics for the treatment of METH 
(and other psychostimulant) addiction as well as delineating the neurotoxic and adverse 
cognitive effects of meth use in order to find new therapeutic targets. 
Synthetic Cathinones 
In recent years, there has been an unprecedented rise in the availability of new 
psychoactive substances (NPS) on international drug markets. NPS is a catch-all term 
that describes new substances of abuse that are unregulated yet mimic the effects of other 
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controlled substances (United Nations, 2013). In 2013, 251 NPS were identified on 
international drug markets, exceeding the number (234) of substances under international 
control for the first time in history (United Nations, 2013). While NPS encompass a 
variety of drug classes, novel designer stimulants known as synthetic cathinones 
(comprising ~23% of all NPS) have emerged as arguably the most problematic in terms 
of adverse effects to users as evidenced by a now large and growing body of case reports 
highlighting bizarre and violent behaviors, toxicity, and death (Prosser & Nelson, 2012; 
Spiller, Ryan, Weston, & Jansen, 2011).  
The use of synthetic cathinones has escalated dramatically in the western world 
since first appearing in Europe in the mid-2000’s, and subsequently in the United States 
in 2009 (Rosenbaum, Carreiro, & Babu, 2012; Spiller et al., 2011);   Concomitant with 
this escalated use has been an unprecedented increase in the variety of these substances 
now available in drug markets (Rosenbaum et al., 2012). Experts predict that many more 
designer stimulants (i.e. multiple generations) are likely to emerge as replacements once 
popular (i.e. older generation) analogues are banned by regulatory agencies, a pattern that 
has already been reported (Baumann, Partilla, & Lehner, 2013; Brandt, Sumnall, 
Measham, & Cole, 2010; D. E. A. United States Department of Justice, 2013b; Baumann 
et al., 2013; Brandt et al., 2010; D. E. A. United States Department of Justice, 2013b). Of 
the many synthetic cathinones reported in drug markets, methylenedioxypyrovalerone 
(MDPV), mephedrone, and methylone, initially comprised the majority (98%) of all 
synthetic cathinones encountered by law enforcement agencies (D. E. A. United States 
Department of Justice, 2011c).  Use of these drugs has led to numerous published reports 
of bizarre and violent behavior, multi-organ toxicity, and death (Rosenbaum et al., 2012; 
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Spiller et al., 2011), forcing regulatory agencies such as the United States Drug 
Enforcement Administration (DEA) to institute emergency bans citing serious hazards to 
public health and safety (D. E. A. United States Department of Justice, 2011b). Despite 
the increasing popularity of these drugs, very little scientific data exists regarding their 
abuse liability and toxicity from long-term use, and even scarcer information exists for 
clinicians regarding effective treatments for synthetic cathinone abuse. Given these facts, 
the scientific study of designer stimulant abuse/addiction liability is of the utmost 
importance for (a) providing targets for pharmaceutical development (b) evidence-based 
information to healthcare experts charged with treating abusers of these drugs, (c) 
guiding government agencies responsible for regulating these substances, and (d) 
informing the public about the potential risks of abuse of and dependence on synthetic 
cathinones.  
Given the significant negative impacts that METH and synthetic cathinone use 
have on both individual users and society, incomplete characterization of their neurotoxic 
and adverse cognitive effects, and the general lack of available treatments, the studies in 
this dissertation have collectively focused on: (1) the assessment of novel glutamatergic 
agents as potential anti-relapse medications for METH addiction; (2) assessing the abuse 
liability of newer synthetic cathinones, and (3) determining the potential neurotoxic and 
adverse cognitive effects following chronic, voluntary intravenous self-administration of 
these psychostimulants. 
In chapter 2, we present experimental data revealing that the metabotropic 
glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) fenobam decreases 
relapse-like behavior to both METH-prime and METH-associated cue-prime 
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reinstatement procedures. Prior to starting these experiment, research had shown that 
similar mGlur5 NAMs were effective at decreasing METH-seeking across various animal 
models of addiction. In contrast to the other mGluR5 NAMs, fenobam had several 
advantageous, the most important of which was a favorable safety profile in humans. 
However, as shown in our results, fenobam displayed non-specific effects on both 
sucrose- and food-seeking behavior during cue-primed reinstatement procedures, 
prompting us to discontinue studies assessing fenobam as a potential 
pharmacotherapeutic treatment.  
In chapter 3, we review the published literature detailing efficacy of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor positive allosteric 
modulators (PAMs) as extinction / cue-exposure therapy adjunctive 
pharmacotherapeutics, a class of drugs which had shown positive effects across a wide 
range of neuropsychiatric disorders. Next, we present data showing that the two novel 
AMPA PAMs CX1837 and CX1739 both facilitate extinction following METH self-
administration procedures, but ultimately failed to decrease relapse-like behavior in 
METH cue-primed reinstatement procedures. As in experiment 2, as a result of 
disappointing effects in reinstatement procedures, subsequent extinction studies using 
AMPA PAMs were discontinued in our laboratory.   
In chapters 4 and 5, we present the first published studies detailing reinforcing 
and rewarding effects of MDPV and methylone, two of the most popular synthetic 
cathinones to emerge as “legal high” psychostimulants on international drug markets. 
Specifically, in chapter 4, potent MDPV reinforcing and rewarding effects in rats are 
shown as robust intravenous self-administration (IVSA) and decreases in intracranial 
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self-stimulation thresholds, suggesting a high addiction potential similar to illicit 
stimulants such as METH. In chapter 5, using almost identical procedures, we also reveal 
reinforcing and rewarding effects of methylone. However, in contrast to MDPV, lack of 
robust escalation in long access (LgA) IVSA and lack of significant ICSS threshold 
decreases suggest that methylone does not possess the compulsive abuse potential of 
MDPV or other illicit psychostimulants (METH or cocaine) with known high abuse 
liability.  
In chapter 6, we shown that α-pyrrolidinovalerophenone (α-PVP) and 4-methyl-n-
ethylcathinone (4-MEC), two synthetic cathinones that largely replaced MDPV and 
methylone on international markets following government bans, also possess potent 
rewarding effects as revealed by significant threshold decreases in ICSS procedures 
nearly identical to those used in chapters 4 and 5. Results from these experiments suggest 
that newer second-generation synthetic cathinone analogues likely have similar addiction 
potential as their first generation counterparts.  
In chapter 7, we conducted several MDPV behavioral sensitization and cross-
sensitization experiments (MDPV + METH) motivated by evidence suggesting that (1) 
MDPV abuse is still prevalent despite governmental bans, (2) that MDPV users are 
typically previous users of illicit amphetamines, and (3) that previous amphetamine use 
appears to increase the potential adverse effects of MDPV suggesting similar 
neurochemical effects. Results from these experiments revealed that behavioral 
responsivity, as shown by increased locomotor behavior, is increased in rats following 
repeated exposure to MDPV when compared to rats repeatedly treated with saline 
vehicle. Interestingly, repeated exposure to METH did not increase behavioral 
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responsivity to a subsequent low-dose MDPV challenge, suggesting that sensitization 
between MDPV and METH is not entirely bi-directional. Together, results from chapter 7 
corroborate human studies suggesting that exposure to both MDPV and METH may 
increase the potential for addiction or adverse neuropsychopathology following abuse of 
these drugs.  
In chapter 8, as a result of our robust MDPV IVSA results in chapter 4 and cross-
sensitization results in chapter 7, we conducted additional MDPV IVSA experiments 
using similar temporal parameters (2 hr short access (ShA) + 6 hr long access (LgA)) in 
chapter 4 to assess whether voluntary administration would lead to neurotoxic or adverse 
cognitive effects seen in other studies with illicit psychostimulants such as METH and 
cocaine. While these IVSA experimental procedures in chapter 4 revealed potent 
reinforcing effects suggestive of high addiction potential in humans, they did no produce 
evidence of neurotoxicity or adverse cognitive effects. When the IVSA experiments from 
chapter 8 and those published by others are interpreted together, psychostimulant IVSA-
induced neurotoxic and adverse cognitive effects appear only in IVSA procedures 
employing both longer periods of voluntary exposure and protracted withdrawal. Taken 
together, results from chapter 4 and 8 together suggest that while traditional IVSA 
procedures are sufficient for establishing abuse liability, they do not appear sufficient for 
producing a significant level of exposure to produce adverse effects. Thus, as the IVSA 
procedures employed in this dissertation do not appear to fully capitulate adverse effects 
reported in human abusers, it is recommended that future research employ IVSA 
experiments with sufficiently long exposure periods combined with protracted 
withdrawal.  
  9 
CHAPTER 2 
ATTENUATION OF REINSTATEMENT OF METHAMPHETAMINE-, SUCROSE-, 
AND FOOD-SEEKING BEHAVIOR IN RATS BY FENOBAM, A METABOTROPIC 
GLUTAMATE RECEPTOR 5 NEGATIVE ALLOSTERIC MODULATOR 
Published in Psychopharmacology, 2012 
Methamphetamine (METH) is a highly addictive psychostimulant with potent 
effects on the central nervous system (Shrem and Halkitis 2008). METH use is highly 
correlated with various medical and neuropsychiatric disorders and has numerous adverse 
neurological and other health effects (Darke et al. 2008; Rusyniak 2011; Scott et al. 
2007).  In many regions of the U.S., METH use has recently reached epidemic levels, and 
the most recent epidemiological data suggest that METH use is again on the rise despite 
decreasing trends in use in the mid- to late-2000’s (Anglin et al. 2000; Maxwell and 
Brecht 2011; Maxwell and Rutkowski 2008).  
METH’s reinforcing effects are generally attributed to its actions as a potent 
releaser of monoamines (Cruickshank and Dyer 2009; Kish 2008; Sulzer 2011). These 
effects are caused by a displacement of monoamines from vesicular stores by METH 
acting as a substrate for vesicular monoamine transporters (VMAT). This results in 
increased cytoplasmic monoamine levels and a subsequent reversal of plasma membrane 
monoamine transporter direction. Attempts at developing pharmacological treatments for 
METH addiction have historically focused on compounds which modulate the actions of 
METH on VMAT, plasma membrane monoaminergic transporters, or GABAergic 
functioning within mesolimbic brain circuits (Ciccarone 2011; Karila et al. 2010; Vocci 
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and Appel 2007).  However, as of yet there are currently no medications approved by the 
U.S. Food and Drug Administration for METH addiction.  
Various studies have shown that METH increases extracellular levels of 
glutamate in forebrain regions such as the striatum, hippocampus, and prefrontal cortex 
(Mark et al. 2007; Rocher and Gardier 2001; Shoblock et al. 2003; Stephans and 
Yamamoto 1995). However, in other regions of the brain such as the nucleus accumbens 
and ventral midbrain, it has been shown that METH can increase, have no effect, or even 
decrease extracellular levels of glutamate (Ito et al. 2006; Shoblock et al. 2003; Zhang et 
al. 2001). Thus, the effects of METH on extracellular glutamate appear to be complex, 
and likely dependent on brain region, dose, and frequency of administration. While most 
research on METH–induced changes in extracellular glutamate has focused on its role in 
excitotoxicity, more recent research has revealed a primary role for glutamatergic 
neurotransmission in mediating the rewarding and reinforcing effects of METH (Gass 
and Olive 2008). Thus, glutamatergic transmission may be a novel therapeutic target for 
the treatment of addiction to METH (Kalivas and Volkow 2011; Olive 2009; Olive et al. 
2012).  
Receptors for glutamate are broadly classified as ionotropic (iGluR) or 
metabotropic (mGluR) receptors. There are 8 mGluR receptor subtypes (mGluR1 – 
mGluR8) which are further subclassified into three distinct families (Group I, II, or III) 
based upon their pharmacology and signaling transduction mechanisms (Conn and Pin 
1997; Pin and Duvoisin 1995). In a seminal study by Chiamulera and colleagues, it was 
shown that mice lacking the mGluR5 gene did not acquire cocaine self-administration 
and were unresponsive to its locomotor stimulant effects (Chiamulera et al. 2001). Since 
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this study, numerous investigators have shown that mGluR5 antagonists reduce 
intravenous drug self-administration and reinstatement of drug-seeking in animal studies, 
as reviewed elsewhere (Duncan and Lawrence 2012; Kenny and Markou 2004; Olive 
2009). We have previously demonstrated that the selective mGluR5 NAM 3-((2-methyl-
1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) attenuates intravenous METH self-
administration while exerting no effects on food self-administration (Gass et al. 2009; 
Osborne and Olive 2008). In addition, MTEP also attenuated reinstatement of METH-
seeking behavior induced by METH-associated cues or acute METH exposure, but did 
not alter cue-induced reinstatement of food-seeking.  Taken together, these studies 
indicate that mGluR5 receptors play a key role in METH reinforcement and METH-
seeking behaviors, and justify further investigation into mGluR5 antagonists as potential 
anti-addiction therapeutics. 
 Fenobam was first developed in the 1970’s as a non-benzodiazepine anxiolytic for 
human use despite unknown pharmacological mechanisms of action (Itil et al. 1978; 
Pecknold et al. 1980; Pecknold et al. 1982). In 2005, it was revealed that fenobam is a 
selective mGluR5 NAM (Porter et al. 2005), renewing interest in fenobam as a potential 
therapeutic for the treatment of various dysfunction of the nervous system. Fenobam 
possesses antidepressant, analgesic, and anxiolytic effects in experimental animals (Jacob 
et al. 2009; Montana et al. 2009), symptoms that often accompany withdrawal from 
chronic METH use (Scott et al. 2007). Fenobam and several other mGluR5 NAMs have 
recently been tested in clinical trials for a number of medical disorders including Fragile 
X syndrome and L-dopa induced dyskinesias (Berry-Kravis et al. 2009; Hagerman et al. 
2008; Jaeschke et al. 2008). While these clinical trials showed that fenobam was 
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generally well tolerated with only moderate side effects, unfortunately, clinical testing of 
fenobam was recently discontinued due to somewhat limited efficacy and large 
variability in plasma levels of the drug following oral administration. Nevertheless, since 
there is a great need to develop medications for the treatment of METH addiction, 
particularly with compounds that demonstrate safety and tolerability in human subjects, 
we sought to determine the effects of fenobam on the reinstatement of METH-seeking 
behavior. To examine the potential generalization of effects on the reinstatement of 
seeking of natural reinforcers, we assessed the effects of fenobam on the reinstatement of 
sucrose- and food-seeking behavior. 
 
Method 
Subjects 
 Fifty-four male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA), 
weighing approximately 250-275 g, were individually housed upon arrival. Animals were 
maintained on a 12 hr light-dark cycle (lights off at 0700 hr) in a temperature and 
humidity controlled rodent colony. All experimentation was conducted during the dark 
phase of the light-dark cycle, with the exception of a 16 hr overnight operant training 
session for METH and sucrose self-administration groups which commenced near the 
end of the dark phase (at approximately 1600 hr) and continued through the light phase 
into the following morning (ending at approximately 0800 hr). Rats undergoing METH 
and sucrose self-administration procedures were given ad libitum access to food and 
water during all phases of the experiment except during drug self-administration and for 
12 hr prior to the initial operant training session. Rats undergoing food self-
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administration procedures were maintained at approximately 85% of their free-feeding 
bodyweight and received food in their home cage for one hour each day approximately 
two hours after operant testing. Rats undergoing locomotor assessment procedures 
received ad libitum access to food and water during all experimental phases. Two rats 
were eliminated from the study due to catheter patency failure. All experimental 
procedures were conducted with the approval of an Institutional Animal Care and Use 
Committee at Arizona State University and in accordance with the Principles of 
Laboratory Animal Care and the 8th Edition of the Guide for the Care and the Use of 
Laboratory Animals (National Research Council, 2011). 
Surgical Procedures 
 Prior to arrival, rats undergoing METH self-administration procedures were 
prepared with intravenous catheters into the jugular vein by Harlan Laboratories Surgical 
Services. Upon arrival, rats were allowed one day of acclimation before vascular port 
implantation.  Rats were anesthetized and implanted with vascular access ports (Model 
313000BM15, Plastics One, Roanoke, VA, USA) as described previously (Gass et al. 
2009). Following surgical procedures, rats were given 5 days of post-operative care 
during which they received daily intravenous infusions of 70 U/ml heparin (0.2 ml 
volume) to maintain catheter patency and 100 mg/ml cefazolin (0.1 ml volume) to protect 
against infection. Rats also received daily subcutaneous injections of 2.5 mg/ml of 
meloxicam (0.15 ml volume) to relieve surgery-related discomfort. During post-operative 
care, observation of weight loss on any day resulted in a 5 ml subcutaneous injection of 
saline to combat dehydration. The surgery site was also treated with topical lidocaine and 
triple antibiotic ointments to facilitate healing of the wound. Rats undergoing locomotor, 
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sucrose reinstatement, or food reinstatement procedures did not undergo catheter 
implantation procedures. 
Methamphetamine, Sucrose, and Food Self-Administration 
Self-administration, extinction, and reinstatement tests were conducted in operant 
self-administration chambers (ENV-008, Med Associates, St. Albans, VT, USA) as 
described previously (Gass et al. 2009). To initiate operant responding for METH and 
sucrose self-administration, rats were underwent overnight sucrose pellet training 
according to a fixed-ratio 1 (FR1) schedule of reinforcement as described elsewhere 
(Gass et al. 2009). Approximately 24 hr following the initial overnight training session, 2 
hr daily self-administration sessions were initiated, whereby presses on the active lever 
resulted in delivery of METH (0.05 mg/kg/infusion, delivered in a volume of 0.06 ml 
over a 2 sec period) on a FR1 schedule of reinforcement for METH trained animals. Each 
active lever press was accompanied by a concurrent illumination of a stimulus light 
located above the active lever, and presentation of an auditory stimulus (~65 dB, 2900 
Hz) for 2 sec. Animals trained to self-administer sucrose underwent the same procedures, 
except each active lever press resulted in delivery of a single 45-mg sucrose pellet 
(TestDiet, Richmond, IN, USA) according to a FR1 schedule of reinforcement. For food 
self-administration procedures, rats did not undergo a16 hr overnight training session and 
began 2 hr self-administration through spontaneous acquisition procedures and active 
lever presses resulted in delivery of a single 45-mg food pellet (Bio-Serv, Frenchtown, 
NJ) according to a FR1 schedule of reinforcement. Self-administration sessions were 
conducted 7 consecutive days per week. For METH self-administration procedures, each 
session was preceded by intravenous infusion of 0.1 ml of 70 U/ml heparin, and followed 
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by infusion of 0.1 ml of 70 U/ml of heparin and 0.1 ml of 100 mg/ml cefazolin. 
Stabilization of self-administration was considered to have been reached when the 
average number of active lever presses during each 2 hr session differed by less than 15% 
for 2 consecutive days, after a minimum of 8 days of self-administration. Self-
administration (SA) data reported represent the average number of active lever presses 
during the final two self-administration sessions prior to extinction training. 
Extinction Procedures 
Extinction sessions were 2 hr in length and commenced following stabilization of 
self-administration. During extinction training, responding on the previously active lever 
no longer produced any programmed consequences, as described previously (Gass et al. 
2009).  Extinction sessions were conducted each day until the number of active lever 
presses per session was less than 25% of the average number of active lever presses 
during the final two days of self-administration responding, and when this level of 
pressing was observed for 2 days.  
Reinstatement Procedures 
Reinstatement test sessions were 2 hr in length and commenced on the day 
immediately following the last extinction session. For all groups of rats (METH-prime, 
METH-cue, sucrose-cue, and food-cue), fenobam or vehicle was injected i.p. 20 min 
prior to the reinstatement sessions.  For the METH-prime group, a single METH injection 
(0.5 mg/kg i.p.) was given 30 minutes prior to reinstatement testing and ten minutes prior 
to fenobam administration.  Following each reinstatement test session, animals were 
placed into additional 2 hr extinction sessions starting on the following day.  These 
additional extinction sessions were carried out until extinction criteria were again met at 
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which point another reinstatement test was conducted on the following day.  Each group 
of rats were subjected to either 3 or 4 reinstatement tests, and each rat received 3 or 4 of 
the different treatments (vehicle or 3 doses of fenobam) in a randomized counterbalanced 
design. After the final reinstatement test, the animals were euthanized by anesthesia with 
isoflurane followed by decapitation. 
Locomotor Procedures 
Locomotor activity was measured as rotational behavior and recorded by Rotorat 
version 1.2 software (Med Associates). Rats were placed into stainless steel bowls (40.6 
cm diameter x 25.4 cm high; model ENV-500, Med Associates) surrounded by a clear 
Plexiglas wall to prevent rats from escaping the apparatus. Rats were connected to spring 
tether secured to the top of the apparatus by a sensitive rotational sensor which recorded 
activity.  A zip-tie collar was placed around the neck of the rat and connected to the 
spring tether via a stainless steel alligator clip.  Measurements taken were full (360° 
turns) and quarter (90°) turns, in both clockwise and counter-clockwise directions. 
Prior to locomotor assessment rats were placed into 90 min daily sessions for two 
days for acclimation to the locomotor apparatus. Following acclimation procedures, 6 rats 
were randomly assigned to receive either fenobam (10 mg/kg, i.p.) or vehicle for the first 
locomotor session.  The next day, rats that previously received fenobam were 
administered, and vice versa.  Locomotor sessions were 90 min in length, and fenobam or 
vehicle injections were given 20 minutes prior to placing rats in the locomotor apparatus.  
Drugs 
 Fenobam (1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea) was 
custom synthesized by Chemir Analytical Services (Maryland Heights, MO, USA). 
  17 
Fenobam was suspended in a vehicle consisting of 0.3% v/v Tween 80 via sonication. For 
reinstatement procedures, fenobam was injected by the intraperitoneal (i.p.) route at doses 
of 5, 10, or 15 mg/kg in an injection volume of 1 ml/kg. These doses were chosen based 
on previous reports that they do not produce significant signs of sedation or anhedonia 
(Cleva et al. 2012; Porter et al. 2005). Fenobam (10 mg/kg) was also injected via the i.p. 
route prior to locomotor assessment. (+)Methamphetamine hydrochloride was obtained 
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in a sterile saline for 
intravenous infusion. For METH-primed reinstatement procedures, METH was prepared 
at a concentration of 0.5 mg/ml in saline and administered i.p. in a volume of 1 ml/kg.  
Statistical Analyses 
For all groups (METH-prime, METH-cue, sucrose-cue, and food-cue), 
verification that extinction training produced significant decreases in the number of 
active lever presses was perfomed by Student’s t-tests. The effects of fenobam on 
reinstatement behavior was analyzed by a one-way repeated measures ANOVA, with the 
number of active or inactive lever presses with dose/experimental phase (extinction, 
vehicle, 5, 10, and 15 mg/kg) serving as the repeated measures. Holm-Sidak post hoc 
tests were used to determine effects of fenobam dose. Furthermore, one-way repeated 
measures ANOVAs were also conducted on the number of inactive lever presses as an 
indicator of possible motoric side effects.  For locomotor assessment, a repeated 
measures ANOVA for full and quarter turns with treatment (fenobam 10 mg/kg vs. 
vehicle) was conducted. When tests of data normality failed, a Friedman ANOVA on 
ranks was utilized. Level of statistical significance was set to p < 0.05 for all tests.  
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Results 
 For all groups, extinction training produced a significant reduction in the number 
of active lever presses during each session (all p’s <0.05). During METH-primed 
reinstatement (n = 12), a significant main effect of fenobam dose/experimental phase on 
active lever presses was observed (F[4,32]=4.341, p<0.01; see Fig. 1a).  Post-hoc 
comparisons revealed a reinstatement following the METH-prime injection as evidenced 
by a significant increase in the number of active lever presses following vehicle 
administration vs. the average of the last 2 days of extinction (p<0.05).  Fenobam at both 
the 10 and 15 mg/kg doses significantly attenuated reinstatement as compared to 
following vehicle treatment (p<0.05 and p<0.01, respectively).    Analysis of inactive 
lever presses did not reveal any significant main effects of dose/experimental phase 
(p>0.05; Table 1).    
 During cue-induced reinstatement of METH-seeking (n = 10), a significant main 
effect of fenobam dose/experimental phase was observed for active lever presses 
(F[4,36]=6.44, p<0.001; see Fig. 1b).  Post-hoc tests revealed a significant increase in 
active lever presses following vehicle administration as compared to extinction 
responding, indicating that METH-associated cues induced a reinstatement of METH-
seeking behavior. Furthermore, fenobam doses of 10 and 15 mg/kg significantly 
attenuated cue-induced reinstatement (p<0.01 and p<0.001, respectively). For inactive 
lever pressing, a repeated measures one-way ANOVA failed on tests of normality, and a 
Friedman’s repeated measures ANOVA on ranks revealed a significant main effect of 
fenobam dose/experimental phase on inactive lever presses (χ2=26.064, p<0.001). 
However, Dunn’s method of multiple comparisons did not reveal any significant 
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differences in the number of inactive lever presses during extinction and any of the 
reinstatement tests (p>0.05; Table 1).  
During cue-induced reinstatement of sucrose-seeking (n=12), a significant main 
effect of fenobam dose/experimental phase was observed for active lever presses 
(F[4,59]=6.653, p=0.001; see Fig. 2a).  Post-hoc tests revealed a significant increase in 
the number of active lever presses during reinstatement tests following vehicle treatment 
as compared to extinction values (p=0.005), demonstrating reinstatement of sucrose-
seeking in response to sucrose-associated cues.  Post-hoc tests revealed significant 
decreases in active lever presses following the 5, 10 and 15 mg/kg doses of fenobam as 
compared with vehicle (p<0.01).  A significant main effect of fenobam dose/experimental 
phase was also found on inactive lever presses (F[4,59]=4.369, p=0.005).  However, 
post-hoc tests revealed no significant differences in the number of inactive lever presses 
between extinction and following vehicle treatment, or between vehicle and all doses of 
fenobam tested (p>0.05; Table 1).   
 During cue-induced reinstatement of food-seeking (n=12), a significant main 
effect of fenobam dose/experimental phase was observed for active lever presses 
(F[4,59]=8.589, p=0.001; see Fig. 2b).  Post-hoc tests revealed a significant increase in 
the number of active lever presses during reinstatement tests following vehicle treatment 
as compared to extinction values (p=0.001), demonstrating reinstatement of food-seeking 
in response to food-associated cues.  Post-hoc tests revealed significant decreases in 
active lever presses following the 5, 10 and 15 mg/kg doses of fenobam as compared with 
vehicle (p<0.001).  For inactive lever presses, no significant effects were observed 
(p>0.05; Table 1).   
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 For locomotor behavior, repeated measures ANOVA did not reveal a significant 
main effect fenobam dose for full or quarter turns (p’s >0.05, Fig. 3).  
 
Discussion 
 The current study demonstrated that fenobam, an mGluR5 NAM that has been 
tested in human subjects for treatment of other medical conditions, effectively reduced 
METH-seeking behavior elicited by either METH-paired cues or a METH priming 
injection.  Specifically, fenobam significantly attenuated reinstatement of METH-seeking 
behavior elicited by both METH-associated cues and by a METH priming injection at 
doses of 10 and 15 mg/kg.  However, an attenuation of cue-induced reinstatement of 
sucrose- and food-seeking behavior was also observed, and at each dose tested (5, 10, and 
15 mg/kg).  These results indicate that fenobam, like previously tested mGluR5 NAMs 
such as 3-((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP), attenuates METH-seeking in 
the reinstatement paradigm (Gass et al. 2009).  However, the reduction in cue-induced 
reinstatement of both sucrose- and food-seeking indicates that fenobam also affects 
seeking of natural reinforcers. 
The demonstration that fenobam attenuates METH-seeking under reinstatement 
conditions extends previous research showing that either genetic or pharmacological 
blockade of mGluR5 receptors leads to reductions in drug reward, reinforcement, and 
relapse-like behavior (Duncan and Lawrence 2012; Olive 2009). While the exact 
mechanisms by which fenobam and other mGluR5 NAMs reduce drug-seeking or 
relapse-like behavior are not completely understood, a likely mechanism is by decreasing 
glutamatergic transmission in the nucleus accumbens (NAcc) and/or ventral tegmental 
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area (VTA). Various studies have revealed that glutamatergic transmision in the NAcc 
mediates reinstatement of drug-seeking for numerous addictive drugs, including 
amphetamines (Cornish and Kalivas 2000; Di Ciano et al. 2001; Gass and Olive 2008; 
Knackstedt and Kalivas 2009; Lalumiere and Kalivas 2008). Furthermore, while drug-, 
cue-, and stress-primed reinstatement of drug-seeking initially engage distinct neural 
circuits, these circuits converge onto the regions of the prefrontal cortex which in turn 
send glutamatergic projections to the NAcc. This prefrontal-NAcc connection has been 
hypothesized as the final common pathway mediating reinstatement of drug-seeking 
(Kalivas and McFarland 2003; Kalivas et al. 2005).  
With regards to mGluR5 receptors, these receptor proteins are widely distributed 
in many regions of the brain, with the NAcc and VTA showing moderate to high levels of 
mGluR5 receptor expression (Mitrano and Smith 2007; Romano et al. 1995; Shigemoto 
et al. 1993). Bilateral microinfusions of the mGluR5 NAM 2-methyl-6-
(phenylethynyl)pyridine (MPEP) or MTEP into the NAcc attenuates the reinstatement of 
cocaine-seeking elicited by drug priming and drug-associated cues (Backstrom and 
Hyytia 2007; Kumaresan et al. 2009) as well as cue-elicited alcohol-seeking behavior 
(Sinclair et al. 2012). Thus, it is likely that systemic administration of fenobam exerts its 
effects on the reinstatement of METH-seeking by modulating the glutamatergic 
transmission within these regions. Further studies are needed to confirm this, as well as 
the role of these regions in mediating fenobam-induced suppression of cue-induced 
reinstatement of sucrose- and food-seeking behavior.  
Another possible mechanism through which fenobam may attenuate METH-, 
sucrose-, and food-seeking is via effects on brain reward function. Fenobam, along with 
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the prototypic mGluR5 NAMs MPEP and MTEP, have been shown to decrease brain 
reward functioning as measured by intracranial self-stimulation (ICSS) (Cleva et al. 
2012; Harrison et al. 2002; Kenny et al. 2005; Kenny et al. 2003). Specifically, doses of 
MPEP (1-9 mg/kg) which significantly decrease drug self-administration, also elevates 
ICSS thresholds. However, others have found that MPEP does not alter ICSS thresholds, 
nor does MPEP decrease amphetamine-induced potentiation of brain stimulation reward 
(Gormley and Rompre 2011). A 3 mg/kg dose of the more selective mGluR5 NAM 
MTEP has been shown to decrease cue- and drug-primed reinstatement of METH-
seeking (Gass et al. 2009) and also elevate ICSS thresholds (Cleva et al. 2012). However, 
only a high dose of fenobam (30 mg/kg, twice the highest dose tested in the current 
study) significantly elevated ICSS thresholds, whereas a 10 mg/kg dose (which 
attenuated cue-induced METH-seeking in the current study) did not significantly increase 
ICSS thresholds (Cleva et al. 2012). Thus, the inhibitory effects of fenobam to reduce 
METH-, sucrose-, and food-seeking are not likely explained by an anhedonic state 
produced by these compounds. In addition, the lack of effects of fenobam on inactive 
lever presses during reinstatement or locomotor activity, as demonstrated in the present 
study, suggest that motor impairing effects of fenobam did not likely contribute to its 
observed effects on reinstatement.  However, the effects of fenobam on ICSS thresholds 
(Cleva et al. 2012) and locomotor activity have only been examined thus far in drug-
naïve animals, and fenobam may have differential effects on brain reward function in 
animals with a history of drug self-administration. This possibility warrants further 
investigation.  
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While the 10 and 15 mg/kg doses of fenobam significantly attenuated the 
reinstatement, all doses of fenobam tested attenuated sucrose- and food-seeking. 
Although mice lacking mGluR5 receptors do not show an attenuation of food self-
administration (Chiamulera et al. 2001), recently it has been shown that mGluR5-
deficient mice do show an attenuation of food-seeking under reinstatement conditions 
relative to wild-type controls (Eiler et al. 2011).  This finding is not without precedent, as 
mGluR5 receptors have been implicated in playing a central role in regulating appetite 
(Bradbury et al. 2005) and pharmacological blockade of mGluR5 receptors has been 
shown to decrease responding for food (Paterson and Markou 2005). Although we have 
previously shown that the selective mGluR5 NAM MTEP does not affect cue-induced 
reinstatement of food-seeking (Gass et al. 2009), non-specific effects of fenobam may 
account for these observations. For example, when compared to MPEP and MTEP, 
fenobam has been observed to exert more non-specific behavioral disruptions in animal 
models of anxiety, possibly due to yet to be identified active metabolites of fenobam 
(Porter et al. 2005). In addition, Jacob and colleagues (Jacob et al. 2009)  revealed 
fenobam-induced learning impairments in both the Morris water maze and contextual 
fear learning paradigms at a dose as low at 10 mg/kg. Furthermore, it was previously 
shown that in humans, high doses of fenobam exerted some psychostimulant and 
psychotomimetic effects in a subset of individuals (Pecknold et al. 1982).  Other side 
effects of fenobam that have been reported in humans include dizziness, nausea and 
sedation (Berry-Kravis et al. 2009). It is therefore possible that such effects may have led 
to the observed reductions in sucrose-, food-, and METH-seeking behavior produced by 
fenobam in the current study. 
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 In summary, we observed that fenobam attenuates the reinstatement of METH-
seeking behavior induced by acute METH exposure as well as METH-associated cues. 
These findings have important implications for the potential use of fenobam or fenobam-
related compounds as novel treatments for METH addiction, since studies examining the 
effects of pharmacological agents that are safe and relatively well-tolerated in humans on 
METH-seeking behavior in preclinical studies are generally lacking. However, we also 
observed that fenobam also suppressed cue-induced reinstatement of sucrose- and food-
seeking. Therefore, fenobam may induce a suppression of general appetitive behaviors, 
and thus optimization of fenobam analogues (Jaeschke et al. 2007) may be warranted for 
further development of mGluR5 NAMs as treatments for METH addiction. 
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CHAPTER 3 
ARE AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS POTENTIAL 
PHARMACOTHERAPEUTICS FOR ADDICTION? 
Published in Pharmaceuticals, 2014 
“Bottom-up”: Subcortical neuroplasticity drives the development of habitual drug-
seeking behavior 
Addiction begins with controlled, episodic use motivated primarily by the positive 
reinforcing and rewarding effects of the drug (Berridge & Robinson, 1998).  These 
hedonic effects, like those of natural reinforcers (i.e., food, water, sex, etc.), are 
predominantly mediated by increased dopamine (DA) transmission from neurons in the 
ventral tegmental area (VTA)  of the midbrain to the ventral striatum (nucleus 
accumbens, NAc) (Berridge & Robinson, 1998). This VTA  NAc pathway is generally 
considered to be the final common “reward” pathway for all reinforcers, both drug and 
otherwise (Feltenstein & See, 2008). DA transmission is also increased in other regions 
such as the amygdaloid complex (Amyg), ventral pallidum, hippocampus and prefrontal 
cortex (PFC) (Feltenstein & See, 2008), which are believed to play more distinct roles in 
executive function, the formation of associations between drugs and external and 
interoceptive cues, and modulation of goal-directed behaviors (Hyman & Malenka, 
2001).  With repeated exposure to rewarding or reinforcing stimuli, DA transmission in 
these circuits leads to cellular alterations that regulate how the organism behaves in the 
presence of motivationally relevant environmental stimuli, and mediate the establishment 
of adaptive responses necessary for acquiring future rewards or reinforcers (Graybiel, 
2008; Spanagel & Weiss, 1999). When a natural reward or reinforcer is consumed, DA 
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transmission in transiently activated and progressively diminishes with repeated 
exposure.  Over time, neutral stimuli become conditioned reinforcers which themselves 
increase DA transmission, predicting the event and motivating the organism to engage in 
appropriate behavioral responses (Berridge & Robinson, 1998; Kalivas, 2007). Thus, 
mesolimbic DA transmission both (1) initially signals the occurrence of motivationally 
relevant events and (2) later predicts the event from associated cues in order to engage in 
efficient goal-directed behaviors. With abused drugs, unlike natural reinforcers, increased 
DA transmission is robust, long-lasting, and pathologically reinforcing (Feltenstein & 
See, 2008). With repeated drug use, associations between the drug and previously neutral 
environmental stimuli (cues) become exceedingly salient conditioned reinforcers 
(associative “overlearning”) which can lead to craving and drive subsequent drug-
seeking. Furthermore, with repeatedly reinforced drug-seeking events, this behavior 
becomes automatic, prepotent, and compulsive (instrumental “overlearning”) (Gass & 
Olive, 2008). Thus, drugs of abuse “hijack” the subcortical systems that subserve normal 
motivational learning, and the combination of these “overlearning” processes produce 
lasting neuroadaptations in DA transmission that progressively lead to an escalated cycle 
of maladaptive (habitual) drug use (Cleva & Gass, 2010).  
Historically, researchers have thought that these neuroplastic changes mediated 
the transition from episodic to compulsive drug use and addiction (Kalivas & O’Brien, 
2008; Kalivas, 2002). However, research has shown that these subcortical neuroplastic 
changes alone are not fully capable in mediating the progression to compulsive drug use. 
Numerous lines of evidence in the last two decades, from both human neuroimaging and 
preclinical animal studies, have revealed that repeated drug use also disrupts prefrontal 
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cortical functioning, resulting in a loss of executive functioning and “top-down” 
inhibitory control that, under normal circumstances, overrides habitual responding when 
exposed to adverse consequences (Goldstein & Volkow, 2011; Jentsch & Taylor, 1999; 
Kalivas et al., 2005; Kalivas & Volkow, 2005). Thus, drug addiction develops from a 
combination of subcortical alterations that drive automatic, habitual responding with a 
lack of top-down inhibitory control that regulates behavior in response to negative 
consequences. Given that most attempts to develop pharmacotherapeutics for addiction 
have predominantly targeted only the subcortical reward systems (attempting to reduce 
craving or block rewarding and reinforcing effects of the drug), it is not surprisingly that 
the vast majority of compounds tested have failed to adequately reduce relapse rates, and 
only a few approved anti-relapse medications exist (and only for nicotine, alcohol, and 
opioids). 
“Top-down”: Repeated drug-induced insults to prefrontal cortices impairs executive 
functioning 
 The PFC is responsible for many higher-order cognitive processes, often 
collectively referred to as executive functions, such as decision-making, response 
inhibition, planning, working memory, and attention (Goldstein & Volkow, 2011; Miller 
& Cohen, 2001; Sofuoglu et al., 2013). As mentioned previously, in addition to increased 
DA signaling in the mesolimbic reward pathway, drugs of abuse also increase DA 
transmission in the PFC (Koob & Volkow, 2010). Evidence suggests that, while acute 
drug effects can increase PFC activity and improve cognitive functioning, repeated drug 
exposure leads to compensatory changes that subsequently both biases attention toward 
drug-related stimuli and impairs multiple domains of executive functioning (for a 
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comprehensive review of drug-induced impairments in executive function domains, see 
(Field & Cox, 2008; Goldstein & Volkow, 2011; Sofuoglu et al., 2013)). In drug 
addiction, impaired functioning in these domains, combined with attention biased 
towards drug-related stimuli, culminates in the inability of the PFC to effectively exert 
“top-down” inhibitory control over habitual drug-seeking behavior (Kalivas & O’Brien, 
2008; Kalivas, 2008).  While “bottom-up” DA transmission is responsible for innervating 
prefrontal regions, reciprocal “top-down” signaling from the PFC is mediated by the 
excitatory neurotransmitter glutamate (Gass & Olive, 2008; Kalivas, LaLumiere, 
Knackstedt, & Shen, 2009; Tzschentke & Schmidt, 2003). In recent years, addiction 
research has begun to reveal that changes in glutamatergic signaling within corticostriatal 
and corticolimbic circuits where DA terminals are embedded are essential in mediating 
drug reward, reinforcement, and the transition to addiction (Gass & Olive, 2009; 
LaLumiere, Smith, & Kalivas, 2012; Peters, Kalivas, & Quirk, 2009; Tzschentke & 
Schmidt, 2003), revealing new potential targets for addiction pharmacotherapeutics 
(Cleva, Gass, Widholm, & Olive, 2010; Kalivas & Volkow, 2011; Olive, Cleva, Kalivas, 
& Malcolm, 2012).   
Glutamatergic mechanisms in memory formation: a brief overview 
Glutamate is the main excitatory neurotransmitter in the mammalian brain and 
responsible for approximately 70% of the chemical transmission in the central nervous 
system (Gass & Olive, 2008). Glutamate binds to two major classes of receptors; 
ionotropic glutamate receptors (N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors) which mediate fast 
excitatory transmission, and metabotropic glutamate receptors (mGluR1-8) which 
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mediate slow modulatory transmission through G-protein mediated signaling pathways 
(Niciu, Kelmendi, & Sanacora, 2012). At the cellular level, learning produces changes in 
excitatory glutamatergic transmission such as long-lasting increases in synaptic strength 
and postsynaptic current amplitudes, increasing the efficacy of communication between 
nerve cells. These changes, known as long-term potentiation (LTP), are generally 
accepted to be the cellular basis for memory formation and storage (Lisman, Yasuda, & 
Raghavachari, 2012).  While there is an overwhelming amount of evidence suggesting 
that each of the glutamate receptor types play a unique role in LTP and learning and 
memory (Nicoll & Roche, 2013), for the purposes of this review, focus will be placed on 
ionotropic AMPA receptors (for a more comprehensive review on glutamate mechanisms 
and LTP, see (Lamprecht & LeDoux, 2004; Niciu et al., 2012)).  Both early and late 
phases of LTP require AMPA receptors.  First, signaling through AMPA receptors is 
necessary to slightly depolarize the membrane to approximately -50 mV, at which point 
the Mg2+ block is released from NMDA receptors, allowing Ca2+ ions to enter the cell.  
While Ca2+ triggers multiple downstream effects including gene transcription and 
translation mechanisms that results changes in the levels of numerous synaptic proteins, it 
also causes an immediate non-genomic increase in AMPA receptor trafficking and 
insertion of AMPA receptors into the plasma membrane, increasing the size and strength 
of postsynaptic responses (P. Chang, Verbich, & McKinney, 2012).  The long-lasting 
increase in postsynaptic AMPA receptors is thought to be necessary for the lasting LTP 
and memory formation. Thus, ligands that increase signaling through AMPA receptors 
facilitate LTP, learning and memory (Lynch & Gall, 2006). 
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As mentioned above, while dopaminergic signaling appears necessary for 
initiating and reinforcing early drug use (positive reinforcement), glutamatergic 
mechanisms within mesocorticolimbic circuits have also emerged as primary mediators 
of the transition to compulsive drug use (Gass & Olive, 2008; Kalivas et al., 2009).  
Specifically, lasting neuroadaptations in corticostriatal and corticolimbic glutamatergic 
transmission are thought to be largely responsible for the behavioral hallmarks of 
addiction including (1) the impaired ability to regulate the drive to obtain and use drugs, 
even in the face of adverse consequences, and (2) a propensity to relapse even after long 
periods of abstinence (Kalivas & O’Brien, 2008; Kalivas & Volkow, 2005; Kalivas, 
2002). In the normal brain, when motivational relevant stimuli are encountered, 
corticolimbic glutamatergic circuits, comprised of the PFC, amygdala, NAc core and 
shell (NAcc and NAcs), interact and send relevant environmental information through the 
NAc to mesostriatal (sensorimotor) circuits involving the dorsal striatum, which in turn 
communicates with other basal ganglia regions such as the globus pallidus and substantia 
nigra. Together, these circuits process environmental stimuli in order to establish 
efficient, goal-directed behaviors. Following repeated drug reinforcement, the influence 
of corticolimbic glutamatergic projections from the PFC and amygdala into the NAc 
progressively diminishes, whereas sensorimotor glutamatergic transmission to the dorsal 
striatum becomes predominant, allowing responses to become automatic (i.e., habitual) 
and allowing corticolimbic circuits to process other relevant stimuli (Jog, 1999; Kalivas, 
2008). However, if reinforcer contingencies change and responses fail to yield expected 
outcomes, engaged corticolimbic circuits function to both inhibit the prepotent response 
and signal the motor cortex to generate new adaptive responses (Berridge & Robinson, 
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1998; Kalivas, 2002). In other words, following repeated drug reinforcement, the 
influence of corticolimbic glutamate projections from the PFC to the NAc on behavior 
progressively diminishes, whereas sensorimotor glutamatergic transmission to the dorsal 
striatum becomes predominant, resulting in more automatic and habitual behaviors. Thus, 
compulsive drug use develops from a combination of pathologically strengthened “habit” 
circuitry combined with impaired corticolimbic circuits, rendering drug addicts with 
impaired behavior regulation who are unable to inhibit drug-seeking behavior in the face 
of adverse consequences (Everitt & Robbins, 2005; Kalivas & Volkow, 2005; Kalivas, 
2002). Given the pivotal role of excitatory transmission in these circuits, treatments 
aimed at rescuing or increasing behavioral regulation and/or impairing drug-related 
“habit” memories may be promising avenues for novel addiction treatments. 
Extinction / exposure strategies: Rescuing behavioral regulation 
One therapeutic approach that has shown some success (although moderate at 
best) in decreasing relapse by enhancing behavioral regulation is cue exposure therapy 
(Conklin & Tiffany, 2002; Havermans & Jansen, 2003; Marlatt, 1990).  In this approach, 
clinicians attempt to extinguish (i.e., “break”) the associations between drug craving, use, 
and drug-related stimuli (such as drug paraphernalia) by repeatedly exposing drug users 
to the drug-related stimuli in the absence of drug availability. In preclinical rodent models 
of addiction, this process is studied using the extinction-reinstatement paradigm (Epstein, 
Preston, Stewart, & Shaham, 2006). Here, a rodent or nonhuman primate is allowed to 
intravenously self-administer (IVSA) a drug, with drug infusions simultaneously paired 
with discrete cues such as a light and/or tone. Following stabilization of drug-taking, 
animals undergo either extinction training (ET), where they are placed in the drug-taking 
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context but the drugs is no longer available (and thus drug-cue associations cannot be 
further strengthened), or no ET where they remain in their home cage (forced abstinence) 
(Epstein et al., 2006). Subsequently, animals are tested for reinstatement (“relapse”) of 
drug-seeking by the presentation of drug-associated discrete cues, a small dose of the 
drug, or a stressful stimulus (Epstein et al., 2006). Historically, a common misconception 
about exposure and extinction therapies has been that the resulting decrease in responding 
occurs due to a process of “forgetting”.  However, evidence suggests that extinction is 
instead a form of new learning that is highly context dependent (Bouton, 2004).  This is 
evidenced by the fact that, despite a loss of responding during extinction procedures, 
responding will often re-appear spontaneously with time (spontaneous recovery), when 
the organism is placed back in the original drug-taking context(s) (renewal), or exposed 
to discrete cues not present during the extinction procedures (cue-induced reinstatement) 
(Bouton, 2002; Crombag, Bossert, Koya, & Shaham, 2008; Rescorla, 2004). These 
phenomena suggest that exposure and extinction strategies do not erase the original drug-
seeking memory engram(s), but instead decrease drug-seeking by strengthening “top-
down” inhibitory control circuits (Cleva et al., 2010). However,  the inconsistent success 
rates of exposure and extinction therapies in humans is likely attributable to due to either 
(1) a lack of proper use of extinction procedures due to misunderstandings about the 
underlying processes of extinction (i.e., new learning vs. forgetting), (2) context-
specificity issues (i.e., lack of extinction training in the actual drug-taking context(s)), (3) 
lack of adequate exposure session time, (4) lack of utilization of highly salient drug cues, 
or other uncontrolled variables (Conklin & Tiffany, 2002; Taylor, Olausson, Quinn, & 
Torregrossa, 2009).    
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Despite mixed results at the clinical level, preclinical studies show that extinction 
training (ET) decreases reinstated drug-seeking when compared to forced abstinence 
procedures where animals simply remain in their home cage for a matched amount of 
time (Fuchs, Branham, & See, 2006; Sutton et al., 2003). Furthermore, reinstatement 
following forced abstinence is primarily mediated by dorsal striatal “habit” circuitry (Di 
Ciano, Robbins, & Everitt, 2008), whereas ET engages prefrontal glutamate projections 
to the NAcs, implying that top-down behavioral regulation circuits are also recruited 
(Knackstedt et al., 2010; LaLumiere & Kalivas, 2008; LaLumiere et al., 2012; Peters, 
LaLumiere, & Kalivas, 2008). Furthermore, similar to human imaging studies that have 
shown that cue-induced drug craving is correlated with anterior cingulate activation 
(Childress & Mozley, 1999), the homologous prelimbic cortex in rats (Ongür & Price, 
2000), which sends glutamatergic projections to the NAcc, is responsible for initiating 
cue-induced drug-seeking (Kalivas & McFarland, 2003; Kalivas & O’Brien, 2008; 
LaLumiere & Kalivas, 2008; McFarland & Kalivas, 2001; McFarland, Lapish, & Kalivas, 
2003). In contrast, ET enhances glutamatergic transmission from the infralimbic cortex 
(ILC) to the NAcs, which is a critical locus for the storage and consolidation of extinction 
learning and subsequent inhibition of cue-induced drug-seeking (Knackstedt et al., 2010; 
LaLumiere, Niehoff, & Kalivas, 2010; LaLumiere et al., 2012; Peters et al., 2008). Thus, 
these two parallel PFC-NAc projections are functionally dichotomous, and compete for 
control of signaling in the NAc to motor circuits that ultimately guide behavior (Kalivas 
& O’Brien, 2008; Kalivas, 2009). In addition, ET leads to persistent changes in various 
plasticity-related proteins in the NAc. Specifically, ET upregulates the expression of the 
GluR1 and GluR2/3 subunits of the AMPA receptor in the NAcs, indicative of the 
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emergence of an LTP-like “up” state in these specific pathways.  Corroborating these 
effects, viral overexpression of these same subunits also decreases reinstatement of 
cocaine-seeking (Ghasemzadeh, Vasudevan, Mueller, Seubert, & Mantsch, 2009; Sutton 
et al., 2003). Conversely, viral overexpression of “pore-dead” GluR1 subunits in the 
NAcc potentiates reinstated cocaine-seeking (Bachtell et al., 2008; Sutton et al., 2003). 
Thus, either potentiation or increasing the number of AMPA receptors in the NAcs, 
antagonism or decreasing the number of AMPA receptors in the NAcc, or both, would 
theoretically tip the balance of glutamatergic signaling to the NAc back towards favoring 
of ILC-NAcs mediated inhibitory control. 
Facilitating ILC-NAcs glutamate signaling 
The fact that ET recruits “top-down” glutamatergic signaling that mediates and is 
responsible for the consolidation of extinction behavior has led to an increase in research 
focusing on these pathways as pharmacotherapeutic targets. Recent studies have shown 
that various glutamate receptor agonists or PAMs enhance the consolidation of both 
extinguished drug-seeking and increase markers associated with synaptic plasticity in the 
ILC-NAcs pathway (Knackstedt et al., 2010; LaLumiere et al., 2010, 2012), suggesting 
that pharmacological compounds that enhance activity or plasticity in this pathway have 
the potential to be novel therapeutic adjuncts to cue exposure therapies (Cleva et al., 
2010).  One promising class of glutamate ligands, called AMPA PAMs (Lynch, 2002, 
2006), are small molecules that, while displaying a wide range of structural differences, 
all enhance glutamatergic signaling through positive modulation of AMPA receptors 
(Arai & Kessler, 2007). The first AMPA PAMs were developed approximately two 
decades ago, and in the time since have been shown to improve learning, memory and/or 
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cognition, in both humans and animal subjects, and in a variety of experimental designs, 
indicating their potential as broad spectrum pharmacotherapeutics (Black, 2005; Lynch & 
Gall, 2006; Lynch, Palmer, & Gall, 2011; Lynch, 2006; Marenco & Weinberger, 2006; 
Swanson, 2009).  AMPA PAMs work in an activity-dependent manner by maintaining 
the open-channel state of AMPA receptors after binding of an endogenous ligand 
(glutamate) (Jin et al., 2005). AMPA PAMs decrease either the rate of desensitization or 
deactivation of the receptor, thereby increasing cation influx into the postsynaptic cell 
(ONeill & Bleakman, 2004).  However, unlike orthosteric (competitive) glutamate 
receptor agonists which can produce severe unwanted side effects such as excitoxicity, 
AMPA PAMs only enhance endogenous activity and are less prone to adverse side 
effects (Christopoulos, 2002) (but see below). For example, evidence shows that AMPA 
PAMs can facilitate learning and memory at doses that do not cause excitotoxic damage, 
a common occurrence with orthosteric agonists (Mattson, 2003; Mehta, Prabhakar, 
Kumar, Deshmukh, & Sharma, 2013; Olney, 1994; Staubli, Rogers, & Lynch, 1994). 
However, it has recently been reported that AMPA PAMs may be more excitotoxic at 
effective doses than previously thought (Shaffer et al., 2013). Nonetheless, most 
published studies have reported that AMPA PAMs generally have a safe profile at 
effective doses (Lynch & Gall, 2006; Lynch, 2006).   
AMPA PAMs and Addiction: Preclinical Studies 
In recent years, a handful of animal studies have assessed the potential use of 
AMPA PAMs for the treatment of addiction. In the first study of this kind (LaLumiere et 
al., 2010), rats were allowed to intravenously self-administer (IVSA) cocaine for two 
weeks in daily 2-hr sessions using standard operant lever pressing procedures. Following 
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self-administration, rats were first placed into brief (15 min sessions) extinction sessions 
for five days after which intracranial ILC injections of the AMPA positive modulator 2-
[2,6-difluoro-4-({2-[(phenylsulfonyl)amino]ethyl}thio)phenoxy]acetamide (PEPA, 30 
ng/side) or vehicle were administered immediately after the extinction session. PEPA is a 
GluR3/4 preferring AMPA PAM that primarily exerts its effects through attenuation of 
AMPA receptor desensitization (Sekiguchi, Nishikawa, Aoki, & Wada, 2002). Next, 
seven additional 2-hr extinction sessions were conducted, after which no post-session 
PEPA infusions were given, in order to assess for retention of extinction learning.  The 
results showed that ILC injections of PEPA facilitated extinction learning (i.e., decreased 
presses on the lever that previously resulted in cocaine delivery) during the final two 15-
min extinction sessions.  Furthermore, PEPA-facilitated extinction also continued 
through the seven 2-hr extinction sessions, as overall responding was significantly 
decreased for all remaining ET sessions.  
In a follow-up study by the same research group (LaLumiere et al., 2012), rats 
underwent cocaine self-administration procedures for 2 weeks.  Following cocaine IVSA, 
rats were again placed into ET for at least 10 sessions and remained in extinction until 
responding decreased to a predetermined criteria (>25 lever presses in 2 consecutive 
sessions). Following extinction procedures, PEPA microinjections into the ILC (0.075 
nmol/hemisphere) were administered immediately prior to testing for cue-induced 
reinstatement. Two reinstatement tests were given, with rats receiving either PEPA or 
vehicle in a randomized, counter-balanced design.  The results demonstrated that PEPA 
significantly decreased cue-induced reinstatement of cocaine-seeking compared to 
vehicle. Importantly, this decrease was not due to alterations in general locomotor 
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activity.  In a subsequent experiment in this study, it was also shown that PEPA-mediated 
decreases in responding were reversed by microinjections of an AMPA receptor 
antagonist into the NAcs. Together, these studies demonstrate that ILC glutamate 
transmission to the NAcs mediates the expression and consolidation of extinction 
behavior in the reinstatement paradigm.   
While these studies demonstrate that facilitating glutamatergic transmission in the 
ILCNAcs pathway with AMPA positive modulators is promising, there are no 
published reports demonstrating that systemic administration of AMPA PAMs, which is 
more translationally relevant for the development of newer treatments for addiction, 
produces similar promising results. Some AMPA PAMs have been reported to possess 
the ability to induce the expression and secretion of brain-derived neurotrophic factor 
(BDNF) (Lynch & Gall, 2006), a neurotrophin that among other things facilitates the 
induction and maintenance of LTP (Bramham & Messaoudi, 2005). Thus, AMPA PAMs 
can be further characterized into BDNF-inducing (BDNF AMPA PAM) or non-BDNF-
inducing (non-BDNF AMPA PAM) subtypes(Arai & Kessler, 2007; Clarkson et al., 
2011). For example, previous work has revealed increased motor recovery following 
experimental stroke in rats following administration of the BDNF AMPA PAM CX1837 
as compared to the non-BDNF AMPA PAM CX1739 (Clarkson et al., 2011), suggesting 
that BDNF-inducing AMPA PAMs may have superior therapeutic potential. 
Recently, in collaboration with Cortex Pharmaceuticals (Glen Rock, NJ), our 
laboratory has collected novel data on the effects of BDNF vs. non-BDNF AMPA PAMs 
on the extinction and reinstatement of methamphetamine-seeking behavior. Following 
two weeks of methamphetamine self-administration in rats, we systemically administered 
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either the BDNF AMPA PAM CX1837 (0.1 and 1 mg/kg i.p., Fig. 4a) or non-
BDNFAMPA PAM CX1739 (0.1, 1, and 10 mg/kg i.p., Fig. 4b) prior to ET sessions. 
Doses of these compounds were based upon recommendations from Cortex 
Pharmaceuticals and earlier reports of efficacious effects at similar doses (Clarkson et al., 
2011) that do not alter generalized locomotor behavior (Silverman, Oliver, Karras, 
Gastrell, & Crawley, 2013). Results revealed that systemic treatment with either CX1837 
or CX1739 significantly facilitated extinction learning (reduction in active lever presses) 
on the first day of extinction tests (see Fig. 4a,b). However, statistical analyses did not 
reveal any significant differences during any of the remaining extinction sessions or any 
main effects of drug type (CX1837 vs. CX1739). Furthermore, the reduction in 
responding seen during ET sessions unfortunately did not lead to significant reductions in 
cue-induced reinstatement of METH-seeking as seen previously following intra-ILC 
central injections of the AMPA PAM PEPA (Fig. 5) 
The observed lack of attenuated reinstatement by these AMPA PAMs is 
disappointing, especially in light of the aforementioned positive results observed with 
intra-ILC administration of PEPA following cocaine self-administration and ET. Reasons 
for the lack of apparent efficacy of either CX1739 or CX1839 in attenuating 
reinstatement may be attributable to the different drug reinforcers used 
(methamphetamine vs. cocaine), and it is possible that self-administration of these two 
psychostimulants produces differential effects on AMPA receptor and/or BDNF 
expression that may reduce the pharmacological effects of AMPA PAMs (Bowers, Chen, 
& Bonci, 2010; Ghitza et al., 2010). Alternatively, some studies have shown opposing 
prelimbic vs. ILC influences on the extinction and reinstatement of drug-seeking 
  39 
behavior (Willcocks & McNally, 2013), and it possible that potentiation of AMPA and/or 
BDNF signaling in both of these regions simultaneously following systemic AMPA PAM 
administration negates any effects of either of these compounds when acting in either 
region alone, as would be achieved by intracerebral administration. Thirdly, it is possible 
that CX1739 and/or CX1837 act on AMPA receptors containing subunit configurations 
that are different than those affected by PEPA (GluR3/4).  
Nonetheless, these results do indicate that further research is needed to ascertain 
the potential therapeutic value of AMPA PAMs in the treatment of drug addiction. 
Specifically, future studies should examine factors such as drug reinforcer, BDNF vs. 
non-BDNF AMPA PAM utilized, and selectivity of these compounds for specific AMPA 
subunit composition and their neuroanatomical localization. Furthermore, it has recently 
been shown that a novel extinction paradigm, known as memory-retrieval extinction, 
leads to a reduction in cocaine, heroin, and alcohol reinstatement when compared to 
standard extinction training (Xue et al., 2012; Zayra Millan, Milligan-Saville, & 
McNally, 2013). Furthermore, reductions in reinstatement are correlated with an 
upregulation of protein kinase M zeta (PKM ζ, an atypical member of the protein kinase 
C family that is thought to be necessary and sufficient for long-term memories and LTP 
(Sacktor, 2010), although this has recently been challenged (Lee et al., 2013; Volk, 
Bachman, Johnson, Yu, & Huganir, 2013). PKM ζ, once synthesized, remains 
persistently active and maintains memories through an increase and maintenance of 
AMPA receptors in the post-synaptic membrane (Sacktor, 2010). Thus, the attenuated 
reinstatement observed following memory-retrieval extinction procedures are likely 
mediated through upregulated AMPA receptor signaling, and further potentiation with 
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AMPA PAMs may theoretically confer added benefits. This hypothesis, however, 
remains to be tested.   
 
Discussion 
Collectively, the results from the studies outlined above suggest that AMPA 
PAMs may have potential as pharmacological adjuncts to traditional cue-exposure 
therapies. However, the data thus far are rather limited, and this suggestion needs to 
remain hypothetical at this point until additional data are collected. Further studies with 
additional BDNF and non-BDNF AMPA PAMs, utilizing different drug reinforcers, and 
potentially additional extinction paradigms such as extinction-retrieval, are needed to 
provide firmer evidence of a therapeutic value of AMPA receptors in the treatment of 
addiction, such as novel pharmacological adjuncts to cue exposure therapy. Nonetheless, 
given that the ILCNAcs glutamate pathway has been shown to mediate both the 
expression and consolidation of learned extinction of drug-seeking behavior, and AMPA 
PAMs exert their effects in an activity-dependent manner, a likely mechanism of the 
observed effects of AMPA PAM administration is potentiated glutamate transmission in 
this pathway. This hypothesis, while currently unconfirmed, suggests a facilitation of 
“top-down” inhibitory control over drug-seeking behavior.  It is therefore possible that 
other AMPA PAM mechanisms may or may not contribute to the potential efficacy of 
these compounds in the context of drug addiction. While it has been suggested in 
previous work that positive effects AMPA PAMs may be mediated, in part, by alterations 
in neurotrophin (BDNF) signaling (Clarkson et al., 2011; Lauterborn et al., 2009; Lynch 
& Gall, 2006; Lynch et al., 2011; Lynch, 1998, 2006), our results did not reveal 
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significant differences between the BDNF AMPA PAM CX1837 and the non-BDNF 
AMPA PAM CX1739, and thus does not suggest a significant role of BDNF signaling in 
the observed facilitated extinction effects. These results should be interpreted with 
caution however, and additional testing with other BDNF-inducing compounds is needed 
before definitive conclusions can be made.  
Conclusions 
Extinction-based cue-exposure therapies have shown limited success decreasing 
relapse in humans.  However, evidence from preclinical studies suggests that extinction 
training, combined with AMPA PAMs treatment, under some circumstances, facilitates 
and consolidates extinction learning. Furthermore, under some circumstances AMPA 
PAM treatment also leads to attenuated cue-induced reinstatement of drug-seeking. These 
promising preclinical findings point to the need for future research aimed at assessing 
whether adjunct treatment with AMPA PAMs could potentially improve the success rate 
of cue-exposure therapies in humans.  
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CHAPTER 4 
POTENT REWARDING AND REINFORCING EFFECTS OF THE SYNTHETIC 
CATHINONE 3,4-METHYLENEDIOXYPYROVALERONE (MDPV). 
Published in Addiction Biology, 2014 
In recent years, there has been a dramatic increase in the use of desiger drugs 
known as synthetic cathinones in both Europe and the United States (Spiller et al., 2011; 
Drug Enforcement Administration,  2011a). Use of synthetic cathinones has emerged 
rapidly, fueled largely by online marketing and widespread availability over the internet 
and in smoke shops and  convenience stores (Kavanagh et al. 2010; Vardakou et al., 
2011).  These synthetic drugs are derivatives of cathinone, a naturally occurring beta-
ketone amphetamine analogue found in khat (Catha edulus), a plant that is abused for its 
stimulant-like effects (Magdum, 2011) . Typically, synthetic cathinones are sold as “bath 
salts”,  “plant food”, and other misleading terms  and marketed as “legal highs” and 
alternatives to traditionally abused stimulants such cocaine and amphetamines  (Drug 
Enforcement Administration, 2011a). While many potential synthetic cathinones exist 
and are predicted to emerge as abused substances in the future, the analogues most 
frequently used at present include mephedrone (4-methylmethcathinone, 4-MMC), 3,4-
methylenedioxypyrovalerone (MDPV), and methylone (3,4-
methylenedioxymethcathinone, MDMC) (Drug Enforcement Administration, 2011a).  As 
of October 2011, mephedrone, MDPV, and methylone have been temporarily classified in 
the United States as Schedule I controlled substances (Drug Enforcement Administration, 
2011b). 
Despite the widespread increase in use of these compounds, very little scientific 
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data exist regarding their reinforcing effects and abuse potential.  Of the three most 
common synthetic cathinones, most scientific investigations have focused on 
mephedrone, and recently it has been shown that rats will readily self-administer 
mephedrone at a dose of 0.24 mg per 10 µl infusion (Hadlock et al., 2011).  While 
mephedrone has been the subject of most popular press coverage and recent scientific 
investigations, MDPV use is also common and has been marketed as a replacement 
mephedrone in places where it has previously been banned (Durham, 2011; Coppola & 
Mondola, 2012) . MDPV is a methylenedioxy analogue of pyrovalerone (Yohannan and 
Bolenko, 2010), a drug with stimulant-like properties (Holliday et al., 1964) that was 
once prescribed to treat chronic fatigue and lethargy (Goldberg et al., 1973) before being 
shown to possess abuse potential in drug addicts (Deniker et al., 1975).  Although the 
precise mechanism(s) of MDPV is currently unknown, it is possible it acts as a 
monoamine uptake inhibitor as pyrovalerone has been shown to inhibit dopamine and 
norepinephrine transporters (DAT and NET, respectively), and to a lesser extent serotonin 
transporters (SERT)(Lancelot  et al., 1992)(Meltzer et al., 2006)(Kelly, 2011)(Coppola & 
Mondola, 2012). MDPV increases extracellular levels of DA in the striatum of mice after 
oral administration (Fuwa et al., 2009).  Behaviorally,  MDPV leads to dose-dependent 
increases in locomotor activity in mice to a greater extent than methamphetamine when 
using identical doses (Marusich et al., 2011).  Together, these data provide early evidence 
that MDPV possesses stimulant-like properties and corroborates users reports describing 
subjective effects similar to those of methylphenidate, cocaine, and amphetamines 
(Psychonaut WebMapping Research Group 2009a,b).   
To our knowledge, there have been no published studies directly exploring the 
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reinforcing and rewarding effects of MDPV.  The present study addressed this issue by 
examining the ability of MDPV to support intravenous self-administration (IVSA) and to 
lower thresholds for intracranial self-stimulation (ICSS). In Experiment 1, the reinforcing 
effects MDPV during IVSA were assessed at three doses (0.05, 0.1, and 0.2 mg/kg per 
infusion) during three phases of experimentation: (1) 2 hr daily access sessions, (2) a 
progressive ratio (PR) schedule of reinforcement, and (3) short (2 hr daily, ShA) vs. long 
(6 hr daily, LgA) sessions.  A separate group of animals underwent the same procedures 
but self-administered methamphetamine (0.05 mg/kg/infusion) as a positive control. In 
Experiment 2, MDPV (0.1, 0.5, 1, and 2 mg/kg, i.p.) was administered acutely to 
determine effects on thresholds for ICSS, a well-established measure of brain reward 
function (Kornetsky & Bain, 1992). 
 
Method 
Subjects 
All experimental procedures were conducted with the approval of the Institutional 
Animal Care and Use Committee at Arizona State University, and according to the Guide 
for Care and Use of Laboratory Animals as adopted by the National Institutes of Health 
(NIH). Forty-one male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA), 
weighing approximately 250 g, were individually housed upon arrival.  Forty-eight rats 
were implanted with jugular vein catheters and vascular access ports and underwent 
IVSA procedures for Experiment 1. Five non-catheterized rats underwent ICSS 
procedures for Experiment 2.  Rats were housed according to NIH standards on a 12 hr 
light-dark cycle and given ad libitum access to food and water during all experimental 
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procedures except during behavioral testing. All experimental sessions took place during 
the dark phase, with the exception of a 16 hr overnight lever-press training sessions and 
PR tests which began at 4:00 p.m. and ended the following morning at approximately 
8:00 a.m. Throughout the course of experiments, 12 of the 48 rats in Experiment 1 were 
removed due to catheter patency failure and one of the 5 rats in Experiment 2 was 
removed due to health-related issues.  
Drugs and Assessment of Purity 
 MDPV was obtained through an internet website www.researchchemz.com  
(Laboratory Supply USA, San Diego, CA).  Ten mg samples of MDPV were analyzed by 
LC-MS for purity at Research Triangle Institute (Durham, NC). Samples were analyzed 
using a Waters Synapt HDMS quadrupole time of flight (Q-TOF) mass spectrometer 
interfaced to a Waters Acquity UPLC system.  Data were acquired using a capillary 
voltage of 3 kV, source temperature of 150 ˚C, desolvation temperature of 500 ˚C, 
sampling cone at 30 V, and extraction cone at 4 V.  The mass spectrometer was externally 
calibrated from 50 - 700 Da using a sodium formate solution, and mass shifts during 
acquisition were corrected for using leucine enkephalin as a lockmass.  Liquid 
chromatography was performed using a BEH C18 column (2.1 x 50 mm, 1.7 µm particles) 
held at 40˚C.  Sample identity was confirmed based on exact mass, retention time, and 
fragmentation match to a certified reference standard from Cerilliant (Round Rock, TX).  
MDPV samples were determined to have an apparent purity of >95%.  For all behavioral 
studies, MDPV and methamphetamine (Sigma-Aldrich, St. Louis, MO) were dissolved in 
sterile saline. For Experiment 2, MDPV was administered i.p. in a volume of 1 ml/kg. 
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Experiment 1: Intravenous Self-administration (IVSA)Procedure 
Surgical Procedures 
Prior to arrival, rats were implanted with intravenous catheters into the jugular 
vein at Harlan Laboratories. On the day following arrival, rats were anesthetized with 
isoflurane (2% v/v) vaporized oxygen at a flow rate of 2 L/min. A 2.5 cm longitudinal 
incision was made between the scapulae for implantation of a threaded vascular access 
port (Plastics One, Roanoke, VA, USA). Threaded vascular access ports were attached to 
be mesh collar sutured underneath the surrounding tissue within the incision. Access 
ports were sealed with a piece of Tygon tubing closed at one end and a protective cap. All 
rats were given allowed to recover from surgery for 5 days prior to the initiation of 
behavioral testing, and during this time animals received daily intravenous infusions of 
70 U/ml heparin (0.2 ml volume) to maintain catheter patency and 100 mg/ml cefazolin 
(0.1 ml volume) to protect against infection. Meloxicam (2.5 mg/ml s.c.) was 
administered for the first 3 days following surgical procedures to provide additional relief 
post-surgical discomfort.  In addition, rats were given ten 45 mg sucrose pellets in their 
homecage four days prior to IVSA procedures to eliminate neophobia to sucrose pellets 
that could delay acquisition of self-administration during 16 hr overnight training 
sessions. 
Apparatus 
Drug self-administration sessions were conducted in operant self-administration 
chambers (ENV-008, Med Associates, St. Albans, VT, USA). All self-administration 
chambers were located inside sound-attenuating cubicles equipped with a house light and 
exhaust fan designed to mask external noise and odors, and were interfaced to a PC 
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computer. Chambers were equipped with two stainless steel response levers located on 
one wall with a 4.2 × 5 cm food pellet receptacle placed between levers. Each response 
lever was located approximately 7 cm above a stainless steel grid floor, and positioned 
above each lever was a 2.5 cm diameter white stimulus light. Located near the top of the 
self-administration chambers was a Sonalert speaker that provided an auditory stimulus 
during drug delivery. Outside each chamber was a syringe pump that was interfaced to 
the computer and delivered the drug solution via a single-channel liquid swivel mounted 
atop the chamber via polyethylene tubing. 
Experimental Design: IVSA Procedures 
 Following recovery from surgical procedures, self-administration sessions 
commenced. During all self-administration sessions, except during progressive ratio 
training, each press on the active lever delivered the reinforcer on an FR1 schedule of 
reinforcement. Reinforcer delivery was accompanied by concurrent illumination of a 
stimulus light and presentation of an auditory stimulus for two seconds followed by a 20-
sec timeout period during which additional lever presses were recorded but produced no 
programmed responses.  Inactive lever presses were recorded but produced no 
programmed consequences. Self-administration procedures were initiated with a 16 hr 
overnight training session whereby active lever presses delivered a 45 mg sucrose pellet 
(TestDiet, Richmond, IN). Approximately 24 hr following sucrose training, rats were 
separated into one of four groups based upon MDPV dose (0.05, 0.1, or 0.2 
mg/kg/infusion) or as a positive control, methamphetamine (0.05 mg/kg/infusion). Each 
drug infusion was delivered in a volume of 0.06 ml.  Next, daily 2 hr self-administration 
sessions were commenced with intravenous MDPV or methamphetamine as the 
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reinforcer. MDPV or methamphetamine was delivered to the vascular access port by 
polyethylene tubing housed in a stainless steel spring tether that was attached to the liquid 
swivel. Self-administration sessions were conducted 7 consecutive days per week, and 
each session was preceded and followed by an intravenous infusion of 0.1 ml of 70 U/ml 
heparin plus 100 mg/ml cefazolin to maintain catheter patency.  Daily 2 hr self-
administration sessions were conducted for a minimum of 10 days and until stability 
criterion was reached (<15% deviation in active lever pressing for each dose group for 
two consecutive days). All groups met stability on day 10. 
 Following ten days of 2 hr IVSA sessions, a 16 hr overnight progressive ratio 
(PR) schedule was conducted to assess the reinforcing efficacy of MDPV. During PR 
tests, the number of lever presses required to obtain a single infusion of MDPV was 
determined by the following the equation: responses per reinforcer delivery = 5 × e(injection 
number - 0.2)
 - 5 (i.e., 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, etc.) (Richardson and Roberts, 
1996). Breakpoints were considered to be met when rats did not emit any lever presses 
for 2 hours. Following PR testing, each dose group of rats (0.05, 0.1, or 0.2 
mg/kg/infusion of MDPV) was divided into two subgroups, such that half of the rats in 
each dose group continued with 2 hr daily self-administration sessions for ten days (short 
access, ShA), while the other half began 6 hr daily sessions (long access, LgA) for ten 
days.  All aspects of the self-administration procedures were identical except for session 
length (2 vs. 6 hr per day). For rats self-administering methamphetamine, all rats were 
assigned to the LgA group to demonstrate escalation of drug intake. 
Experiment 2: ICSS Procedures 
Surgical Procedures 
  49 
Rats were anesthetized with isoflurane (2% v/v) vaporized oxygen at a flow rate 
of 2 L/min and placed into a stereotaxic frame.  A stainless-steel bipolar electrode 
(PlasticsOne, Roanoke, VA, USA, 2 mm diameter, insulated except at the ventral tip) was 
implanted into the medial forebrain bundle (AP -0.05 mm; ML ± 1.7 mm, DV -8.3 mm 
from dura). Four skull screws and dental cement were used to permanently secure 
electrodes to the skull.  To counterbalance for any hemispheric differences, half the 
animals received electrodes in the left hemisphere and the other in the right hemisphere.  
Following surgery, rats were given 7 days to recover before beginning ICSS procedures 
during which they received daily injections of 2.5 mg/ml meloxicam (0.15 ml volume) to 
minimize post-surgical discomfort. 
Apparatus 
All ICSS testing was conducted in operant chambers (ENV-007CT, Med 
Associates). Chambers were housed inside sound-attenuating cubicles equipped with an 
exhaust fan to mask external noise and odors. Chambers contained a house light on the 
back wall and a front wall mounted nose-poke aperture with LED stimulus lights located 
inside the access hole (ENV-114M, Med Associates).  The nose-poke aperture was 2.5 cm 
in diameter, located 5 cm above the stainless steel grid floor, and contained an infrared 
detector placed 0.64 cm from the front edge of the panel for recording responses. Located 
outside chambers was a dual programmable ICSS stimulator (PHM-150B/2, Med 
Associates) that was interfaced to a computer to deliver electrical current to the electrode.  
Chambers were interfaced to a PC computer using Med-PC IV software that controlled 
all stimulation parameters, test functions, and data collection (Med Associates).   
Experimental Design: ICSS Procedures 
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The procedure for measuring reward thresholds was a modified version of the 
discrete trials current-threshold method (Kornetsky et al., 1979; Markou and Koob, 
1992). During all ICSS phases, stimulation availability was signaled by illumination of 
the nose poke aperture by the LED stimulus light complex. Rats initiated training on a 
FR1 schedule of reinforcement where nose pokes resulted in the delivery of a 200 µsec 
square-wave cathodal pulses at 100 Hz at a current of 120 µA.  After acquisition criteria 
were met (> 600 responses in 30 min for 2 sessions), rats began discrete-trials training 
procedures. Each discrete trial began with a free stimulation of 120 µA, followed by a 7.5 
second period during which the first response (trial response) yielded an identical 
stimulation. Following the trial response, LED lights turned off and subsequent responses 
(inter-trial interval (ITI) responses) were recorded, but yielded no stimulation.  
Progression through discrete trials training required rats to meet criterion (>60% of total 
response were trial responses) at four ITI lengths (2, 5, 10, and 15 sec). Upon completing 
training, rats then began discrete-trials current-threshold determination procedures.  Each 
current threshold determination session began with 120 µA of current and progressed 
through 4 cycles of ascending and descending current intensities.  At a given current 
intensity, trial blocks began with a free stimulation, followed by 7.5 seconds during 
which the animal could emit a nose-poke response to receive an identical stimulation.  
Following a single trial response, LED stimulus lights turned off initiating an ITI period 
between 7.5 and 15 seconds (mean of 10 second) that separated trials.  Responses during 
the ITI interval further lengthened the ITI by 12.5 seconds.  When animals emitted 
appropriate responses on ≥3 of 5 trials, electrical stimulation decreased by 5 µA for the 
next 5-trial block. Block intensities continued to descend until rats responded ≤2 out of 5 
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trials during a given trial block, at which point the current intensities reversed into 
ascending mode, with increases in current intensities of5 µA each for the subsequent 
block. Thus, the procedure determined the minimum amount of current (threshold) for 
which the rat was willing to respond. Thresholds were calculated by averaging the 
midpoint of current intensities between positive (responses on ≥3 of 5 trials) or negative 
(responses on ≤2 of 5) trial blocks. Rats received a minimum of 10 days of baseline 
threshold assessment and were required to meet stable baseline criteria prior to 
administration of MDPV, defined as when the average of thresholds for the last 4 days 
minus the first 4 days of an 8-day window was less than 10% of the average of the full 8 
days. Rats continued to receive baseline testing throughout the course of the experiment 4 
days per week.  Rats received vehicle injections 20 min prior to placement in ICSS 
procedures. MDPV doses were assigned randomly and injections given 20 minutes prior 
to threshold determination procedures.  All rats, with the exception of one that was 
removed halfway through MDPV testing due to loss of cranial implant, underwent 2 
determinations of each dose of MDPV, and 5 determinations of vehicle. 
Statistical Analysis 
 All statistical analyses were conducted using IBM SPSS Statistics version 19 
(Armonk, New York, USA).  All data points represent mean ± SEM. A significance 
criterion of p<0.05 was used for all analyses. For the first 10 IVSA sessions, the ability of 
MDPV to maintain responding was first analyzed separately for each dose of MDPV by a 
mixed analysis of variance (ANOVA) with lever (active vs. inactive) and session as 
factors. Post-hoc one-way ANOVAs were also conducted to determine the number of 
sessions required to obtain lever discrimination. The total number of MDPV infusions 
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obtained per session was analyzed by a mixed ANOVA with MDPV dose and session as 
factors. Holm-Sidak post-hoc tests determined overall dose effects, and one-way 
ANOVAs followed by Holm-Sidak post-hoc tests further determined dose effects during 
each session. Analysis of the total number of infusions obtained during PR sessions at 
different doses of MDPV were analyzed by a one-way between subjects ANOVA 
followed by Holm-Sidak post-hoc tests. The 0.05 mg/kg dose of methamphetamine and 
MDPV was analyzed separately by an independent samples t-test. For ShA vs LgA IVSA 
sessions, the effects of session length (ShA vs. LgA) on total infusions obtained was 
analyzed by mixed ANOVA for each dose of MDPV or methamphetamine.  Post-hoc one-
way ANOVAs further explored differences in the number of infusions obtained across 
MDPV doses for each session. To determine escalation of drug intake, mixed ANOVAs 
for each dose of MDPV or methamphetamine were conducted with infusions obtained in 
ShA vs. LgA (first 2 hr only) and session as factors. Post-hoc tests compared each session 
separately.  For the 0.1 and 0.2 mg/kg dose groups, repeated measures ANOVAs were 
conducted separately for ShA, LgA, and LgA (first 2 hr) to determine if drug intake 
escalated across time (session 1 – 10) as determined by significant increases over the first 
session of the ShA vs. LgA phase. For Experiment 2, raw ICSS current intensity 
thresholds (in µA) for all baseline sessions conducted after drug-administration tests 
began were first compared to vehicle sessions with a t-test to assess for potential injection 
effects. Next, ICSS current intensity thresholds were obtained following all doses, 
including vehicle, and converted to scores reflecting the percent change from thresholds 
obtained following vehicle administration for each rat. Threshold measures following 
vehicle treatment were calculated by averaging ICSS thresholds obtained across the 5 
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vehicle test days. Percentage change scores were analyzed by one-way repeated measures 
ANOVA. 
Results 
Experiment 1: Self-Administration of MDPV in 2 hr/day Sessions 
For the 0.05 mg/kg dose group, a significant main effect of lever (F[1,13]=8.67, 
p<0.01) and session (F[9,117]
 
=2.64, p<0.01) was observed, but a lever x session 
interaction was not found. Presses on the active lever were significantly greater than 
those on the inactive lever for sessions 4 through 10 (p<0.01), indicating that rats 
successfully learned to discriminate between active and inactive levers after 4 
experimental sessions (Fig. 6a). 
For the 0.1 mg/kg dose group, a significant main effect of lever (F[1,13]=6.06, 
p<0.05) was observed, but significant effects of session or a lever x session interaction 
were not observed. Presses on the active lever were significantly greater than those on the 
inactive lever for sessions 4 through 10 (p<0.01), indicating that rats successfully learned 
discriminate between the active and inactive levers after 4 experimental sessions (Fig. 
6b). 
For the 0.2 mg/kg dose group, a significant effect of lever (F[1,16]=14.06, 
p<0.01), session (F[9,144]=3.872, p<0.001), and a lever x session interaction 
(F[9,144]=2.731, p<0.01) were observed. Presses on the active lever were significantly 
greater than those on the inactive lever for all sessions (p<0.01), indicating that rats 
successfully discriminated between the active and inactive levers (Fig. 6c). Similar lever 
discrimination was observed in rats self-administering methamphetamine (data not 
shown). 
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When analyzing overall drug intake (number of drug infusions), significant main 
effects of MDPV dose (F[2,24]=6.96, p<0.01), session (F[9,216]=3.791, p<0.01), and a 
dose x session interaction (F[18, 216]=2.15, p<0.01) were observed.  The overall number 
of infusion obtained per 2 hr session across all 10 sessions was significantly greater in the 
0.05 mg/kg dose group as compared to 0.2 mg/kg dose groups (p<0.05) and approached 
significance compared to the 0.1 mg/kg dose group (p=0.07).  Post-hoc comparisons 
revealed significant differences in the number of infusions obtained in the 0.05 vs. 0.1 
mg/kg dose groups, and in the 0.05 vs. 0.2 mg/kg dose group for sessions 6 through 10 
(p<0.05, Fig. 6d) 
Progressive Ratio Responding 
Under a PR schedule of reinforcement, a significant effect of MDPV dose 
(F[2,24]=7.472, p<0.01) was observed for the total number of infusions obtained prior to 
cessation of responding (i.e., breakpoints) (Fig. 7).  Post-hoc tests revealed that the 
number of infusions obtained in the 0.2 mg/kg dose group were significantly greater than 
those in the 0.05 (p<0.001) and the 0.1 mg/kg (p<0.05) dose groups. Thus, there appeared 
to be positive relationship between MDPV dose and breakpoints for MDPV 
reinforcement. Rats self-administering methamphetamine exhibited breakpoints that were 
similar to those in rats self-administering the 0.05 mg/kg dose of MDPV and a t-test 
revealed no significant difference, p >0.05. 
Self-Administration of MDPV during ShA vs. LgA 
For the 0.05 mg/kg dose group, no significant effects of session or session length 
were observed (Fig. 8a).  For the 0.1 mg/kg dose group, a significant effect of session 
length (F[1,7]=18.644, p<0.01) was observed, but no effect of session or a session length 
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x session interaction were found. The number of infusions obtained was significantly 
greater in LgA vs. ShA groups for all experimental sessions (p<0.05).  Additionally, a 
significant effect of session was observed for LgA rats (F[9,27]=2.285, p<0.05), but not 
for ShA, such that the number of infusions obtained during sessions 8, 9 and10 were 
significantly greater than those observed during session 1 (p <0.05, Fig. 8b). 
For the 0.2 mg/kg dose group (Fig. 8c), a significant effect of session length 
(F[1,7]=50.209, p<0.001) was observed, but no effect of session nor a session length x 
session interaction was observed. The number of infusions obtained was significantly 
greater in LgA vs. ShA groups for all experimental sessions (p<0.01).  A significant effect 
of session for LgA rats was observed (F[9,27]=2.288, p<0.05), and post-hoc tests 
revealed that the number of infusions obtained was significantly higher during sessions 4 
through 10 as compared to session 1 (p<0.05). Taken together, these results revealed that 
rats self-administering the 0.1 or 0.2 mg/kg/infusion dose of MDPV under LgA 
conditions displayed escalated drug intake across experimental sessions. 
 Additional analyses were conducted to determine if escalation of intake also 
occurred during the first 2 hr of 6 hr LgA sessions. No significant increases in the number 
of infusions during the first 2 hr of LgA sessions were evident in rats self-administering 
the 0.1 mg/kg dose of MDPV. However, in rats self-administering the 0.2 mg/kg dose, a 
significant effect of session (F[9,36]=3.924, p <0.005) was observed. Post-hoc tests 
revealed significant differences in the number of infusions obtained during the first 2 hr 
of LgA during sessions 3 through 10 as compared with session 1 (p<0.001). Thus, only 
rats self-administering the 0.2 mg/kg dose of MDPV displayed escalated drug intake 
during the first 2 hr of LgA. 
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 Rats self-administering methamphetamine under LgA conditions (Fig. 8d), a 
significant effect of session was observed for the number of infusions obtained during the 
entire 6 session (F[9,72]=7.413, p <0.001) as well as during the first 2 hrs of the LgA 
sessions (F[9,72]=6.359, p <0.001)  Post-hoc tests revealed significant differences in the 
number of infusions obtained during the entire LgA during sessions 5 through 10 as 
compared with session 1 (p<0.001), as well as significant differences in number of 
infusions obtained in the first 2 hr of LgA during sessions 6 through 10 as compared with 
session 1 (p<0.001). 
Experiment 2: Effects of MDPV on Thresholds for ICSS 
 An independent samples t-test revealed no significant differences between 
baseline and vehicle scores (t[58] = -1.39, p > 0.05). A significant effect of MDPV dose 
(F4,35=11.549, p<0.001) on thresholds for ICSS was observed (Fig. 9).  When compared 
to vehicle, ICSS thresholds following MDPV administration were significantly lower at 
all doses tested (p<0.05). 
 
Discussion 
 To our knowledge, this is the first systematic verification of the reinforcing effects 
of MDPV in rats. The current study revealed that during daily 2 hr IVSA sessions, all 
doses of MDPV tested maintained active lever responding across experimental sessions, 
and rats successfully discriminated between active and inactive levers by the 4th day of 
self-administration.  Furthermore, significant dose effects on MDPV intake were 
observed as measured by the total number of infusions obtained during experimental 
sessions.  Following stable responding on IVSA procedures, a PR test revealed a positive 
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relationship between MDPV dose and reinforcing efficacy, as measured by breakpoints 
for MDPV self-administration. Breakpoints for methamphetamine reinforcement at a 
dose of 0.05 mg/kg/infusion were similar to those obtained for the same dose of MDPV. 
Under extended access conditions (6 hr/day), an escalation of MDPV intake at the 0.1 
and 0.2 mg/kg doses was observed for the entire extended access session, and this also 
occurred during the first 2 hr of LgA sessions for the 0.2 mg/kg dose, but not for other 
doses. Extended access to methamphetamine also produced escalation of drug intake.  
Finally, a reduction in ICSS thresholds across all doses of MDPV following acute 
administration was observed, indicating an increase in brain reward function.   
 The IVSA method was chosen for the present study given the high degree 
correspondence between drugs that can have addictive potential in humans and drugs that 
function as reinforcers in IVSA procedures in animals (Collins et al., 1983). In order to 
establish that a drug functions as a reinforcer in IVSA procedures, a number of criteria 
need to be met, including higher responding  on the active vs. inactive lever, and 
responding must show orderly and differential effects across a range of drug doses 
(Meisch, 1987). The first criterion was verified across the first 10 days of IVSA 
procedures during which all MDPV doses maintained active lever pressing while inactive 
lever pressing progressively declined. These results suggest that responding occurred due 
to the reinforcing effects of MDPV and not as the result of any indirect locomotor or 
general response-enhancing effects of MDPV. The second criterion was also met when 
results revealed an orderly inverse dose-effect on total drug intake (i.e., number of 
infusions obtained) such that animals received the fewest infusions for the 0.2 mg/kg 
dose, followed sequentially by the 0.1 and 0.05 mg/kg doses.  This inverse pattern 
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between dose and drug intake replicates findings of abused stimulants under continuous 
schedules of reinforcement, and likely represents the upper end of the typical inverse U-
shaped pattern typically seen across wider dose ranges (Panlilio, 2011).  In addition, the 
results of the present study are strikingly similar to self-administration patterns for 
methamphetamine under nearly identical experimental conditions and doses (present 
study and (Gass et al., 2009).  This finding provides evidence of similar potencies 
between MDPV and methamphetamine. Together, these findings indicate that MDPV 
likely possess a potential for abuse similar to that of methamphetamine and other 
stimulants.    
 The progressive ratio schedule of reinforcement has been used extensively to 
evaluate the reinforcing efficacy of drugs of abuse, as it is an index of the motivation to 
obtain infusions of the drug in the face of increasing behavioral demand. PR schedules 
have consistently shown a positive relationship between dose and reinforcer efficacy, and 
this relationship has been consistently observed with other abused stimulants such 
cocaine (Roberts et al., 1989), d-amphetamine, and methamphetamine (Richardson and 
Roberts, 1996). The results from the present study also revealed this positive relationship 
between MDPV dose breakpoints for MDPV reinforcement. As with responding on the 
FR1 schedule above, under the same PR schedule with identical doses (0.1 and 0.2 
mg/kg/infusion), breakpoints for MDPV self-administration were similar to those we and 
others have previously observed for methamphetamine (Gass et al., 2009; Richardson and 
Roberts, 1996) as well as D-amphetamine (Richardson and Roberts, 1996). In addition, 
breakpoints for MDPV self-administration under PR conditions at a dose of 0.05 
mg/kg/infusion were similar to those observed in rats self-administering the same dose of 
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methamphetamine, further demonstrating methamphetamine-like potency and reinforcing 
efficacy of MDPV. 
While demonstrating that a drug functions as a reinforcer is an important first step 
in determining abuse liability, such observations do not unequivocally indicate the 
potential for addiction potential in humans (Ahmed, 2011).  One of the defining 
characteristics of drug addiction is an escalation in drug use, often due to tolerance to the 
reinforcing effects of the drug (American Psychiatric Association, 2004).  As a result, a 
common procedure for modeling human patterns in animals has been termed the 
“escalation model” (Ahmed and Koob, 1998). In this procedure, animals are given 
extended access to the drug (typically 6 – 12 hr/day access sessions) vs. traditionally 
employed shorter access (1 – 2 hr/day). As a result of extended access to the drug, 
animals display an escalation in drug intake that parallels intake patterns characteristic of 
compulsive drug-seeking and addiction in humans (Ahmed, 2011).  The current study 
revealed that, during extended access to MDPV, rats responding for the two highest doses 
of MDPV displayed a significant escalation in overall drug intake across the final 10 
experimental sessions. Furthermore, this escalation was also seen during the first 2 hrs of 
LgA sessions for the high dose of 0.2 mg/kg. These findings are similar to those reported 
for other addictive stimulants including cocaine (Ahmed and Koob, 1998), D-
amphetamine (Gipson and Bardo,  2009) and methamphetamine (Kitamura et al., 2006), 
and the present study also demonstrated escalation of methamphetamine intake at a dose 
of 0.05 mg/kg/infusion .  Unlike these studies, however, our results revealed escalation of 
drug intake at higher rather than lower doses. These data suggest that MDPV may possess 
some unique reinforcing properties that are not reflective of other prototypical stimulants 
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such as methamphetamine. While additional comparative studies are needed to further 
corroborate these findings, the current results further strengthen the possibility that 
MDPV possesses the potential for compulsive use in humans. 
 Olds and Milner first discovered that rats would show a place preference for and 
perform an operant task to receive ICSS (Olds and Milner, 1954), and numerous studies 
have revealed that both ICSS and drug reinforcers likely active the same brain reward 
circuitry (Wise, 1996).  Drug-induced lowering of ICSS thresholds is generally accepted 
to be due to the facilitation of brain reward functioning, providing a direct measure of the 
hedonic and rewarding properties of drugs of abuse (Panlilio, 2011), and nearly all 
abused stimulants including cocaine (Esposito et al., 1978), amphetamine (Horovitz et al., 
1972), and methamphetamine (Sarkar and Kornetsky, 1995) lower ICSS thresholds.  The 
current results reveal that, when using the discrete-trials current threshold procedure, 
MDPV lowers ICSS thresholds across a wide range of doses as compared to vehicle.  
Thus, these findings both parallel previous findings with other addictive stimulants and 
provide further evidence that MDPV possesses similar rewarding properties. 
 In summary, the current study demonstrates that the synthetic cathinone MDPV 
possesses potent reinforcing properties and suggests a high degree of abuse potential in 
humans. The results revealed that MDPV dose-dependently functions as a reinforcer on a 
continuous reinforcement schedule.  A positive relationship between MDPV dose and 
reinforcer efficacy was demonstrated in during progressive ratio testing, and breakpoints 
for MDPV reinforcement at the lowest dose tested were similar to those for the same dose 
of methamphetamine.  Extended access to MDPV produced escalated intake over time for 
the two higher doses, indicative of a compulsive pattern of intake characteristic of 
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addiction in humans. Finally, the ability of MDPV to lower thresholds for ICSS provides 
further evidence of hedonic and rewarding effects of MDPV. Taken together, these results 
suggest that that MDPV possesses a strong potential for compulsive use and addiction in 
humans.  These findings have important implications for future research on synthetic 
cathinone addiction, as well the development of appropriate drug policies and legislative 
measures regarding its status as a controlled substance. 
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CHAPTER 5 
THE REINFORCING AND REWARDING EFFECTS OF METHYLONE, A 
SYNTHETIC CATHINONE COMMONLY FOUND IN “BATH SALTS.” 
Published in Journal of Addiction Rresearch and Therapy, 2012 
Methylone (3,4-methylenedioxymethcathinone (MDMC), 2-methylamino-1-(3,4- 
methylenedioxyphenyl)propan-1-one, or bk-MDMA) is a member of the designer drug 
class known as synthetic cathinones. These emerging drugs of abuse are derivatives of 
cathinone, a beta-ketone amphetamine with known abuse potential (Patel, 2009) and the 
primary active alkaloid of the Catha edulis (Khat) plant (Magdum, 2011). In recent years, 
synthetic cathinones have become increasingly popular as “legal highs” due to online 
marketing, media coverage, and availability in convenience stores, head shops, and the 
internet (D. E. A. United States Department of Justice, 2011c). While most commonly 
sold as “bath salts”, these drugs have been falsely sold as many different commercial 
products such as “plant food”, “room odorizer”, and “iPod cleaner”, and typically contain 
labels stating “not for human consumption” as a means of evading regulatory controls (D. 
E. A. United States Department of Justice, 2011a).  Desired effects of these drugs include 
euphoria, appetite suppression, and increases in energy, focus, libido, and empathy 
(Prosser & Nelson, 2012). However, an increasing number of calls to national poison 
control centers (American Association of Poison Control Centers, 2012) and numerous 
reports of toxicity (Prosser & Nelson, 2012), adverse psychological and behavioral 
effects (Spiller et al., 2011), and death (8-10) have been reported.  While many synthetic 
cathinone analogues have been discovered in drug seizures, the three most common are 
methylenedioxypyrovalerone (MDPV), methylone, and mephedrone (D. E. A. United 
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States Department of Justice, 2011c).  In October 2011, these three substances were 
temporarily classified as Schedule I substances in the United States (D. E. A. United 
States Department of Justice, 2011b). Interestingly, only mephedrone and MDPV were 
permanently classified as Schedule I substances with the Synthetic Drug Abuse 
Prevention Act in July 2012 (One Hundred Twelfth Congress of the United States of 
America, 2012) while the temporary schedule I status of methylone was extended until 
April, 2013 (D. E. A. United States Department of Justice, 2012).  Despite these new 
regulatory controls, U.S. Poison Control Centers continue to receive calls regarding “bath 
salts” (American Association of Poison Control Centers, 2012), likely from continued 
abuse of mephedrone, MDPV, and methylone along with unscheduled structurally similar 
analogues. 
While the rise in abuse of synthetic cathinones is now well documented, little 
information exists about the relative abuse liability of these compounds and whether 
consumption patterns are primarily episodic (i.e., recreational) or compulsive (i.e., 
characteristic of addiction). Given recent permanent scheduling for only mephedrone and 
MDPV, it is not surprising that most investigations of abuse potential have focused on 
these two synthetic cathinones, and relatively little attention has been given to methylone.  
We have recently shown that rats will dose-dependently maintain intravenous MDPV 
self-administration in short access (ShA, 2 hr/day) intravenous self-administration 
(IVSA) sessions.  We also demonstrated significant dose effects for reinforcer efficacy 
(i.e., breakpoints) between each of the doses tested (0.05, 0.1, and 0.2 mg/kg/infusion) on 
a progressive ratio schedule of reinforcement. Finally, under long access (LgA, 6 hr/day) 
conditions, rats in the two highest dose groups also displayed escalated MDPV intake 
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suggesting the potential for compulsive use in humans.  The reinforcing effects of MDPV 
were complemented with significant dose-dependent reductions in ICSS thresholds, 
indicative of hedonic and rewarding properties (Watterson et al., 2014). With regards to 
mephedrone, studies by other investigators have shown that rats will self-administer 
mephedrone intravenously under ShA conditions (Hadlock et al., 2011), and in mice 
mephedrone elicits conditioned place preference (CPP) and increases in locomotor 
activity (Kehr et al., 2011), leads to locomotor sensitization (Lisek et al., 2012), and 
lowers ICSS thresholds (J. Robinson, Agoglia, Fish, Krouse, & Malanga, 2012).  
The existing behavioral and neurochemical data suggest that methylone may 
possess the potential for compulsive use. Behavioral studies have shown that methylone 
elicits CPP at doses of 2.5 mg/kg or higher in mice (Miyazawa, Kojima, & Nakaji, 2011) 
and substitutes for 3,4-methylenedioxymethamphetamine (MDMA) in a drug-
discrimination paradigm (Dal Cason, Young, & Glennon, 1997). Furthermore, methylone 
possesses psychomotor stimulant effects in mice, but to a lesser extent compared to 
methamphetamine (Dal Cason et al., 1997; Marusich, Grant, Blough, & Wiley, 2012).   
As mentioned above, synthetic cathinones are similar in chemical structure to 
amphetamines. Methylone is the benzylic ketone analog of MDMA and, not surprisingly, 
has been shown to have similar neurochemical effects on monoamine transporters.  
Uptake inhibition studies have reported that methylone blocks the reuptake of 
norepinephrine, dopamine, and serotonin plasma membrane transporters (NET, DAT, and 
SERT, respectively) with a profile similar to that of methamphetamine and MDMA, but 
with greater potency than methamphetamine for SERT, and three-fold less potency for 
SERT compared to MDMA (22,23). Methylone has also been shown to be a less potent at 
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inhibiting the vesicular monoamine transporter 2 (VMAT2) compared to 
methamphetamine, MDMA (Cozzi et al., 1999), and mephedrone (López-Arnau, 
Martinez-Clemente, Pubill, Escubedo, & Camarasa, 2012).  However, while uptake 
assays suggest that methylone functions as a transporter blocker, these assays are unable 
to discern between drugs that are transporter blockers versus those that are monoamine 
releasing agents, as tissue accumulation of radiolabeled transmitters is decreased by both 
drug types (Baumann et al., 2012). However, additional studies have clarified these 
discrepancies and reveal that methylone is a non-selective monoamine releaser with 
properties similar to MDMA (Baumann et al., 2012; Nagai, Nonaka, & Satoh Hisashi 
Kamimura, 2007). Also, in comparison to MDMA, methylone produces qualitatively 
similar, but less potent, increases in extracellular monoamine levels in the nucleus 
accumbens (Baumann et al., 2012). 
These neurochemical effects, along with the few behavioral studies outlined 
above, suggest that methylone may possess the potential for compulsive use.  However, 
to our knowledge, there are no published reports showing that laboratory animals will 
acquire intravenous self-administration of methylone or if extended access to methylone 
(i.e., 6 hr/day) leads to escalated drug intake, a consumption pattern predictive of 
compulsive use in humans (Ahmed, 2012).  The present study examined whether 
methylone would support IVSA at doses of 0.05, 0.1, 0.2, or 0.5 (mg/kg/infusion) under 
short (ShA, 2 hr/day) and long (LgA, 6 hr/day) access conditions. A separate group of 
animals was tested for effects of methylone (0.1-10 mg/kg i.p.) on current intensity 
thresholds for ICSS. 
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Method 
Subjects 
All experimental procedures were conducted with the approval of the Institutional 
Animal Care and Use Committee at Arizona State University and according to the Guide 
for Care and Use of Laboratory Animals as adopted by the National Institutes of Health. 
Male Sprague-Dawley rats (n=48), weighing approximately 250 g upon arrival, were 
implanted with jugular vein catheters at Harlan Laboratories (Livermore, CA, USA) and 
used for intravenous self-administration procedures.  An additional 4 non-catheterized 
male Sprague-Dawley rats, weighing approximately 250 g (Harlan Laboratories) were 
used for ICSS procedures.  Upon arrival, all rats were individually housed on a 12-hour 
light-dark cycle and provided ad libitum access to food and water during all procedures, 
except during surgical and behavioral testing procedures.  All experimental procedures 
were conducted during the dark phase with the exception of 16 hr overnight progressive 
ratio tests which began at approximately 4:00 PM and ended the following morning at 
approximately 8:00 AM.   
Drugs  
Methylone was synthesized by the Department of Discovery and Analytical 
Sciences at Research Triangle Institute (RTI) International (Research Triangle Park, NC, 
USA). Methylone was dissolved in sterile physiological saline for intravenous self-
administration and intraperitoneal administration. 
Experiment 1: IVSA Procedures 
Surgical Procedures 
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Following one day of acclimation to housing conditions, rats were anesthetized 
with isoflurane (2% v/v) vaporized oxygen at a flow rate of 2 l/min.  A 2.5-cm 
longitudinal incision was made between the scapulae for implantation of a threaded 
vascular access port (Plastics One, Roanoke, VA, USA).  A mesh collar attached to the 
port was sutured underneath the surrounding tissue within the incision.  Access ports 
were sealed with a piece of Tygon tubing and protective cap. Rats received one week of 
post-operative care including daily infusions of 0.4 ml Timentin (66.6 mg/ml, in 70 U/ml 
heparinized saline) to protect against infection and ensure catheter patency.  Meloxicam 
(2.5 mg/kg, s.c.) was administered for the first 3 days following surgery procedures to 
provide relief from post-surgical discomfort.  Rats also received approximately 8–10 
pieces of a sweetened cereal in their home cage each day during the recovery period to 
minimize post-surgical weight loss.   
Apparatus 
Operant drug self-administration sessions were conducted in modular self-
administration chambers (ENV-008, Med Associates, St. Albans, VT, USA).  All self-
administration chambers were located inside sound-attenuating cubicles containing a 
house light and exhaust fan designed to mask external noise and odors, and were 
interfaced to a personal computer.  Chambers contained two stainless steel response 
levers located on one wall with a 4.2 x 5 cm food pellet receptacle placed between the 
levers. Response levers were located approximately 7 cm above the grid floor and 
positioned above each lever was a 2.5-cm diameter white stimulus light.  Located near 
the top of the chambers was a Sonalert speaker that provided an auditory stimulus during 
drug delivery.  Syringe pumps were located outside each chamber, interfaced to a PC 
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computer, and delivered methylone solution via a single-channel liquid swivel mounted 
atop the chambers via polyethylene tubing.    
Experimental Design: IVSA Procedures 
Following recovery from surgical procedures, rats began experimental sessions 
and were allowed to spontaneously acquire intravenous self-administration in 2-hour 
daily (ShA) sessions for 21 days.  IVSA procedures were conducted 7 days a week as 
described elsewhere (13,27).  Briefly, active lever presses delivered the drug reinforcer 
on an FR1 schedule of reinforcement.  Methylone was delivered to the vascular access 
port by polyethylene tubing housed in a stainless steel spring tether that was attached to a 
liquid swivel. Reinforcers were accompanied by activation of a stimulus light and tone 
complex for 2 sec, followed by a 20-sec timeout period during which additional lever 
presses were recorded but produced no consequences.  Inactive lever presses were also 
recorded, but produced no programmed responses at any time during the experiment.  
Rats were randomly assigned to one of four groups based upon methylone dose (0.05, 
0.1, 0.2, or 0.5 mg/kg per infusion). Each drug infusion was delivered in a volume of 0.06 
ml. Both before and after each IVSA session, access ports were flushed with 0.2 ml 
Timentin (66.6 mg/ml, in 70 U/ml heparinized saline) to protect against infection and 
ensure catheter patency. 
 Following 21 days of ShA IVSA, rats were in a 16 hr overnight progressive ratio 
(PR) sessions.  For PR sessions, methylone was delivered on a schedule determined by 
the following equation: responses per reinforcer delivery =5 x e(injection number - 0.2) - 5 (i.e. 1, 
2, 4, 6, 9, 12, 15, 20, 25, 32, 40, etc.) (N. R. Richardson & Roberts, 1996).  Breakpoints 
were considered to be obtained when rats did not emit any active lever presses for 2 hr.  
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Following PR tests, all rats were placed into 6 hr LgA sessions on a FR1 schedule for 10 
additional days to assess escalation of drug intake.  Finally, following 10 days of LgA 
sessions, rats were placed into an additional PR session to assess any changes in 
reinforcer efficacy following extended access. For both PR and LgA sessions, all aspects 
of IVSA sessions were identical except for session length and number of lever presses 
required for an infusion.   
 Based on earlier MDMA self-administration studies (Schenk et al., 2007), 
methylone was considered to function as a reinforcer for individual rats when responding 
on the active lever exceeded 10 lever presses per session.  Figure 11b shows the 
percentage of rats for each dose group that responding greater than 10 times on the active 
lever for each experimental session.  
Experiment 2: ICSS Procedures 
Surgical Procedures 
Rats were anesthetized with isoflurane (2% v/v) vaporized oxygen at a flow rate 
of 2 l/min and placed into a stereotaxic frame. A twisted stainless steel bipolar electrode 
(PlasticsOne, Roanoke, VA, USA; 2 mm diameter, insulated except at the ventral tip) 
was implanted into the medial forebrain bundle (anterior-posterior -0.05 mm; medial-
lateral, 1.7 mm, dorsal-ventral, -8.3 mm from dura and bregma). Four skull screws and 
dental cement were used to permanently secure electrodes to the skull. To counterbalance 
for any hemispheric differences, half of the animals received electrodes in the left 
hemisphere and the other in the right hemisphere. Following surgery, the rats were given 
7 days of recovery prior to commencement of ICSS procedures, during which they 
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received daily injections of 2.5 mg/ml meloxicam (0.15 ml volume) to minimize post-
surgical discomfort. 
Apparatus 
All ICSS testing was conducted in modular chambers (ENV-007CT; Med 
Associates). Chambers were housed inside sound-attenuating cubicles equipped with an 
exhaust fan to mask external noise and odors. Chambers contained front wall mounted 
nose-poke aperture with light-emitting diode (LED) stimulus lights located inside the 
access hole (ENV-114M; Med Associates). The nosepoke aperture was 2.5 cm in 
diameter, located 5 cm above the stainless steel grid floor, and contained an infrared 
detector placed 0.64 cm from the front edge of the panel for recording responses. Located 
outside the chamber was a dual programmable ICSS stimulator (PHM-150B/2; Med 
Associates) that was interfaced to a PC which delivered electrical current to the electrode. 
MED-PC IV software was used to control all stimulation parameters, test functions, and 
data collection. 
Experimental design: ICSS procedures 
The procedures for determination of ICSS thresholds was a modified version of 
the discrete trials current-threshold method (Kornetsky et al., 1979; Markou & Koob, 
1992).  For a detailed review of the procedures used here, please see methods in 
(Watterson et al., 2014). Briefly, following acquisition procedures, reward threshold 
training commenced and rats were tested for a minimum of 10 days until stable baseline 
levels of reward thresholds were achieved (defined as when the average of thresholds for 
the last 4 days minus the first 4 days of an 8-day window was less than 10% of the 
average of the full 8 days). Rats continued to undergo baseline (i.e., no drug 
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administration) testing throughout the course of experiments every three days.  Rats 
received vehicle injections 20 min prior to ICSS threshold determination procedures 
every 3 days. Methylone doses (0.1, 0.5, 1, 3, 5, and 10 mg/kg, i.p.) were assigned 
randomly and injections given 20 min prior to threshold determination procedures every 
three days. All rats received 4 to 5 threshold determinations at each dose of methylone 
and at least 10 threshold determinations following administration of saline vehicle. 
Statistical Analysis 
All statistical analyses were conducted using SPSS version 20 (Armonk, NY, 
USA).  All data points represent the mean ± standard error of the mean (SEM).  A 
significance criterion of p<0.05 was used for all analyses. For Experiment 1 during the 
initial 21 days of self-administration procedures, individual methylone doses were 
analyzed by a mixed analysis of variance (ANOVA) with lever (active versus inactive) as 
between measures factors and session number (1–21) as the repeated measures factor.  
Post-hoc one-way ANOVAs were conducted to determine when successful lever 
discrimination occurred. The total number of infusions obtained during experimental 
sessions was also analyzed with a mixed ANOVA with methylone dose (0.05, 0.1, 0.2, 
and 0.5 mg/kg) as between measures factors and session number (1-21) as the repeated 
measures factor.  Holm-Sidak post-hoc tests further analyzed dose effects for each 
session.  The total number of infusions obtained during PR tests was analyzed in a mixed 
ANOVA with dose as the between measures and PR tests (before and after LgA) as the 
repeated measures with Holm-Sidak post-hoc tests.  For LgA sessions, the total number 
of infusions obtained during experimental sessions was analyzed with a mixed ANOVA 
with methylone dose and session number (1-10) as the repeated measures factor. 
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Furthermore, one-way repeated measures ANOVAs were conducted for each dose 
separately to analyze for escalation of drug intake across experimental sessions.  Data 
from rats removed from the study due to overdose or loss of catheter patency were 
removed from statistical analyses.  For Experiment 2, raw ICSS current intensity 
thresholds (in µA) obtained following all doses and vehicle were converted to scores 
reflecting the percent change from mean baseline scores obtained following stabilization 
for each rat. Threshold measures following baseline days were calculated by averaging 
ICSS thresholds obtained across all baseline days following initial stabilization. 
Percentage change scores were analyzed by one-way repeated measures ANOVA.  
 
Results 
Lever Discrimination During ShA  
Throughout the course of the study, 3 of 48 rats were removed from experimental 
procedures due to catheter patency failure. Also, 2 additional rats in the 0.5 
mg/kg/infusion group died on LgA days 7 and 10, respectively, presumably due to 
overdose. For the 0.05 mg/kg dose group (as shown in Fig. 10a), significant main effects 
of lever (F[1,21]=8.54, p<0.01) and session number (F[20,420]=2.07, p<0.01) were 
observed, as well as a significant lever X session number interaction (F[20,420]=2.73, 
p<0.001).  Presses on the active lever were significantly greater than on the inactive lever 
for sessions 3–21 (p<0.05) indicating that rats in the 0.05 mg/kg dose group successfully 
discriminated between the active and inactive levers after 3 experimental sessions.   
 For the 0.1 mg/kg dose group (as shown in Fig. 10b), significant main effects of 
lever (F[1,20]=8.59, p<0.01) and session number (F[20,400]=2.15, p<0.01) were 
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observed, as well as a significant lever X session number interaction (F[20,400]=2.48, 
p<0.001).  Presses on the active lever were significantly greater than on the inactive lever 
for sessions 6–21 (p<0.05) indicating that rats in the 0.1 mg/kg dose group successfully 
discriminated between the active and inactive levers after 6 experimental sessions.   
 For the 0.2 mg/kg dose group (as shown in Fig. 10c), significant main effects of 
lever (F[1,20]=6.07, p<0.05) and session number (F[20,400]=3.03, p<0.001) were 
observed, as well as a significant lever X session number interaction (F[20,400]=4.49, 
p<0.001).  Presses on the active lever were significantly greater than on the inactive lever 
for sessions 8–21 (p<0.05) indicating that rats in the 0.2 mg/kg dose group successfully 
discriminated between the active and inactive levers after 8 experimental sessions.   
 For the 0.5 mg/kg dose group (as shown in Fig. 10d), significant main effects of 
lever (F[1,22]=30.42, p<0.05) and session number (F[20,440]=6.25, p<0.001) were 
observed, as well as a significant lever X session number interaction (F[20,440]=7.14, 
p<0.001).  Presses on the active lever were significantly greater than on the inactive lever 
for sessions 2–21 (p<0.05) indicating that rats in the 0.1 mg/kg dose group successfully 
discriminated between the active and inactive levers after 2 experimental sessions.   
Infusions During ShA 
For overall methylone intake (as determined from the total number of drug 
infusions obtained, Fig. 11a) significant main effects of methylone dose (F[3,41]=6.477, 
p<0.001) and session (F[20,820]=25.67, p<0.001) were observed, along with a significant 
dose X sessions interaction (F[60,820]=4.579, p<0.001).  The overall number of 
methylone infusions obtained per 2 hr session across all 21 sessions was significantly 
greater in the 0.5 mg/kg group versus the 0.05 mg/kg group (p<0.01) and the 0.1 mg/kg 
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group (p<0.01).  Post-hoc tests revealed a greater number of infusions obtained at the 0.5 
mg/kg dose versus the 0.05 and 0.1 mg/kg dose group for days 11–21 (p<0.05).  
Progressive Ratio Tests 
Analysis of breakpoints (Fig. 12a) during PR sessions revealed significant main 
effects of methylone dose (F[3,37]=9.209, p<0.001) and PR session (F[1,37]=34.691, 
p<0.001). However, a significant dose X PR session interaction was not observed 
(F[3,37]=1.166, p>0.05).  For all doses tested, breakpoints decreased significantly from 
the first PR test (5.93 ± 0.52, mean ± SEM) to the PR test following LgA (3.34 ± 0.33, 
mean ± SEM).  Post-hoc tests revealed that the total number of infusions obtained in the 
0.5 mg/kg dose group was significantly greater than that of the 0.05 mg/kg (p<0.001), 0.1 
mg/kg (p<0.001), and 0.2 mg/kg doses (p<0.01). While there were no significant 
differences observed among the three lower doses, there did appear to be a positive 
relationship between methylone dose and breakpoints.   
Assessment of Escalated Intake During LgA 
Analysis of the total number of infusions obtained during LgA sessions (Fig. 12b) 
revealed a significant main effect of dose (F[3,38]=7.035, p<0.001). However, there was 
no significant main effect of session (p>0.05), and a dose X session interaction only 
revealed a trend towards significance (F[27,342]=1.466, p=0.06).  Pairwise comparisons 
revealed significant overall differences between the 0.05 mg/kg vs. the 0.2 and 0.5 mg/kg 
doses (p<0.05 and 0.001, respectively). No other pairwise comparisons between doses 
were significant. Analysis of escalation for each dose independently did not reveal 
escalated intake across experimental sessions for the 0.1 mg/kg and 0.2 mg/kg doses 
(p>0.05). Significance was obtained for both the 0.5 mg/kg (F[9,81]=2.315, p<0.05) and 
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0.05 mg/kg doses (F[9,81]=4.829, p<0.05). However this occurred as a result of reduced 
numbers of infusions across the 10 LgA sessions.  For the 0.5 mg/kg dose group, pairwise 
comparisons did not reveal significant differences between individual sessions.  For the 
0.05 mg/kg group, pairwise comparisons revealed that the significance occurred only 
between day 1 and day 2 (p<0.01). No other pairwise comparisons were significant.  
Assessment of ICSS Thresholds 
Repeated measures ANOVA did not reveal a significant effect of methylone dose 
on ICSS thresholds (Fig. 13), however a trend was observed (F[7,163]=1.783, p=0.09). 
Evidence of Toxicity 
In addition to the IVSA and ICSS results outlined above, it is also important to 
mention that during LgA sessions, a number of adverse effects of methylone self-
administration were observed.  The most common adverse effects were porphyrin 
staining and foaming at the mouth that typically began during sessions 3-4 of LgA 
conditions. These effects were observed in nearly all animals in the 0.5 mg/kg and 
roughly half of the 0.2 mg/kg group during the course of LgA procedures and, once 
manifested, typically continued until completion of the experiment.  Additionally, two 
rats in the 0.5 mg/kg group self-administered methylone to the point of seizure (after 114 
and 138 total infusions each), and despite being immediately removed from the self-
administration chamber, died within 20 mins of removal. 
 
Discussion 
The present study revealed that methylone serves as a reinforcer as rats dose-
dependently acquired IVSA of methylone through spontaneous acquisition procedures.  
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In Experiment 1, during 21 days of 2-hr daily access sessions, orderly dose-dependent 
differences in overall drug intake were observed across groups and rats successfully 
discriminated between active and inactive levers by days 3, 6, 8, and 2 for the 0.05, 0.1, 
0.2, and 0.5 mg/kg per infusion groups, respectively.  These findings indicate that 
responding occurred due to the reinforcing effects of methylone and not from any non-
specific response-enhancing effects of methylone.  This study further revealed a positive 
dose-dependent relationship between methylone dose and reinforcer efficacy as measured 
by breakpoints obtained during PR sessions both prior to and following LgA. 
Furthermore, while methylone intake was greater in LgA when compared to asymptotic 
responding during ShA sessions, none of the dose groups displayed escalated drug intake 
across experimental sessions.  Finally, Experiment 2 revealed that methylone did not 
significantly decrease ICSS thresholds, suggesting a lack of effect on brain reward 
function. 
To our knowledge, this study is the first to systematically verify that methylone 
serves as a reinforcer in the IVSA paradigm in drug-naïve animals.  To date, discussions 
about reinforcing effects and abuse liability of synthetic cathinones have largely come 
from its comparison to amphetamine-type stimulants such as methamphetamine and 
MDMA. Most often, methylone has been compared to MDMA due to its similar 
chemical structure, similar in vitro binding and in vivo neurochemical data, and the early 
reports that methylone produced subjective effects similar to MDMA, but lacked the 
“unique magic” produced by MDMA (Bossong, Van Dijk, & Niesink, 2005). Given this 
precedent, a comparison of the current results to previous work with MDMA serves as a 
logical starting point. However, it is important to state from the outset that comparisons 
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of the present results with earlier findings must be interpreted with caution, as each of 
these studies employed somewhat different experimental procedures. Initial MDMA 
IVSA experiments by multiple investigators that revealed that MDMA functions as a 
reinforcer in rats.  However, inconsistent and low response rates indicated that MDMA 
was a weak-to-moderate reinforcer since only a subset of animals acquired self-
administration (Bossong et al., 2005; Cole & Sumnall, 2003). Additional IVSA studies 
with rhesus monkeys and baboons also revealed similar weak-to-moderate reinforcing 
properties (Beardsley, Balster, & Harris, 1986; Fantegrossi et al., 2004). Later studies by 
Schenk and colleagues found that in a subset of rats, MDMA could support higher rates 
of self-administration than those observed in earlier reports (Schenk et al., 2007; Schenk, 
Colussi-Mas, Do, & Bird, 2012; Schenk, Gittings, Johnstone, & Daniela, 2003), 
corroborating reports in humans that compulsive use is possible in certain individuals 
(Jansen, 1999). When compared to the collective results from these studies of MDMA 
self-administration, methylone appears to support more robust self-administration 
responding than does MDMA, albeit with a rightward shift in the inverted dose-effect 
curve.  All methylone doses tested in the present study supported IVSA, and lever-
discrimination occurred for all rats on days 3, 6, 8, and 2 for the 0.05, 0.1, 0.2, and 0.5 
mg/kg/infusion groups, respectively.  Furthermore, as revealed in Fig. 11b, while only 
about 40-60% of rats pressed the active lever more than 10 times a session for the 0.05 
mg/kg group between sessions 15-21, the 0.1, 0.2, and 0.5 mg/kg/infusion groups 
demonstrated group acquisition percentages that were approximately 60, 80, and 100%, 
respectively.  Thus, at the higher doses, a larger percentage of rats acquired methylone 
IVSA in 2 hr daily sessions than rats self-administering MDMA in 6 hr daily access 
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sessions (i.e., 60% for both the 0.25 mg/kg/infusion and 1 mg/kg/infusion MDMA dose 
groups) using nearly identical acquisition criterion (>10 lever presses per session) 
(Schenk et al., 2007).  More recent work by Schenk and colleagues revealed that across 
25 days of 2 hr IVSA sessions MDMA (1.0 mg/kg/infusion), only 49% (63 of 128 rats) 
acquired a total of ≥ 90 infusions across experimental sessions (Schenk et al., 2012). The 
present study revealed that only 5 rats failed to accumulate ≥ 90 infusions by the end of 
session 21, with 3 of those rats being in the 0.05 mg/kg group, 1 in the 0.1 mg/kg group, 
1 in the 0.2 mg/kg group, and 0 in the 0.5 mg/kg group (data not shown). Together, these 
results are also consistent with previous studies showing that lower doses of methylone 
(≥2.5 mg/kg/i.p.) vs. MDMA (≥9 mg/kg/i.p.) elicit conditioned place preference in mice 
(Miyazawa et al., 2011; Robledo, Balerio, Berrendero, & Maldonado, 2004; Salzmann, 
Marie-Claire, Le Guen, Roques, & Noble, 2003; Tzschentke, 2007)(19,41-43).  
In addition, it is also important to mention differences in lever pressing behavior 
for methylone observed in the present study as compared to our previously findings with 
MDPV (Watterson et al., 2014), as these are the first two published studies to establish 
initial dose-effect curves for IVSA of these two synthetic cathinones.  Specifically, the 
highest methylone dose tested in the present study (0.5 mg/kg/infusion) lead to a 
maximum number of lever press of approximately 100 after roughly twenty 2 hr IVSA 
sessions.  In our previous MDPV study, the lowest dose tested (0.05 mg/kg/infusion) lead 
to approximately 200 active lever presses after only seven 2 hr IVSA sessions.  Thus, 
while future studies must establish full IVSA dose-effect curves before direct 
comparisons can be made between methylone and MDPV, our initial results suggest that 
MDPV is a much more potent reinforcer than methylone.   
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While our 2 hr IVSA acquisition data suggest stronger reinforcing properties of 
methylone compared to MDMA, our PR data appear similar to those obtained from 
previous studies on PR responding for MDMA.  For example, the total number of 
infusions obtained for MDMA doses of 0.25 and 1.0 mg/kg/infusion were approximately 
4.5 and 12.5, respectively (Schenk et al., 2007), whereas our present methylone results 
with (0.2 and 0.5 mg/kg/infusion) revealed similar breakpoints with approximately 5.5 
and 9.5 infusions, respectively. When compared to previous results with MDPV and 
prototypical stimulants d-amphetamine and methamphetamine, and using an identical PR 
procedures and doses (0.05, 0.1, and 0.2, mg/kg/infusion), methylone breakpoints in the 
present study were comparatively much lower (Gass et al., 2008; N. R. Richardson & 
Roberts, 1996; Watterson et al., 2014). Specifically, methylone breakpoints for these 
doses were approximately 4, 5, and 5.5, respectively, whereas our MDPV breakpoints 
were approximately 8, 10, and 15, respectively. Thus, the reinforcer efficacy of 
methylone appears to be significantly lower than that of MDPV. In addition to the initial 
progressive ratio tests following ShA procedures, the PR tests following extended access 
revealed similar dose effects, but compared to initial PR tests, the overall reinforcing 
efficacy was lower during the second test.  This apparent decease in motivation to seek 
methylone following LgA is in contrast to previous work with cocaine (Paterson & 
Markou, 2003) and methamphetamine (Sunmee Wee, Wang, Woolverton, Pulvirenti, & 
Koob, 2007) which have been shown to elicit greater PR responding following extended 
access. To our knowledge, PR data following LgA has not been reported for MDMA. 
These results suggest that methylone likely possesses a reinforcer efficacy that more 
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closely resembles MDMA and is similarly weaker compared to other prototypic 
stimulants (Ahmed, 2012)..                                                                                                                                                                    
In addition to the results obtained during ShA and PR procedures, LgA sessions 
did not lead to escalated drug intake across experimental sessions.  Our previous findings 
of responding for MDPV reinforcement under extended access conditions revealed 
escalated intake across LgA sessions (Watterson et al., 2014), similar to previous findings 
with cocaine and methamphetamine (Ahmed & Koob, 1998; Kitamura et al., 2006).  
While others have found evidence of escalated MDMA intake (Schenk, 2009), this 
phenomenon only occurred with extended testing, and to our knowledge,  there are no 
reports of escalated MDMA intake across experimental LgA following prior asymptotic 
responding on ShA. While none of the doses of methylone tested here led to escalated 
intake, it is possible that escalation of intake might occur with higher doses of methylone 
(i.e., 1.0 mg/kg/infusion), as we have shown that only higher doses of the MDPV produce 
escalation of intake (Watterson et al., 2014). Furthermore, while these data suggest that 
the potential for compulsive use of methylone in humans appears less likely than 
prototypic stimulants, replication of these results with additional animal experiments, as 
well as human studies, are ultimately needed before conclusions about abuse liability can 
be made.   
Despite our non-significant ICSS results, a trend towards dose-dependent 
threshold decreases suggest that methylone may possesses hedonic properties, 
corroborating reports of euphoric subjective effects in humans (Spiller et al., 2011; 
Warrick et al., 2012).  Furthermore, while it could be argued that higher doses and/or 
greater experimental power (observed power in the present study was 0.326) may have 
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yielded significance, the decrease in reward thresholds produced by methylone here 
appear similar, but slightly weaker in magnitude, to those previously reported for MDMA 
(Hubner, Bird, & Rassnick, 1988; Lin, Jackson, Atrens, Christie, & McGregor, 1997), 
and are much less robust than decreases reported for cocaine, d-amphetamine, 
methamphetamine, and MDPV (Vlachou & Markou, 2011; Watterson et al., 2014).  In 
the present study, the highest dose of methylone (10 mg/kg) produced threshold 
reductions that were smaller (13%) than the lowest dose (0.1 mg/kg) of MDPV (16%) 
previously tested under identical ICSS procedures (Watterson et al., 2014). Thus, while 
our self-administration data suggests that methylone functions as a stronger reinforcer 
than MDMA, our ICSS data suggest similar or weaker rewarding properties compared to 
MDMA.  This effect is somewhat surprising in light of the more robust self-
administration and stronger rewarding effects of methylone, as revealed in CPP studies 
mentioned above, as compared to MDMA. Thus, replication of these findings is needed 
before definitive conclusions can be reached.  
In addition to the aforementioned measures of abuse liability, rats in the two 
higher dose groups showed signs of toxicity including porphyrin staining, foaming at the 
mouth, and death. For the two rats in the 0.5 mg/kg/infusion group which self-
administered methylone to the point seizure and death, the total infusions obtained during 
this session were 114 and 138. Interestingly, both of these subjects had previously 
obtained a higher number of infusions in earlier LgA sessions, the highest being 214 and 
198, respectively. Thus, these fatalities appear to be the result of repeated methylone self-
administration and not necessarily the acute effects of a single high dose. These 
observations reveal the need for further studies regarding the toxic effects of methylone 
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that may provide additional information about various reports of toxicity and death 
associated with methylone use in humans (Cawrse et al., 2012; Pearson et al., 2012; 
Warrick et al., 2012).  
Overall, these results fit with previous research showing that the ratio of 
dopamine-serotonin release induced by psychostimulants is positively correlated with 
self-administration patterns, ICSS threshold-lowering ability, and addiction liability 
(Bauer, Banks, Blough, & Negus, 2013a; Rothman & Baumann, 2003; Schenk et al., 
2007; S Wee et al., 2005). The in vitro release data from Baumann (2011) revealed a 
DAT/SERT transporter mediated release for methylone (1.82) to be similar to MDMA 
(0.97), along with qualitatively similar microdialysis release data.  In contrast, 
methamphetamine and d-amphetamine DAT/SERT ratios are 152.0 and 219.5, 
respectively (Baumann et al., 2012; S Wee et al., 2005). While our results generally 
conform to this hypothesis, the results here also demonstrate the importance of behavioral 
experiments in assessing pharmacological nuances not explicitly revealed in 
neurochemical assays.  Prior to the current study, methylone was primarily compared to 
MDMA and predicted to exert similar effects. However, our data revealed more robust 
self-administration during 2 hr sessions than previously shown for MDMA, predictive of 
a greater addiction liability and suggestive of other possible neurochemical differences 
between methylone and MDMA not accounted for in previous monoamine assays.  
Furthermore, given the lack of escalation in LgA, relatively weak PR responding, and 
weak variable ICSS results, our study demonstrates the importance of testing beyond 
basic self-administration. The lack of escalation during LgA and weak variable ICSS 
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effects may be reflective of lower dopamine-serotonin ratios and more indicative of lower 
compulsive use liability (episodic vs. compulsive use).   
Finally, it is also important to mention some limitations of the current study. The 
primary limitation of the current study is a relatively small number of subjects in both the 
IVSA experiments (n=48) and ICSS experiments (n=4). One of the main conclusions 
made from the current study is that methylone possesses a relatively low abuse liability 
given the lack of escalation in LgA.  While it does not appear likely that any dose group 
would display significant escalated intake, it is possible that with additional subjects, 
escalated intake might have been observed in a subset of animals.  Further studies are 
needed to evaluate this possibility. In addition, ICSS experiments were performed with 
only 4 rats, and it is possible that additional subjects would have yielded statistical 
significance, as only a trend towards significant (p=0.09) was observed. Another 
limitation of the current study is that is was conducted with drug-naïve animals. While 
demographic information regarding methylone users is scarce, it is possible that 
individuals with previous experience with illicit stimulants may be more sensitized to the 
reinforcing properties methylone.  These possibilities warrant further investigation. 
Finally, it is important to reiterate that while our results suggest more potent reinforcing 
properties of methylone as compared to MDMA, and weaker reinforcing properties 
compared to MDPV and other prototypic stimulants, our study is the first to demonstrate 
methylone IVSA. Thus, replication of our initial IVSA results, as well as additional 
studies directly comparing methylone to MDMA and other psychostimulants, is needed 
before definitive conclusions can be made. 
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In general, the IVSA results from the present study reveal that MDMA functions 
as a moderate reinforcer that appears stronger than MDMA given the more rapid rate and 
greater percentage of rats acquiring self-administration compared to previous MDMA 
self-administration studies. However, the weak PR responding and lack of escalated 
methylone intake in LgA indicate that methylone is weaker than prototypic stimulants. 
These results are complimented by our ICSS results which reveal a trend towards 
lowering ICSS thresholds similar to previous studies on MDMA.  These results provide 
initial evidence which suggests that methylone possesses an abuse liability similar to or 
slightly greater than MDMA, but significantly lower other prototypic stimulants.  In 
humans, MDMA is generally considered to have a low addiction liability as consumption 
patterns are generally intermittent rather than compulsive (De La Garza, Fabrizio, & 
Gupta, 2007). This is not without exception, however, as MDMA dependence has been 
reported in some individuals (Jansen, 1999).  Extrapolating from our results, one would 
predict that methylone dependence may be possible in a subset of individuals, but that 
consumption patterns would also generally stay intermittent and typically not advance to 
compulsive use.  However, this conjecture requires validation from additional human 
experimental and epidemiological research, and definitive conclusions about human 
consumption patterns cannot be made at this time. Nonetheless, our findings provide an 
initial behavioral characterization of the reinforcing and rewarding effects of methylone 
and have important implications for future synthetic cathinone research, treatment 
specialists, and the development of appropriate regulatory policies.   
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CHAPTER 6 
EFFECTS OF α-PYRROLIDINOVALEROPHENONE (α-PVP) AND 4-METHYL-N-
ETHYLCATHINONE (4-MEC), TWO SYNTHETIC CATHINONES COMMONLY 
FOUND IN SECOND-GENERATION “BATH SALTS”, ON ICSS THRESHOLDS IN 
RATS. 
Published in International Journal of Neuropsychopharmacology, 2014 
 
For the first time in history, the number of unregulated novel psychoactive 
substances on international drug markets now exceeds those under international control 
(United Nations, 2013). One of the most problematic classes of novel psychoactive 
substances to emerge are synthetic cathinones, comprising approximately 18% of all 
unregulated substances in international markets (United Nations, 2013).  Synthetic 
cathinones first appeared in Europe in the mid 2000’s and in the United States around 
2009, and their use led to numerous reports of abuse, bizarre behavior, toxicity, and death 
(Prosser & Nelson, 2012; Rosenbaum et al., 2012).  The rise in popularity of synthetic 
cathinones is linked to their ease of procurement over the internet, and in gas stations, 
smoke shops, and novelty stores (Spiller et al., 2011).  Synthetic cathinones have been 
falsely marketed as numerous products, the most recognizable being “bath salts”, and are 
typically labeled “not for human consumption” or “for research purposes only” in order 
to evade drug laws (N. D. I. C. United States Department of Justice, 2011).  While many 
synthetic cathinone derivatives exist, 3,4-methylenedioxypyrovalerone (MDPV), 
mephedrone, or methylone initially comprised approximately 98% of all synthetic 
cathinones encountered in U.S. drugs seizures (D. E. A. United States Department of 
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Justice, 2011a). Citing imminent threats to public health and safety, the U.S. DEA used 
their emergency scheduling authority to temporarily classify these three drugs (now often 
referred to as first-generation bath salts) as Schedule I substances in October of 2011 (D. 
E. A. United States Department of Justice, 2011b). As of 2013, these first-generation 
synthetic cathinones are now permanently classified as Schedule I substances in the U.S. 
(One Hundred Twelfth Congress of the United States of America, 2012; D. E. A. United 
States Department of Justice, 2013a).  
On January 22, 2013, the U.S. DEA published a request for information 
specifically regarding 8 additional synthetic cathinones, two of the most prominent being 
4-methyl-N-ethcathinone (4-MEC) and alpha‐pyrrolidinopentiophenone (α-PVP) (DEA, 
2013). Their similarity in chemical structure suggests that α-PVP and 4-MEC likely 
emerged as replacements for MDPV and mephedrone, respectively (see Fig. 14).  
While literature regarding the neurochemistry, toxicology, and abuse liability of 
first generation synthetic cathinones has emerged in recent years (Spiller et al., 2011; 
Coppola and Mondola, 2012;  Baumann et al., 2013; Simmler et al., 2013; Watterson et 
al., 2013; Watterson and Olive, 2014), relatively little information exists regarding 
second-generation analogues such as α-PVP and 4-MEC (D. E. A. United States 
Department of Justice, 2013b). With regards to abuse liability, the potential for 
compulsive use (i.e. addiction) of stimulant drugs generally increases as dopamine to 
serotonin transporter (DAT/SERT) reuptake (IC50 values) and/or release (EC50 values) 
ratios increase (i.e. synaptic levels of DA are greater than 5-hydroxytryptamine, 5-HT).  
On the other hand, higher SERT/DAT ratios are generally associated with more 
entactogenic effects and episodic abuse patterns (Bauer et al., 2013a; Rothman & 
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Baumann, 2003, 2006).  Studies have revealed that α-PVP is a potent dopamine and 
norepinephrine transporter (DAT and NET, respectively) inhibitor, has relatively little 
affinity for the serotonin transporter (DAT/SERT IC50 >781) (Marusich et al., 2014; 
Meltzer et al., 2006), increases extracellular dopamine (DA) release in the striatum 
(Kaizaki, Tanaka, & Numazawa, 2014), and has locomotor enhancing properties similar 
to MDPV (DAT/SERT IC50 ≈ 806-816) and methamphetamine (DAT/SERT  IC50 ≈ 10 – 
25; DAT/SERT EC50 ≈ 152) (Baumann, Partilla, Lehner, et al., 2013; Kaizaki et al., 2014; 
Marusich et al., 2014; Rothman & Baumann, 2003). On the other hand, in vitro assays 
have shown that 4-MEC inhibits the reuptake of DAT, NET and SERT with 
approximately equal affinity,  but is also acts as 5-HT releaser with a similar DAT/SERT 
ratio (DAT/SERT IC50 ≈ 1.85) (Iversen et al., 2013; Simmler, Rickli, Hoener, & Liechti, 
2014) to methylone (DAT/SERT IC50 ≈ 2; DAT/SERT EC50 ≈ 1.82; Baumann et al., 
2012a) and 3,4-methylenedioxymethamphetamine (MDMA; DAT/SERT EC50 ≈ 0.97; 
Baumann et al., 2012a). To our knowledge, the effects of 4-MEC on locomotor activity 
have not been reported.  It also is important to note here that DAT/SERT ratios differ 
slightly between laboratories and/or as a result of cell types used (e.g. rat brain 
synaptosomes, HEK 293 cells expressing human transporters, etc.).  Thus, despite their 
somewhat unique in vitro profiles, these newer synthetic cathinones appear to exert 
effects on monoaminergic signaling, and suggest that α-PVP will have stimulant effects 
and high compulsive abuse potential similar to METH and the first generation synthetic 
cathinone MDPV (Aarde, Huang, Creehan, Dickerson, & Taffe, 2013; Watterson et al., 
2014). In contrast, 4-MEC is predicted to have entactogenic effects and relatively lower 
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compulsive abuse potential (i.e., episodic use) similar to MDMA and the first generation 
synthetic cathinone methylone (Watterson et al., 2012).  
  However, there are currently no published behavioral studies that have directly 
assessed the potential abuse liability of α-PVP and 4-MEC.  Thus, the current study 
sought to determine the effects of α-PVP and 4-MEC, along with methamphetamine for 
comparison, on thresholds for intracranial self-stimulation (ICSS) using a discrete trials 
current threshold determination procedure (Markou and Koob, 1992). The discrete trials 
current threshold ICSS task is a commonly employed to assess abuse liability, with 
reductions in ICSS thresholds representing facilitation of brain reward functioning, and 
increases in ICSS threshold representing anhedonic/depression-like effects and inhibition 
of brain reward function (Markou & Koob, 1992; Vlachou & Markou, 2011).  
 
Method 
Subjects 
All procedures were conducted with the approval of the Institutional Animal Care 
and Use Committee at Arizona State University in accordance with the Guide for Care 
and Use of Laboratory Animals as adopted by the National Institutes of Health (NIH). 
Male Sprague-Dawley rats (n=5 for α-PVP, n=5 for 4-MEC, and n=4 for METH) were 
obtained from Harlan Laboratories (Livermore, CA, USA), and weighed approximately 
250 g on arrival.  Rats were individually housed according to NIH standards on a 
reversed 12-hour light–dark cycle (lights off at 6:00 AM) and given ad libitum access to 
food and water during all experimental procedures, except during behavioral testing. All 
behavioral testing occurred during the dark phase between 8:00 AM – 6:00 PM.  
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Drugs 
α-PVP and 4-MEC were both obtained through internet websites 
(NicePriceResearchChems.biz and www.researchchemz.com, respectively).  10 mg 
samples of both drugs were analyzed by liquid chromatography–mass spectrometry for 
purity and chemical composition at the Research Triangle Institute (Durham, NC, USA). 
Samples were dissolved in methanol and analyzed using a Waters Synapt HDMS 
(Milford, MA, USA) quadrupole time-of-flight mass spectrometer interfaced to a Waters 
Acquity UPLC system. Data were acquired using a capillary voltage of 3 kV, source 
temperature of 120°C, desolvation temperature of 450°C, sampling cone at 30 V and 
extraction cone at 3 V. The mass spectrometer was externally calibrated from 50 to 700 
Da using sodium formate solution, and mass shifts during acquisition were corrected 
using leucine enkephalin as a lockmass. Liquid chromatography was performed using a 
BEH C18 column (2.1 X 50 mm, 1.7 µm particles) held at 30°C. Sample identity was 
confirmed based on exact mass, retention time and fragmentation match to a certified 
reference standard from Cerilliant (Round Rock, TX, USA). Both samples were 
determined to have an apparent purity of >95%. For all behavioral studies, α-PVP, 4-
MEC, and methamphetamine hydrochloride (METH, Sigma Aldrich, St. Louis, MO) 
were dissolved in 0.9% sterile saline and administered via the intraperitoneal (i.p.) route 
in a volume of 1 ml/kg.  
ICSS Surgical Procedures   
Rats were anesthetized with isoflurane (2% v/v) vaporized oxygen and 
unilaterally implanted (right and left hemispheres counterbalanced across rats) with a 
stainless steel bipolar electrode (PlasticsOne, Roanoke, VA, USA; 2 mm diameter, 
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insulated except at the ventral tip) into the medial forebrain bundle (anterior-posterior -
0.05 mm; medial-lateral ±1.7 mm, dorsal-ventral -8.3 mm from dura) and secured to the 
skull with skull screws and dental cement. Rats were given 7 days to recover from 
surgery before commencement of ICSS procedures, during which they received daily 
injections of 2.5 mg/ml meloxicam (0.15 ml volume) to minimize post-surgical 
discomfort.  
ICSS Apparatus 
All ICSS testing was conducted in operant conditioning chambers (ENV-007CT; 
Med Associates) housed in sound-attenuating cubicles equipped with an exhaust fan to 
mask external noise. Chambers were equipped with a house light and a nose-poke 
aperture containing a light-emitting diode (LED) stimulus light (ENV-114M; Med 
Associates). The nose-poke aperture was 2.5 cm in diameter, located 5 cm above a 
stainless steel grid floor, and contained an infrared detector placed 0.64 cm from the front 
edge of the panel for recording responses. Located outside the chambers was a dual 
programmable ICSS stimulator (PHM-150B/2; Med Associates) interfaced to a computer 
to deliver electrical current to the electrode. Chambers were interfaced to a PC using 
Med-PC IV software that controlled all stimulation parameters, test functions, and data 
collection. 
ICSS testing procedures  
The discrete-trials current threshold procedure ICSS used in the present study 
were identical to those described in previous publications from our laboratory (Watterson 
et al., 2012, 2014; Watterson, Watterson, et al., 2013), also see Markou and Koob, 1992; 
Vlachou and Markou, 2011). During all ICSS testing procedures, stimulation availability 
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was signaled by illumination of the LED stimulus light located within the nose-poke 
aperture. Training began by allowing rats to spontaneously acquire nose-poke responses 
on an FR1 schedule of reinforcement, which delivered a 200-ms square-wave cathodal 
pulse of 120 µA at 100 Hz. Rats were required to exert a minimum of 600 nose-pokes in 
a 30 min session for two sessions in order to progress to discrete trials training. During 
discrete trials training, each trial began with a free stimulation of 120 µA, followed by a 
7.5-s period during which the LED light remained on until the rat emitted a response that 
would yield an identical stimulation. Following the initial trial, the LED light was turned 
off and an inter-trial interval (ITI) was initiated, during which responses were recorded 
but yielded no stimulation. Progression through discrete trial training required rats to 
meet criterion (> 60% of total (trial + ITI) responses were correct trial responses) at four 
ITI lengths (2, 5, 10 and 15 s). Once rats completed discrete trials training, discrete trial 
current threshold determination procedures began. All discrete trials current threshold 
sessions began with a stimulus intensity of 120 µA and progressed through four cycles of 
ascending and descending blocks of trials. At a given current intensity, 5-trial blocks 
began with a free stimulation, followed by a 7.5-s interval during which rats could emit a 
nose-poke response to receive an identical stimulation. Following a single trial response, 
the LED stimulus light was turned off, initiating an ITI period between 7.5 and 15 s 
(mean 10 s) that separated trials. Responses during the ITI further lengthened the ITI by 
12.5 s. When rats emitted an appropriate response on ≥3 out of 5 trials, electrical 
stimulation was decreased by 5 µA for the next five-trial block. Stimulation intensities 
continued to descend until the rats responded ≤2 out of 5 trials during a given trial block, 
at which point the current intensities reversed into ascending mode, with 5 µA increases 
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in current intensity for the subsequent blocks. Therefore, the discrete trial current 
threshold procedure determined the lowest amount of current intensity (threshold) for 
which rat was willing to emit responses.  For each session, raw threshold scores were 
calculated by averaging the midpoint of current intensities between positive (responses 
on ≥3 out of 5 trials) or negative (responses on ≤2 out of 5) trial blocks. 
  Prior to all drug and vehicle testing, rats received a minimum of 10 days of 
baseline threshold assessment and were required to meet stable baseline criteria.  These 
criteria were determined by threshold means for the most recent 8 sessions, as well as 
sub-means for the first and last 4 of these sessions. The difference in sub-means was 
divided by the overall mean, and threshold stability is considered to be met if the 
resulting percentage was less than 5 (Sidman, 1960). Baseline testing continued 
throughout experimentation to monitor stability, and drug testing was stopped if animals 
no longer displayed stability across baseline scores. In all cases, loss of stability either 
occurred as a result of loosening or complete detachment of the electrode implant from 
the skull.   
Drugs were administered 20 min prior to placement into ICSS procedures. Drug 
doses were given in a randomized block design such that rats received each dose once 
before beginning another block of testing. At the beginning of experiment, all subjects 
were to receive 5 determinations of each dose; however, loss of electrode implant or 
baseline stability meant some subjects received less. Rats that were administered 4-MEC 
received 2 – 5 determinations at each dose and all rats that were administered α-PVP 
received 1-4 determinations at each dose.  A 100 mg/kg dose for 4-MEC and 5 mg/kg 
dose for α-PVP were also administered, but only once and only for a subset of rats (N=4 
  93 
for α-PVP; N = 3 for 4-MEC) due to apparent aversive effects as indicated by robust 
ICSS threshold elevations. Because only a subset of rats received these higher doses, 
ICSS threshold determinations were not included in the statistical analysis.  Rats 
receiving METH received 2 – 3 determinations at each dose with the exception of the 3 
mg/kg dose which was only assessed once in rats also because of ICSS threshold 
increases. However, because all rats received a 3 mg/kg determination, ICSS thresholds 
at this dose for METH were included in statistical analyses.  
Statistical Analyses 
All statistical analyses were conducted using SigmaPlot (Systat Software, Inc. San 
Jose, CA, USA).  A significance criterion of P < 0.05 was used for all analyses.  For each 
rat, raw ICSS current intensity thresholds (in µA) for all vehicle and drug sessions 
conducted once drug administration began were converted to scores reflecting the percent 
change from the mean of baseline thresholds obtained after reaching stabilization. For 
each dose, including vehicle, scores reflect the average percent change from the baseline 
score which immediately preceded its determination for each individual animal. In 
addition to dose means, corresponding 95% confidence intervals (Fig. 2) were calculated 
and significance (between individual doses and vehicle) occurred when the 95% 
confidence intervals between individual doses and vehicle did not overlap (Cardinal and 
Aitken, 2006).  
In order to perform dose-effect comparisons across the different drugs tested, for 
each animal doses were log transformed and a linear slope (line of best fit) was calculated 
on group means for the descending portion of dose-effect curves starting with the lowest 
dose tested and ending with the dose producing the largest observed mean maximal 
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reduction in ICSS thresholds. Linear slopes were then used to calculate ED50 values for 
each drug and animal. Maximal reductions for each animal, regardless of dose, were also 
calculated. Next, slopes for the log transformed drug doses on the linear portion of the 
descending slopes (ED50 values in mg/kg) and maximal ICSS threshold decreases for 
METH, α-PVP, and 4-MEC were compared by a one-way between subjects ANOVA 
with bonferroni post-doc tests. Slope and ED50 values from previously published data 
(Watterson et al.,2012; Watterson et al. 2014) were also calculated (see Table 2), but 
were not compared statistically due to the possibility of cohort effects. 
 
Results 
 For 4-MEC (Fig. 15A), significant reductions in ICSS thresholds versus vehicle 
was seen in the 10 (M = -11.86) and 30 (M = -15.09) mg/kg dose groups.  For a-PVP 
(Fig. 15B), significant reductions versus vehicle were seen in the 0.3 (M = -13.79) and 1 
(M = -19.03) mg/kg doses.  For METH (Fig. 15C), significant reductions versus vehicle 
were seen in the 0.3 (M = -13.40) and 1 (M = -19.82) mg/kg doses.   
 For α-PVP, 4-MEC, and METH, higher doses (5, 100, and 3 mg/kg, respectively) 
produced elevations in ICSS threshold values, with only METH producing significant 
elevations (mean ± 95% CI; α-PVP, 19.83 ± 38.64; 4-MEC, 28.00 ± 31.72; METH, 84.39 
± 69.48%).  
The slope, ED50, and maximal effect values are shown in Table 2. There were no 
significant differences in slopes of the linear portions of the dose-response curves 
between the three drugs (F[2,11] = 1.63, p > 0.05). For ED50 values, a significant effect 
of drug was observed (F[2,11] = 46.05, p < 0.001, and post-hoc analyses revealed 
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significant differences between METH and 4-MEC, METH and α-PVP, and METH and 
4-MEC (all p’s < 0.001). For comparison purposes, slope and ED50 values for MDPV 
and methylone were also calculated from previously published data(Watterson et 
al.,2012; Watterson et al. 2014), but not compared statistically. Finally, there were no 
significant differences observed in maximal reductions in ICSS thresholds (F[2,11] = 
1.64, p > 0.05).  
 
Discussion 
To our knowledge, there are currently no published studies directly assessing the 
potential abuse liability of the second generation synthetic cathinones α-PVP or 4-MEC.  
The present study revealed that, similar to methamphetamine in the present study and to 
MDPV and methylone in previous studies (Bonano, Glennon, De Felice, Banks, & 
Negus, 2014; Watterson et al., 2012, 2014), both α-PVP and 4-MEC dose-dependently 
decreased ICSS thresholds in a discrete trials current threshold procedure.  ICSS 
threshold reductions are commonly accepted as indicative of facilitated brain reward 
function and the interoceptive rewarding effects of drugs of abuse, and thus provide 
evidence of abuse potential in humans (Vlachou & Markou, 2011). At the highest doses 
tested, α-PVP (5 mg/kg), 4-MEC (100 mg/kg), and METH (3 mg/kg) no longer 
decreased, but instead produced increased ICSS thresholds (although these increases 
were not significant for α-PVP or 4-MEC). Increases in ICSS thresholds have been 
postulated to indicate decreases in brain reward function, aversive effects, and/or 
depression-like anhedonia (Vlachou & Markou, 2011). These higher doses were only 
assessed once in the current study and only in a subset of animals receiving 4-MEC and 
  96 
α-PVP due to the appearance of apparent aversive effects, and thus were not included in 
statistical analyses. However, these observations suggest that high doses of all three of 
these psychostimulants may result in the emergence of deficits in brain reward function 
and/or aversion and anhedonia.  
 For α-PVP, the observed decreases in ICSS thresholds were very similar those 
reported here for METH as well as those previously reported for MDPV (Watterson et 
al., 2014). The most robust threshold decrease observed for α-PVP was ~19% at the 1 
mg/kg dose was similar to the 1 mg/kg dose of METH presented here (~20%) and the 0.5 
mg/kg dose of MDPV (~18%) (Watterson et al., 2012). Both METH and α-PVP resulted 
in significant ICSS threshold reductions at the 0.3 and 1 mg/kg doses. However, at the 3 
mg/kg dose, METH led to an increase in ICSS thresholds (84.39 ± 69.48, mean ± 95% 
CI), an effect not seen in until a dose of 5 mg/kg α-PVP was administered (19.83 ± 38.64; 
mean ± 95% CI). Although these effect were not previously observed with MDPV doses 
tested up to 2 mg/kg (Watterson et al., 2014), it is likely that higher doses of MDPV 
would also produce elevations in ICSS thresholds effects similar to those observed in the 
current study with high doses of α-PVP and METH.  In addition, slope of the descending 
portion of the dose-effect curves for α-PVP was most similar to those observed after 
METH (-46.70 vs -50.23), along with the maximal ICSS threshold reductions (25.76% vs 
21.11%) and ED50 values (0.35 mg/kg vs 0.20 mg/kg, see Table 2). Thus, α-PVP and 
METH are approximately equipotent in reducing ICSS thresholds; however, when 
compared to our previously published data on MDPV, maximal ICSS threshold 
reductions and slopes for both α-PVP and METH were approximately half those 
produced by MDPV (maximal reduction = 42.03%, slope = -96.07) under identical 
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experimental procedures (Watterson et al., 2014). The ED50 dose for MDPV was the 
same α-PVP at 0.35 mg/kg. Again, however, this dose was determined by maximal ICSS 
reductions which were approximately twice as robust for MDPV (42.03%) as α-PVP 
(25.76%).  Thus, the ability of α-PVP to reduce ICSS thresholds is most similar to that of 
METH but approximately half that of MDPV.  
 For 4-MEC, the changes in ICSS thresholds observed in the present study closely 
resemble those previously observed for methylone (Watterson et al., 2012), albeit with a 
rightward shift in the dose response curve.  The most robust decrease produced by 4-
MEC was at the 30 mg/kg dose (~15%), similar to the 0.3 mg/kg doses of α-PVP (~14%) 
and (METH (~13%) in the present study and lowest dose MDPV (0.1 mg/kg, ~17%) 
tested previously (Watterson et al., 2014), and most robust, but non-significant, 
methylone dose (10 mg/kg, ~13%) previously reported (Watterson et al., 2012).  This 
maximal ICSS threshold decrease is also similar to that produced by MDMA (Hubner et 
al., 1988), but significantly less than maximal decreases produced by MDPV and METH 
(Watterson et al., 2014). At the 100 mg/kg dose (only assessed in a subset of animals, see 
Methods), 4-MEC increased ICSS thresholds (28.00% ± 31.73; mean ± 95% CI) 
indicative of a biphasic dose-response pattern that is typical of other illicit stimulants 
(Vlachou and Markou, 2011). In addition, neither the slope of the descending portion of 
the dose-effect curve for 4-MEC (-21.12) nor the maximal ICSS threshold decrease 
(17.40%) were different from α-PVP or METH. However, the ED50 value for 4-MEC 
was significantly different from α-PVP and METH, indicating that 4-MEC is less potent 
than these drugs. When compared to our previously published ICSS data for methylone 
(Watterson et al., 2012), 4-MEC lead to similar maximal ICSS threshold reductions (-
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17.40% vs -21.50%), but much higher ED50 values (6.41 vs. 1.00) and a slightly steeper 
slopes (-21.12 vs. -17.59).  However, our previously published study on methylone did 
not assess doses higher than 10 mg/kg; thus, it is possible that methylone may have led to 
greater maximal ICSS threshold reductions at higher doses.  While the results from the 
present study suggest that 4-MEC appears to be less potent than methylone, yet more 
effective in reducing ICSS thresholds, further experimentation is needed before definitive 
conclusions can be made.  
 The present study is, to our knowledge, the first to directly assess the potential 
abuse liability of second generation synthetic cathinones. These results reveal that, like 
the first generation synthetic cathinones now classified as Schedule I substances for their 
high abuse potential, replacement synthetic cathinones possess similar rewarding effects 
as measured in ICSS procedures, and thus likely possess similar degrees of abuse liability 
in humans.  Furthermore, as with first generation synthetic cathinones, these newer 
replacement cathinones appear to produce rewarding effects similar to the illicit 
stimulants methamphetamine and MDMA (Hubner et al., 1988; Vlachou & Markou, 
2011). When considering the ICSS data from the present study, along with data 
previously published for MDPV (Watterson et al., 2014) and methylone (Watterson et al., 
2012) under identical ICSS experimental conditions, the rank order potency of these 
drugs is MDPV > METH ≈ α-PVP > methylone ≈ 4-MEC.   
 Synthetic cathinones, like prototypical psychostimulants, primarily exert their 
effects through substrate releasing or plasma membrane transporter blocking effects at 
monoaminergic terminals (Iversen et al., 2013; Lehner & Baumann, 2013; Marusich et 
al., 2014; Meltzer et al., 2006; Simmler et al., 2014). As mentioned previously, numerous 
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studies suggest that there is a large degree of correspondence between ICSS threshold 
reductions, propensity for drug self-administration, and the balance between effects on 
DA vs. 5-HT transmission in the mesolimbic reward pathway (Bauer et al., 2013a; Bauer, 
Banks, Blough, & Negus, 2013b; Rothman & Baumann, 2003, 2006; S Wee et al., 2005).  
Specifically, higher DA/5-HT transporter affinity/release ratios correlate with increased 
self-administration propensity, more robust decreases in ICSS thresholds, and greater 
abuse liability as indicated by a progressively increased risk for compulsive use.  
Alternatively, lower DA/5-HT ratios correlate with reduced propensity for self-
administration, less robust decreases in ICSS thresholds, and a lower potential for 
compulsive drug intake. When considering all of the ICSS data from the present study 
along with previously published data on first generation synthetic cathinones (Watterson 
et al., 2012, 2014) and prototypical psychostimulants (Hubner et al., 1988; Vlachou & 
Markou, 2011), these data generally support a strong positive relationship between 
differential effects on DA/5-HT signaling and rewarding effects, as revealed by maximal 
ICSS thresholds and steepness of slope of the descending portion of dose response curve. 
However, individual comparisons of the in vitro DAT/SERT affinities of all of these 
compounds is not appropriate, since some act primarily as presynaptic plasma membrane 
transporter blockers (MDPV and α-PVP), others are transporter substrates and 
monoamine releasers (METH, methylone, and MDMA), or a combination of both (4-
MEC). Thus, direct comparison of DAT/SERT data (i.e., IC50 values) derived from 
inhibition of transporter function as assessed in competitive binding assays and data from 
monoamine release assays (i.e., EC50 values) is problematic. However, when considering 
the aforementioned rank order potency (MDPV > α-PVP > 4-MEC) based on ICSS 
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threshold decreases and slopes of dose response curves within the class of monoamine 
transporter blockers, this rank order of potency is in close agreement with DAT/SERT 
ratios derived from IC50 values obtained in previous in vitro studies (MDPV (806-816) > 
α-PVP (806) > 4-MEC (1.85) (Baumann et al., 2012b; Baumann et al., 2013; Marusich et 
al., 2014; Simmler et al., 2014). As mentioned previously, 4-MEC is also a weak 5-HT 
releaser (Simmler et al., 2014) which likely further decreases its abuse liability. When 
considering maximal ICSS threshold decreases and slopes of the dose response curve for 
monoamine releasers, their rank-order potency is METH > methylone, which corresponds 
with their DAT/SERT ratios derived from EC50 values obtain in vitro (METH (152) > 
methylone (1.82 – 2))(Baumann et al., 2012; Baumann et al., 2013).   
Taken together, we predict that α-PVP possesses a potential for compulsive abuse 
(i.e. addiction) that is roughly similar to that of METH and MDPV, but much greater than 
that of 4-MEC, methylone, and MDMA.  Accordingly, we also predict that 4-MEC will 
have a relatively lower potential for compulsive use than that of MDPV and METH, 
would be most similar to methylone and MDMA (i.e. episodic use), and may exert 
primarily entactogenic effects.    
  Finally, it is also important to mention that both first and second generation 
synthetic cathinones are often sold as mixtures. Specifically, synthetic cathinones 
products have been shown to often contain more than one cathinone, as well as other 
adulterants including illicit amphetamines, piperazines, cutting/binding agents, caffeine, 
and topical anesthetics (Brandt et al., 2010; German, Fleckenstein, & Hanson, 2014). 
Thus, while abuse liability assessment of these individual drugs is now emerging, 
assessment of the effects and abuse potential of combinations of these drugs will be more 
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difficult, yet should be a central focus of future research.  Together, the results of the 
present study suggest that second generation synthetic cathinones likely possess a similar 
potential for abuse as their first generation predecessors as well as the illicit 
amphetamines they are designed to mimic.  Furthermore, these findings have important 
implications for future research on synthetic cathinone abuse, dependence, and legislative 
efforts to classify these drugs according to the proper controlled substance schedule 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  102 
CHAPTER 7 
SENSITIZATION TO THE LOCOMOTOR STIMULANT EFFECTS OF 3,4-
METHYLENEDIOXYPYROVALERONE (MDPV) AND CROSS-SENSITIZATION 
TO METHAMPHETAMINE IN RATS 
Synthetic cathinones, often falsely marketed as “bath salts” or “legal high” 
alternatives to illicit psychostimulants such as methamphetamine (METH), cocaine, or 
3,4-methylenedioxymethampehtamine (MDMA), are a class of designer stimulants that 
have become increasingly popular drugs of abuse in recent years.  In the United States, 
3,4-methylenedioxypyrovalerone (MDPV), mephedrone, and methylone initially 
emerged as the most prominent “bath salts” constituents, comprising 98% of all synthetic 
cathinones obtained in drug seizures prior to their permanent classification as Schedule I 
substances (One Hundred and Twelfth Congress of the United States of America, 2012).  
Of these three, MDPV was the most commonly abused in the U.S. (Bonano et al., 2014; 
Uralets, Rana, Morgan, & Ross, 2014) and identified in numerous case reports of 
synthetic cathinone related toxicity, bizarre behaviors, and death ( Spiller et al., 2011; 
Murray et al., 2012; Penders and Gestring, 2011; Ross et al., 2012; Penders et al., 2013; 
Wright et al., 2013; Wyman et al., 2013).  
 Despite being permanently classified as a Schedule I substance in 2012, MDPV 
continues to be abused (NMS Labs, 2014) and recent reports of MDPV addiction have 
emerged (Nouredine Sadeg et al., 2014). While MDPV-related toxicity is now well 
established, the scientific assessment of abuse liability is still in its infancy (Watterson et 
al., 2013: Gregg and Rawls, 2014). Preclinical animal studies have revealed that MDPV 
has potent reinforcing (Aarde et al., 2013; Watterson et al., 2014) and rewarding effects 
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(De Felice et al., 2013; Bonano et al., 2014; Watterson et al., 2014), fully substitutes for 
cocaine and methamphetamine in drug discrimination tests (Fantegrossi et al., 2013; 
Gatch, Taylor, & Forster, 2013), and elevates locomotor activity in a manner indicative 
of psychostimulants (Baumann et al., 2012; Fantegrossi et al., 2013; Aarde et al., 2013; 
Marusich et al., 2012, 2014) . In humans, concurrent use of MDPV and other illicit 
stimulants is prevalent and evidence suggests that prior stimulant use enhances severity 
of adverse sympathomimetic effects during acute MDPV use (Spiller et al., 2011). 
However, despite mounting preclinical literature suggesting an abuse potential of MDPV, 
and human literature suggesting enhanced vulnerability to MDPV toxicity with prior 
amphetamine use, there are currently no published reports detailing whether MDPV use 
alters behavioral sensitivity and responsiveness, and thus potentially abuse vulnerability, 
for traditional illicit psychostimulants (e.g. METH). Conversely, prior research has not 
yet established whether use of traditional psychostimulants such as METH enhance 
behavioral sensitivity and responsiveness and thus abuse potential of MDPV. One 
method for assessing lasting changes in behavioral sensitivity and responsiveness is via 
locomotor sensitization, in which repeated exposure to a drug leads to a progressive and 
enduring enhancement of locomotor behavior elicited by a subsequent drug challenge 
(Vanderschuren & Kalivas, 2000).   
With regards to synthetic cathinones, it has been previously demonstrated that 
prior exposure to mephedrone produces sensitization in rats when given a subsequent 
mephedrone or cocaine challenge (Lisek et al., 2012; Gregg et al., 2013a, 2013b; Shortall 
et al., 2013). Furthermore, repeated oral administration of cathinone, the parent 
compound of synthetic cathinones and the primary psychoactive alkaloid found in Catha 
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edulis, also leads to locomotor sensitization in rats (Banjaw et al., 2005; Banjaw and 
Schmidt, 2005, 2006).  However, to our knowledge, the phenomenon of locomotor 
sensitization has not yet been established for MDPV. Therefore, the purpose of the 
present study was to assess the ability of repeated MDPV administration to produce 
locomotor sensitization. We also sought to determine if cross-sensitization between 
MDPV and METH could be observed. 
Method 
Subjects 
Male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA), weighing 
approximately 250-275 g upon arrival, were housed in a humidity- and temperature-
controlled colony, maintained on a 12:12 reversed light/dark cycle and were provided ad 
libitum access to food and water except during locomotor testing procedures.  All 
experimentation was conducted during the dark phase (7 AM – 7 PM).  All experimental 
procedures were conducted with the approval of the Institutional Animal Care and Use 
Committee at Arizona State University and in accordance with the principles of the 
National Research Council’s Guide for the Care and Use of Laboratory Animals (2011).  
Drugs 
MDPV was purchased from Laboratory Supply USA (San Diego, CA, USA). A 
10-mg sample of MDPV was analyzed by liquid chromatography–mass spectrometry for 
purity at the Research Triangle Institute (Durham, NC, USA) and determined to have an 
apparent purity of >95%, as previously reported (Watterson et al., 2014). For all 
experiments, MDPV and methamphetamine (Sigma-Aldrich, St. Louis, MO, USA) were 
dissolved in sterile saline and administered intraperitoneally (i.p.) in a volume of 1 ml/kg.  
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Locomotor Testing Procedures 
Locomotor activity was assessed using a Rotorat system apparatus (Med 
Associates, Mt. St Albans, VT). This apparatus measures rotational ambulation and 
locomotor behavior quantified by quarter turns (90° rotations) in a bowl-shaped arena as 
previously described in our laboratory (Kufahl et al., 2013; Watterson et al., 2013). For 
all experiments, drug or vehicle injections were administered i.p. immediately prior to 
being placed into the arena for 90 minutes. Prior to all drug administration procedures, all 
rats received two days of acclimation to the testing apparatus. On the first acclimation 
day, rats were placed into and allowed to freely explore the arena for 90 min during 
which no locomotor activity was recorded.  On the second day, rats were first fitted with 
a plastic neck collar. Next, rats received a saline injection immediately prior to being 
placed into the arena and allowed to freely explore the arena for 90 minutes.  Locomotor 
activity was recorded by a rotating actuator mounted at the top of the arena that was 
connected to the rat via a stainless steel spring tether and a metal clamp affixed to the 
plastic collar. For all subsequent sessions, locomotor activity was assessed with identical 
90 min procedures. Saline was used as vehicle for all experiments.  
Experiments 1a and 1b – MDPV-induced Locomotor Sensitization with 24 hr Inter-test 
Intervals  
Initial doses of MDPV of 1 and 5 mg/kg were chosen based upon previously 
published findings by our laboratory and others of lowered thresholds for intracranial 
self-stimulation at similar doses (Bonano et al., 2013; Watterson et al., 2014; De Felice et 
al., 2014) as well as acute locomotor stimulant properties of MDPV (Aarde et al., 2013; 
Fantegrossi et al., 2013; Gatch et al., 2013; Marusich et al., 2014, 2012). In Experiment 
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1a, rats were injected with either MDPV 5 mg/kg (N = 8) or vehicle (N=8) and placed 
into locomotor chambers for 90-min sessions for 5 consecutive sessions (24 hours apart: 
Sessions 1-5 = Days 1 - 5).  Experiment 1b followed the same timeline, but rats were 
injected with either MDPV 1 mg/kg (N=8) or vehicle (N=8) for 5 consecutive days (24 
hrs apart: Sessions 1-5 = Days 1 - 5) prior to placement into locomotor chambers.  
Following a 5 day incubation period, rats with a 5 mg/kg or vehicle dosing regimen 
history received a 1 mg/kg challenge prior to the final locomotor test session. For rats 
receiving either 1 mg/kg or vehicle, a challenge dose of 0.5 mg/kg was administered prior 
to the final locomotor test session.  
Experiment 2 - MDPV-induced Locomotor Sensitization with 48 hour Inter-treatment 
Intervals 
For experiment 2, rats received either MDPV 1 mg/kg (N = 10) or vehicle (N=8) 
immediately prior to 90 min sessions for five sessions (48 hrs apart: Sessions 1-5 = Days 
1 - 9).  Following a 5-day incubation period, all rats regardless of dosing history received 
a vehicle injection immediately prior to a 90-min test session to assess for any residual 
non-specific locomotor effects (e.g. context related locomotion). The next day, all rats 
received a MDPV 0.5 mg/kg challenge dose prior to the final locomotor test session.   
Experiment 3 - Cross-sensitization of METH-induced Locomotor Sensitization to MDPV  
For Experiment 3, rats were treated with either METH 1 mg/kg (N = 16) or 
vehicle (N=16) immediately prior to 90-min sessions for five sessions (48 hrs apart: 
Sessions 1-5 = Days 1 - 9). The 48 hour inter-test interval was chosen to be consistent 
with Experiment 2. Following a 5-day incubation period, all rats regardless of dosing 
history were received saline immediately prior to a test session to assess for any residual 
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non-specific locomotor effects. The next day, all rats received a MDPV 0.5 mg/kg 
challenge dose prior to the final locomotor test session.   
Experiment 4 - Cross-sensitization of MDPV-induced Locomotor Sensitization to METH 
For Experiment 4, rats were administered either MDPV 5 mg/kg (N=6), MDPV 1 
mg/kg (N=10) or vehicle (N=8), immediately prior to 90-min sessions for five sessions 
(48 hrs apart: Sessions 1-5 = Days 1 – 9). The 48 hour inter-test interval was chosen to be 
consistent with Experiments 2 and 3 in which sensitization to the locomotor stimulant 
effects of MDPV were observed (see Results). Following a 5-day incubation period, all 
rats regardless of dosing history received saline injection immediately prior to a test 
session to assess for any residual non-specific locomotor effects. The next day, all rats 
received a METH 0.5 mg/kg challenge dose prior to the final locomotor test session. 
Statistical Analyses 
Data analysis was conducted using Prism 5 software (GraphPad, La Jolla, CA).  
For all experiments, the dependent measure was total number of quarter turns (sum of 
clockwise and counter-clockwise quarter turns) occurring during each of the five 90 min 
sessions, as well as during saline and challenge test sessions.  For Experiments 1 - 3, 
locomotor activity across the five repeated treatment sessions were analyzed with 2 × 5 
mixed-model ANOVAs, with dose (vehicle, drug) as the between-subjects factor and 
session (1-5) as the within-subjects factor. One-way repeated measures ANOVAs were 
always conducted for vehicle and drug groups individually with post hoc pairwise 
comparisons to compare session effects. For Experiment 4, locomotor activity across the 
five repeated treatment sessions was analyzed with a 3 × 5 mixed-model ANOVA, with 
dose (vehicle, MDPV 1 mg/kg, MDPV 5 mg/kg) as the between-subjects factor and 
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session (1-5) as the within-subjects factor.  For both saline and drug challenge tests, 
locomotor activity measures were analyzed with independent samples t-tests 
(Experiments 1 – 3) and Dunnett’s test (Experiment 4). More specifically, for Experiment 
1a, the drug challenge (MDPV 1 mg/kg) sensitization test between rats with MDPV (5 
mg/kg) vs vehicle dosing history was analyzed with an independent samples t-test. For 
Experiment 1b, the drug challenge (MDPV 0.5 mg/kg) sensitization test between rats 
with MDPV (1 mg/kg) vs vehicle dosing history was analyzed with independent samples 
t-test.  For Experiment 2, both the saline and drug challenge (MDPV 0.5 mg/kg) 
sensitization tests between rats with MDPV (1 mg/kg) vs vehicle dosing histories were 
analyzed with an independent samples t-test.  For Experiment 3, the saline and drug 
challenge (MDPV 0.5 mg/kg) sensitization tests between rats with METH (1 mg/kg) vs 
vehicle dosing histories were analyzed with an independent samples t-test.  For 
experiment 4, saline and drug challenge sensitization (METH 0.5 mg/kg) tests were 
analyzed with a Dunnett’s multiple-comparison test for the 1 and 5 mg/kg MDPV groups 
using vehicle as the common control (C. Dunnett, 1955; Holson, Freshwater, Maurissen, 
Moser, & Phang, 2008). Numerical results are displayed as mean ± SEM, where 
appropriate. 
 
Results 
Acclimation and Repeated Treatment Sessions 
Experiment 1a 
For experiment 1a (Fig. 16a) statistical analyses revealed a significant difference 
in baseline locomotor activity such that rats subsequently assigned to the saline treatment 
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group (874.88 ± 148.33 turns) displayed more quarter turns than rats subsequently 
assigned to the MDPV 1 mg/kg group (468.76 ± 91.56 turns) (t[7]=2.60, p<0.05). For the 
five treatment sessions (sessions 1-5; days 1-5), there was a significant main effect of 
session (F[4,56] = 4.30, p <0.05),  dose (F]1,14) = 88.05, p<0.001), and a dose × session 
interaction (F[4,56]=7.49, p<0.05).  Post-hoc analyses revealed that total quarter turns 
were significantly greater during sessions 1 and 2 than session 5 (p < 0.05). No other 
session differences were observed. No significant differences were found across sessions 
in rats receiving saline. Post hoc tests also revealed significantly increased locomotor 
activity in rats receiving MDPV 1 mg/kg than rats receiving saline across all treatment 
sessions (p<0.05). 
Experiment 1b 
For experiment 1b (Fig. 16b), statistical analyses did not reveal a significant 
difference in locomotor activity for the initial acclimation session such that rats 
subsequently assigned to the saline treatment group (763.89 ± 169.21 turns) displayed 
similar numbers of quarter turns than rats subsequently assigned to the MDPV 5 mg/kg 
group (640.63 ± 85.13 turns, p>0.05). For the next five days of testing (sessions 1-5; days 
1-5), there was neither a significant main effect of session nor a significant dose × session 
interaction. However, there was a significant main effect of dose (F[1,15] = 21.12, p < 
0.001), with rats receiving MDPV 5 mg/kg displaying more quarter turns (2117.175 ± 
799.68) than rats receiving saline (642.98 ± 104.23).   
Experiment 2 
For experiment 2 (Fig. 17a), statistical analyses did not reveal a significant 
difference in locomotor activity for the initial acclimation session such that rats 
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subsequently assigned to the saline treatment group (524.00 ± 86.75 turns) or MDPV 1 
mg/kg group (510.50 ± 75.24). For the five treatment sessions (sessions 1-5; days 1-9), a 
2-way mixed ANOVA revealed a significant main effect of session (F[4,64] = 4.12, p < 
0.01), dose (F[1,16] = 87.825, p < 0.001), and a significant dose × session interaction 
(F[4,64] = 2.75, p < 0.05).  Post-hoc analyses revealed a significant differences in 
locomotor activity across treatment sessions in the MDPV 1 mg/kg group (F[4,36] = 
4.35, p < 0.01), with locomotor activity in session 3 significant greater than all other 
sessions (p-values < 0.05). Locomotor activity in session 1 was significantly lower than 
that in sessions 2 and 3, but not 4 or 5. No significant differences were found across 
sessions in rats receiving saline. Furthermore, locomotor activity in rats receiving MDPV 
1 mg/kg was significantly higher than rats receiving saline across all treatment sessions 
(p-values < 0.05).  
Experiment 3 
 For experiment 3 (Fig. 18a), here were no significant differences in baseline 
locomotor activity between rats subsequently assigned to the saline treatment group 
(463.00 ± 72.30 turns) or METH 1 mg/kg groups (442.75 ± 49.70 turns). For the five 
treatment sessions (sessions 1-5; days 1-9), 2-way mixed ANOVA revealed a significant 
main effect of session (F[4,120]=3.42, p< 0.05), dose (F[1,30]=28.246, p<0.001, and a 
significant dose × session interaction (F[4,120]=3.31, p<0.05. Post-hoc analyses revealed 
a significant difference across treatment sessions in the METH 1 mg/kg group 
(F[4,60]=4.14, p<0.01), with sessions 1, 2 and 3 being significantly lower than session 5, 
and session 2 being significantly lower than session 4. No significant differences in 
locomotor activity were found across sessions in rats receiving saline. Rats treated with 
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METH 1 mg/kg showed  significantly greater activity than rats receiving saline across all 
treatment conditions (p-values <0.05).  
Experiment 4 
 For experiment 4 (Fig. 19a), there were no significant differences in baseline 
locomotor activity between rats subsequently assigned to the saline treatment group 
(497.88± 96.47 turns), MDPV 1 mg/kg group (513.90± 91.62 turns) or MDPV 5 mg/kg 
group (529.30 ±90.46 turns). For the five treatment sessions (sessions 1-5; days 1-9), 2-
way mixed ANOVA did not reveal a significant main effect of session but did reveal a 
significant main effect of dose (F[1,21]=5.07, p<0.05) and a significant dose × session 
interaction (F[8,84]=2.614, p<.05). Pairwise comparison revealed significant differences 
between the saline and MDPV 1 mg/kg groups as well as between the saline and MDPV 
5 mg/kg groups (p-values < 0.05).  One-way ANOVA revealed significant differences 
between sessions 1 and 3 (days 1 and 5, respectively; p-values < 0.05). For both sessions 
(1 and 3), the locomotor activity in the saline treatment group was significantly different 
from the MDPV 5 mg/kg group (p-values < 0.05).  
Sensitization Tests 
Experiment 1a and 1b 
The results of sensitization tests following drug challenge are shown in Figure 16. 
In Experiment 1a (Fig. 16a), no significant differences in locomotor activity following 
the MDPV 0.5 mg/kg challenge dose were observed between rats with a history of 
MDPV 1 mg/kg or saline (see Fig. 16a). In Experiment 1b (Fig. 16b), rats with a history 
of saline treatment showed increased locomotor activity following administration of 
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MDPV (1 mg/kg) as compared to rats with a history of MDPV (5 mg/kg) treatment 
(t[7]=2.63, p<0.05, see Fig. 16b). 
Experiment 2 
In Experiment 2 (Fig. 17b), rats with a history of repeated treatment with 1 mg/kg 
MDPV demonstrated an elevated locomotor response to the 0.5 mg/kg challenge of 
MDPV as compared to rats with a history of saline treatment (t[7]= 3.04, p < 0.05). In 
contrast, no significant differences between treatment groups were observed in the 
locomotor response to saline challenge (p>0.05; see Fig. 17b).   
Experiment 3 
In Experiment 3 (Fig. 18b), there were no significant differences in the locomotor 
response to the 0.5 mg/kg MDPV challenge between rats with a history of repeated 
METH vs. saline treatment (p>0.05). Furthermore, there were no significant differences 
in locomotor response to the saline challenge between rats with a history of METH vs. 
saline treatment (p>0.05; see Fig. 3B).  
Experiment 4 
In Experiment 4 (Fig. 19b), Dunnett’s test revealed that rats with a history of 
repeated treatment of 1 mg/kg MDPV exhibited increased locomotor activity in response 
to a 0.5 mg/kg METH challenge as compared to saline treated animals (p < 0.05).  
However, rats with a history of treatment with 5 mg/kg MDPV did not exhibit increased 
locomotor activity in response to the 0.5 mg/kg MDPV challenge (p=0.13).  There were 
also no significant differences in locomotor responses following saline challenge between 
rats with a history of METH 1 mg/kg vs. saline treatment or MDPV 5 mg/kg vs. saline 
(see Fig. 4B).  
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Discussion 
 The present study revealed that acute systemic administration of MDPV leads to 
increased locomotor behavior when compared to saline vehicle controls, and that 
repeated intermittent (48 hr interval) acute administration also leads to an enhancement of 
locomotor activity when subjects were subsequently tested with a challenge dose of either 
MDPV or METH, indicating the development of locomotor sensitization and cross-
sensitization to METH, respectively.  However, when MDPV treatments were separated 
by 24 hrs, sensitization to the locomotor stimulant effects of an MDPV challenge was not 
observed. Furthermore, rats receiving intermittent (48 hr interval) administration of 
METH did not display cross-sensitization to a subsequent MDPV challenge. In all 
experiments in which sensitization or cross-sensitization occurred, enhanced locomotor 
activity was not observed following saline challenge, suggesting that augmented 
locomotion during drug challenge tests were drug-specific and not driven by contextual 
conditioning factors such as re-exposure to the testing environment. To our knowledge, 
this is the first report of locomotor sensitization to MDPV, as well as cross-sensitization 
to METH, following repeated MDPV administration.  
 The augmented locomotor response seen following repeated exposure to 
psychostimulants is a robust and common phenomenon observed in laboratory animals 
(T. Robinson & Berridge, 2000, 2001; Steketee & Kalivas, 2011). The expression of 
behavioral sensitization is thought to reflect lasting neural adaptations that develop with 
repeated drug exposure (i.e. the incubation of sensitization) (Vanderschuren & Kalivas, 
2000). Furthermore, evidence suggests that these neuroadaptations may, at least in part, 
contribute to the transition to compulsive drug use (Cornish & Kalivas, 2001; Robinson 
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& Berridge, 2000), as repeated drug exposure not only potentiates behavioral 
responsivity and sensitivity to the drug, but also the development of drug self-
administration and reward (Vezina, Lorrain, Arnold, Austin, & Suto, 2002; Vezina, 2004; 
Zernig et al., 2007). Drug-induced increases in locomotor activity are mediated by 
increases in extracellular dopamine in limbic and motor circuits. Similarly, the 
progressive increase in locomotor activity characteristic of sensitization is also paralleled 
by augmented dopamine neurotransmission in limbic and motor regions such as the 
nucleus accumbens (Kalivas & Stewart, 1991; Vezina et al., 2002; Vezina, 2004).  
  The primary mechanism of action of MDPV is similar to cocaine in that it is a 
potent inhibitor of presynaptic plasma membrane dopamine and norepinephrine 
transporters (DAT and NET, respectively), with little effects on presynaptic plasma 
membrane serotonin transporters (SERT) (Baumann et al., 2013; Baumann et al., 2013; 
Eshleman et al., 2013; Simmler et al., 2013). Compared to cocaine, however, the potency 
of MDPV at inhibiting DAT and NET are 50 and 10 times greater, respectively 
(Baumann, Partilla, & Lehner, 2013; Baumann, Partilla, Lehner, et al., 2013). 
Furthermore, like cocaine, MDPV induces outward (hyperpolarizing) electrical currents 
in human DAT cells expressed in Xenopus laevis oocytes. Alternatively, inward DAT 
currents are produced by other synthetic cathinones such and mephedrone and methylone, 
as well as METH (Cameron et al., 2013, 2013). Unlike MPDV, these psychostimulants 
primarily exert their neurochemical effects as monoamine substrate releasers with 
varying levels of preference across DAT, NET and SERT as well as vesicular 
monoamine transporters (Baumann et al., 2013, 2012a). Systemic administration of 
MDPV elevates extracellular dopamine levels in the nucleus accumbens with at least 10 
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times greater potency than cocaine and with much longer lasting effects (Baumann et al., 
2013; Baumann et al., 2013; Marusich et al., 2014). In locomotor assays, MDPV is a 
powerful locomotor stimulant (Aarde et al., 2013; Fantegrossi et al., 2013; Gatch et al., 
2013; Marusich et al., 2012, 2014) and it is likely that these locomotor effects are 
mediated by D1 receptors in the nucleus accumbens as has been shown for other 
psychostimulants (Lobo & Nestler, 2011; Smith, Lobo, Spencer, & Kalivas, 2013).  Thus, 
consistent with previous studies on cocaine and amphetamines, the ability of MDPV to 
induce locomotor sensitization is likely mediated by its ability to augment extracellular 
dopamine levels in limbic and motor regions via potent DAT inhibition.  
Cross-sensitization has been shown to occur with both cocaine and amphetamines as well 
as other drug classes (Akimoto et al., 1990; Kalivas and Stewart, 1991; Fitzgerald et al., 
1996).  Although the primary pharmacological mechanisms of action differ across drug 
classes, the ability to increase mesolimbic dopaminergic transmission is common 
amongst drugs of abuse and is thought to mediate their locomotor stimulant properties 
(Robinson et al., 1988; Kalivas and Duffy, 1990; Fitzgerald et al., 1996). As such, cross-
sensitization is thought to occur when two drugs share overlapping mechanisms of action, 
albeit often differing from their primary mechanism of action (Steketee & Kalivas, 2011). 
Thus, while MDPV increases extracellular dopamine through DAT inhibition, and 
METH increases extracellular dopamine through monoamine substrate releasing effects, 
the net common effect of increased dopamine transmission on post-synaptic dopamine 
receptors is a likely possibility.  Specifically, persistent increases in DA transmission by 
both drugs could increase postsynaptic responsiveness to dopamine through either 
increases in DA receptor density or sensitivity (Kalivas & Stewart, 1991). Furthermore, 
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repeated exposure to both cocaine and amphetamines also enhance glutamate signaling in 
corticolimbic circuits (Kalivas et al., 2009), which likely also plays a role in the 
locomotor sensitizing effects of MDPV and its cross-sensitization to METH (Steketee & 
Kalivas, 2011).  However, glutamatergic effects of MDPV exposure have yet to be 
explored, but should be a central focus on future research on this synthetic cathinone.  
The lack of cross-sensitization to MDPV in animals with a history of METH 
exposure is puzzling given that a cross-sensitizing effect of METH was observed in rats 
with a history of MDPV exposure. Many experimental variables may have contributed to 
these negative observations, including  drug dose, number of exposures, dosing schedule, 
route of administration, and species/strain effects (Phillips et al., 2011). Thus, the 
possibility remains that bidirectional cross-sensitization between MDPV and METH may 
occur under certain experimental conditions. Given the mechanistic similarity between 
cocaine and MDPV, we predicted full cross-sensitization for both drugs. It is possible, 
however, that the lack of bidirectional cross-sensitization may be related to known effects 
of METH on serotonergic transmission, which is known to modulate rewarding and 
reinforcing effects of various psychostimulants (Rothman & Baumann, 2006). Clearly, 
further studies would be needed to dissect the precise monoaminergic mechanisms 
underlying cross-sensitization, or lack thereof, between MDPV and METH.  
 In experiments where sensitization to a drug challenge occurred, we observed no 
significant increases were observed when subjects were given a saline challenge test the 
previous day. The lack of a sensitization response in animals when tested with saline is 
important as evidence suggests that the convergence of drug exposure and associated 
environmental stimuli (context) together contribute to sensitized responding (Vezina et 
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al., 1989; Vezina and Leyton, 2009).  Because the expression of sensitization is often 
context-dependent, future research should assess whether repeated exposure to MDPV or 
METH in a separate distinct environment (e.g. home cage) would also produce sensitized 
responding when tested in an alternative environment.  
 The lack of locomotor sensitization to MDPV observed in Experiments 1a and 1b, 
where the inter-treatment interval was 24 hrs, is not without precedent.  Previous work 
has revealed that intermittent drug administration with longer inter-treatment intervals 
(e.g. 24 or 48 hrs vs. 3, 6, or 12 hrs) produces greater locomotor sensitization for 
methamphetamine, cocaine, and morphine (Kuribara, 1996).  In comparison with 
cocaine, MDPV-induced elevations in extracellular dopamine are much longer in 
duration, likely reflecting either a longer half-life and/or centrally active metabolites such 
as 3,4-dihydroxypyrovalerone (3,4-catechol-PV) and 4-hydroxy-3-methoxypyrovalerone 
(4-OH-3-MeO-PV) (Anizan et al., 2014). Research on the pharmacokinetic and/or 
pharmacodynamics of MDPV and its bioactive metabolites is generally lacking and 
should be a focus of future research studies.   
Repeated intermittent exposure to psychostimulant drugs not only increases 
locomotor behavior during subsequent drug exposure, but can also enhance drug self-
administration behavior, reward, and the development of psychostimulant-related 
psychosis. The findings presented here suggest that repeated use of MDPV can increase 
the sensitivity and behavioral responsivity to the drug, which may lead to increased 
vulnerability to addiction to MDPV and/or METH. Increased responsivity to MDPV may 
also explain he increased propensity to develop psychostimulant-induced psychosis or 
toxicity with subsequent use (Spiller et al., 2011; Prosser and Nelson, 2012). While the 
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present study only evaluated cross-sensitization of the locomotor stimulant effects of 
MDPV to that of METH, cross-sensitization across other drug classes has also been 
reported, and future research should focus on the drug-drug combinations for MDPV as 
well as other synthetic cathinones.   
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CHAPTER 8 
ASSESSMENT OF NEUROTOXIC AND COGNITIVE EFFECTS FOLLOWING 
CHRONIC INTRAVENOUS MDPV AND METH SELF-ADMINISTRATION 
Acute MDPV use has led to numerous reports of toxicity and death (Coppola & 
Mondola, 2012; Kesha et al., 2013; Mas-Morey et al., 2013; Mugele, Nañagas, & 
Tormoehlen, 2012; Murray et al., 2012; Penders & Gestring, 2011; Prosser & Nelson, 
2012; Ross et al., 2012; Spiller et al., 2011; Stoica & Felthous, 2013; Wright et al., 2013; 
Wyman et al., 2013). In fact, the majority of the published reports on MDPV exposure 
and use are case reports detailing the various adverse effects of acute exposure and 
overdose. More recently, however, evidence has emerged suggesting that the dangers of 
MDPV extend far beyond the adverse effects that can accompany acute overdose and/or 
toxicity. Specifically, studies have revealed that MDPV is highly reinforcing (Aarde et 
al., 2013; Watterson et al., 2014) and rewarding in animals (Bonano et al., 2014; De 
Felice et al., 2013; Watterson et al., 2014) and has methamphetamine and cocaine-like 
subjective effects (Fantegrossi et al., 2013; Ross et al., 2012; Ross, Watson, & 
Goldberger, 2011). Furthermore, human users often report a persistent desire to continue 
using MDPV despite these adverse effects, resulting in binge-like patterns of 
consumption that can last for days (Fass, Fass, & Garcia, 2012; Johnson, Johnson, & 
Portier, 2013; Maxwell, 2013; Penders, Gestring, & Vilensky, 2012; Penders & Gestring, 
2011; Ross et al., 2012; Slomski, 2012). While relatively scarce in comparison to case 
reports reporting intoxication, excited delirium, serotonin syndrome, hallucinatory 
psychosis, multi-organ toxicity, and death, reports of MDPV addiction have recently 
begun to appear in the literature (Sadeg et al., 2013; Winder, Stern, & Hosanagar, 2012). 
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To make matters worse, only protocols for supportive care following overdose have been 
established. Treatment strategies for MDPV addiction are not scientifically established, 
and basic research aimed at discovering pharmacotherapeutic targets for MDPV addiction 
is also scarce (Glennon, 2014; Jordan & Harrison, 2013).  Thus, the emergence of reports 
detailing MDPV addiction and the lack of any established treatments highlight the 
importance of basic preclinical research focusing on assessing the consequences of 
chronic, long-term use and finding potential neurological targets for the development of 
effective cognitive, behavioral, and/or pharmacotherapeutic treatments (Glennon, 2014).   
 As previously mentioned, MDPV is a potent DAT and NET reuptake inhibitor, 
with weak effects at SERT, that most closely resembles the neurochemical properties of 
cocaine (Baumann, Partilla, & Lehner, 2013; Baumann, Partilla, Lehner, et al., 2013). 
However, when compared with cocaine, MDPV is at least 50 times more potent in 
inhibiting DAT, 10 times more potent in inhibiting NET, and is at least 10-times more 
potent and longer lasting at increasing extracellular dopamine levels in the nucleus 
accumbens. For example, elevations in extracellular DA levels are significantly elevated 
above baseline levels 60 minutes after administration of MDPV,  whereas cocaine-
induced elevations return to baseline approximately 40 minutes after administration 
(Baumann, Partilla, & Lehner, 2013; Baumann, Partilla, Lehner, et al., 2013). Behavioral 
effects of MDPV, however, most closely resemble METH, with similar or greater 
reinforcing, rewarding, and locomotor stimulant effects (Aarde et al., 2013; Marusich et 
al., 2012;Watterson, et al., 2013; Watterson et al., 2014). Together, these effects suggest 
that long-term repeated exposure to MDPV may cause similar neurological toxic effects 
and cognitive deficits that are often reported after chronic heavy use of cocaine and/or 
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METH (Simon et al., 2001). However, to date, there are currently no studies assessing 
possible of neurotoxicity following long-term chronic MDPV use.  
 Human imaging studies have revealed that repeated use of METH or cocaine is 
correlated with substantial and enduring macroscale changes in regional volumes of and 
functional activity in various brain regions (Aron & Paulus, 2007; Ersche, Williams, 
Robbins, & Bullmore, 2013). In addition to neurotoxic effects secondary to 
cerebrovascular infarcts, seizures, and stroke, commonly reported structural 
abnormalities in psychostimulant users include changes in striatal volumes (Ersche, 
Jones, Williams, Robbins, & Bullmore, 2013; Ersche, Williams, et al., 2013; Franklin et 
al., 2002; Hanlon, Dufault, Wesley, & Porrino, 2011), decreased gray matter volumes in 
frontal as well as cingulate, limbic and paralimbic cortices, and shrinkage of the 
hippocampus. These changes are correlated with deficits in various domains of cognitive 
functioning include impaired inhibitory control, abnormal preservation, decreased 
attentional control, impairments in learning and memory, among other deficits (Baicy & 
London, 2007; Wood, Sage, Shuman, & Anagnostaras, 2014). However, as with all 
studies using human subjects, the possibility exists that these brain abnormalities or 
cognitive deficits reflect pre-existing differences or polysubstance abuse, instead of the 
toxic effects of a particular drug (Aron & Paulus, 2007; Ersche, Williams, et al., 2013; 
Majewska, 1996).   
 While it is possible that such pre-existing differences precede psychostimulant 
abuse, animal studies have demonstrated a causal relationship between psychostimulant 
use and toxicity at the cellular level that likely mediate this macroscale alterations.  The 
most commonly reported cellular neurotoxic effects are alterations in monoaminergic 
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signaling (mostly DA and 5-HT) as a result reduced presynaptic monoamine plasma 
membrane and vesicular transporters, formation of reactive oxygen and nitrogen species, 
DA quinones, and inflammatory cytokines (Berman, O’Neill, Fears, Bartzokis, & 
London, 2008; Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007; German et al., 2014; 
Halpin, Collins, & Yamamoto, 2013; Krasnova & Cadet, 2009; Larsen, Fon, Hastings, 
Edwards, & Sulzer, 2002; Majewska, 1996; Marshall & O’Dell, 2012; Panenka et al., 
2012; Schwendt, Rocha, & See, 2009; Zhu, Xu, & Angulo, 2006).  Others have also 
reported that psychostimulant use can lead to neurodegeneration through autophagic and 
apoptotic mechanisms (Cadet, Jayanthi, & Deng, 2003; Cunha-Oliveira et al., 2006; 
Davidson, Gow, Lee, & Ellinwood, 2001; Krasnova & Cadet, 2009; Nassogne, Louahed, 
Evrard, & Courtoy, 1997; Zhu et al., 2006).  As a result of these neurodegenerative 
effects, astroglial proliferation (i.e. reactive astrogliosis) can also occur, reflecting both 
neuroinflammation early after insult or neuronal scarring long after insult (Krasnova & 
Cadet, 2009; Simões et al., 2008).  Together, the loss of both terminals and cell bodies 
presumably underlie, at least partially, volumetric reductions and gray matter loss in the 
forebrain, striatum, and hippocampus reported following repeated psychostimulant use.  
 Given the facts that MDPV is highly reinforcing in rodents and there is evidence 
of compulsive use in humans, as well as an absence of studies examining neurotoxic and 
adverse cognitive effects of chronic long-term MDPV use, the overall purpose of the 
following experiments was to assess potential toxic effects, specifically 
neurodegeneration and astrogliosis, as well as cognitive deficits (decreased working 
memory and set shifting ability) following intravenous MDPV self-administration. 
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Furthermore, for comparison purposes separate groups of animals self-administered 
either METH or, as a non-drug control, sucrose.  
 
Method 
Subjects 
 All experimental procedures were conducted with the approval of the Institutional 
Animal Care and Use Committee at Arizona State University and were according to the 
Guide for Care and Use of Laboratory Animals as adopted by the National Institutes of 
Health (NIH). For all experimental procedures, rats were housed according to NIH 
standards on a 12-hour light–dark cycle and behavioral testing sessions took place during 
the dark phase.  
For experiment one, twenty-four male Sprague Dawley rats (Harlan Laboratories, 
Livermore, CA, USA), weighing approximately 250 g, were individually housed upon 
arrival. Rats were given ad libitum access to food and water during all experimental 
procedures, except during behavioral testing. Sixteen rats were implanted with jugular 
vein catheters and vascular access ports (see below for surgical methods) and underwent 
IVSA procedures. Eight additional rats placed into sucrose self-administration procedures 
did not receive surgery.  
For experiment 2, twenty-four male Sprague Dawley rats (Harlan Laboratories, 
Livermore, CA, USA), weighing approximately 250 g, were individually housed upon 
arrival. After 2 acclimation days, all rats were placed into delayed-match-to-position and 
S+/S- reversal learning task training (see below for experiment 2 methods) before 
beginning IVSA procedures. Throughout all behavioral procedures in experiment 2, rats 
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were given 1 hour access to food following cognitive testing procedure (approximately 
11 AM each day) prior to subsequent placement into self-administration procedures to 
maintain 85% of their free-feeding bodyweight throughout experimental testing. Rats 
were given ad libitum to water during all experimental procedures, except during 
behavioral testing. Sixteen rats were implanted with jugular vein catheters and vascular 
access ports and underwent IVSA procedures. Eight additional rats placed into sucrose 
self-administration procedures did not receive surgery. Four rats receiving catheterization 
lost patency prior to beginning IVSA experiments and were switched to oral self-
administration.  
Sucrose, drugs and Assessment of Purity 
MDPV was obtained through an Internet website (http:// 
www.researchchemz.com) (Laboratory Supply USA, San Diego, CA, USA). A 10-mg 
sample of MDPV was analyzed by liquid chromatography–mass spectrometry for purity 
at the Research Triangle Institute (Durham, NC, USA). Samples were analyzed using a 
Waters Synapt HDMS (Milford, MA, USA) quadrupole time-of-flight mass spectrometer 
interfaced to a Waters Acquity UPLC system. Data were acquired using a capillary 
voltage of 3 kV, source temperature of 150°C, desolvation temperature of 500°C, 
sampling cone at 30V and extraction cone at 4V. The mass spectrometer was externally 
calibrated from 50 to 700 Da using sodium formate solution, and mass shifts during 
acquisition were corrected using leucine enkephalin as a lockmass. Liquid 
chromatography was performed using a BEH C18 column (2.1 ¥ 50 mm, 1.7 µm particles) 
held at 40°C. Sample identity was confirmed based on exact mass, retention time and 
fragmentation match to a certified reference standard from Cerilliant (Round Rock, TX, 
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USA). MDPV samples were determined to have an apparent purity of >95%. For all 
behavioral studies, MDPV and methamphetamine (Sigma-Aldrich, St. Louis, MO, USA) 
were dissolved in sterile saline. Rats placed into sucrose self-administration procedures 
received one 45 mg sucrose pellet (Test- Diet, Richmond, IN, USA) as a reinforcer. 
During cognitive testing procedures (see below under experiment 2), chocolate and 
banana flavored 45 mg sucrose pellets (Bio-Serv, NJ, USA) served as reinforcers for 
DMTP and S+/S- procedures, respectively.  However, it should be noted that for DMTP 
procedures after LgA session 6, chocolate pellets became unavailable due to 
manufacturing issues with the vendor, at which point standard 45 mg sucrose pellets were 
used.  
Surgical Procedures 
For IVSA surgical procedures (experiments 1 and 2), rats were anesthetized with 
isoflurane (2% v/v, Butler Schein Animal Health, Dublin, OH, USA) vaporized in 
oxygen at a flow rate of 2 l/min. Rats received pre-incision injections of buprenorphine 
(0.05 mg/kg, s.c., Reckitt Benckiser, Richmond, VA, USA) and meloxicam (1 mg/kg, 
s.c., Boehringer Ingelheim, St. Joseph, MO, USA). Surgical sites were shaved and 
cleaned with 1% iodine. A ∼2 cm incision was made in order to isolate the right or left 
jugular vein. A sterile silastic catheter filled with 100 U/ml heparin was inserted 2.5cm 
into the vein. The catheter was secured to the surrounding tissue with sutures, and the 
opposite end of the catheter was tunneled subcutaneously to the dorsum where it exited 
the skin between the scapulae. The catheter was secured to the surrounding tissue by 
sutures and a mesh collar attached to a threaded vascular access port (Plastics One, 
Roanoke, VA, USA). Access ports were sealed with a piece of Tygon tubing (Cole-
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Parmer, Vernon Hills, IL, USA) closed at one end and a protective cap. Rats received one 
week of post-operative care including daily infusions of 0.4 ml Timentin (66.6 mg/ml, in 
70 U/ ml heparinized saline) to protect against infection and ensure catheter patency. 
Meloxicam (2.5 mg/ml, s.c.) was administered for the first 3 days following surgical 
procedures to provide additional relief of post-surgical discomfort. In addition, the rats 
were given ten 45 mg sucrose pellets in their home cage 4 days prior to IVSA procedures 
to eliminate neophobia to sucrose pellets that could delay acquisition of self-
administration during the two 2 hr training sessions.  
Experiment 1: IVSA Apparatus 
Drug and sucrose self-administration sessions were conducted in operant self-
administration chambers (ENV-008; Med Associates, St. Albans, VT, USA). All self-
administration chambers were located inside the sound-attenuating cubicles equipped 
with a house light and exhaust fan designed to mask external noise and odors, and were 
interfaced to a personal computer (PC). Chambers were equipped with two stainless steel 
response levers located on one wall with a 4.2 x 5 cm food pellet receptacle placed 
between levers. Each response lever was located approximately 7 cm above a stainless 
steel grid floor, and positioned above each lever was a 2.5-cm diameter white stimulus 
light. Located near the top of the self- administration chambers was a Sonalert speaker 
that provided an auditory stimulus during drug delivery. For drug self-administration, 
outside each chamber was a syringe pump that was interfaced to the computer and 
delivered the drug solution via a single-channel liquid swivel mounted atop the chamber 
via polyethylene tubing. Sucrose pellets were delivered through the food pellet receptacle 
between the two levers.  
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Experiment 1: Self-administration Procedures 
Following recovery from the surgical procedures, self-administration sessions 
commenced with two 2-hour sucrose self-administration sessions to initiate lever 
pressing. During all self-administration sessions, each press on the active lever delivered 
the reinforcer on a fixed-ratio 1 (FR1) schedule of reinforcement. Reinforcer delivery 
was accompanied by concurrent illumination of a stimulus light and presentation of an 
auditory stimulus for 2 seconds, followed by a 20-second timeout period, during which 
additional lever presses were recorded but produced no programmed responses. Inactive 
lever presses were recorded but produced no programmed responses. Rats were separated 
into one of three reinforce groups with 8 subjects initial per group; however, one rat from 
each of the MDPV and METH IVSA groups was removed from the study for catheter 
patency failure. The three results groups were: an MDPV group receiving 0.05 mg/kg per 
infusion (N=7), a METH group receiving 0.05 mg/kg per infusion (N=7), or a sucrose 
group (N=8) receiving a single 45 mg sucrose pellet per reinforcer delivery. Each drug 
infusion was delivered in a volume of 0.06 ml. MDPV and methamphetamine reinforcers 
were delivered to the vascular access port by polyethylene tubing housed in a stainless 
steel spring tether that was attached to the liquid swivel. Sucrose pellets were delivered to 
the pellet receptacle located between the active and inactive levers. Self-administration 
sessions were conducted 7 consecutive days per week, and each session was preceded 
and followed by an intravenous infusion of 0.1 ml Timentin (66.6 mg/ml, in 70 U/ ml 
heparinized saline) to maintain catheter patency. Daily 2-hr self-administration sessions 
were conducted for 16 days. Next, all rats began extended access sessions during which 
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the session length was extended to six hours. All other aspects of the self-administration 
procedures remained the same.  
Tissue Processing 
 24 hours following the last 6-hour self-administration session, rats were deeply 
anesthetized with sodium pentobarbital, 150 mg/kg i.p. and perfused transcardially with 
100 ml of phosphate-buffered saline (PBS, pH=7.4) followed by 200 ml 4% w/v 
paraformaldehyde in PBS (pH=7.4). Next, the skull was processed by removal of the 
skin, ears, fascia, eyes, and cartilaginous nose tips from the skull. The skull was post-
fixed in 4% w/v paraformaldehyde at 4°C for 12 hours. Next, the skull is removed and 
immersed in PBS at 4°C. PBS was replaced every 24 hours for the first five days at 
which point the skull was agitated for 2-3 minutes. Next, brains were removed from the 
skull, cryoprotected with 30% sucrose for 2 days at 4°C, and cut into coronal sections (40 
µm thickness) on a cryostat (Leica CM9000). Coronal adjacent serial sections (in groups 
of 6) were taken through the regions of interest and placed sequentially into cell culture 
dish wells containing 0.1 M phosphate buffer (i.e., 1 well per intended stain). Serial 
sections for orbital staining began at bregma +3.20 mm.  Serial sections for striatal 
(caudate, putamen, nucleus accumbens core and shell) sections began at bregma +1.60 
mm and serial sections for the hippocampus began at bregma -3.14 mm.   
Astrogliosis Assessment: Glial Fibrillary Acid Protein (GFAP) Immunohistochemical 
Staining Procedures 
For immunohistochemical staining, sections were incubated in 10% methanol to 
quench endogenous peroxidase activity, washed in PBS, preblocked for 1 hr in PBS 
containing 0.1% Tween 20, 1 M glycine, and 5% v/v donkey serum, followed by 
  129 
overnight incubation with GFAP primary (1:5000) antisera (product code AB7260, 
Abcam, MA, USA) at 4°C. On the next day, sections are washed, incubated with 
biotinylated secondary antisera (1:500; Jackson ImmunoResearch), following by 
chromogenic detection using a HRP-based Vectastain Elite ABC kit and nickel-enhanced 
diaminobenzidine (DAB) as a substrate (Vector Laboratories) to generate gray/black 
color. Sections were again washed, mounted onto microscope slides, and coverslipped 
with VectaMount Permanent mounting media. Photomicrographs were taken under 
brightfield microscopy at 10x magnification (Leica Microsystems; Bannockburn, IL, 
USA) using a digital camera interfaced to a PC computer. 
Neurodegeneration Assessment: Fluoro-jade C Staining Procedures 
For assessment of neurodegeneration, sections were stained with FluoroJade C 
(product code AG325, Merck Millipore, MA, USA) using procedures previously 
described elsewhere (Gass & Olive, 2009; Schmued, Stowers, Scallet, & Xu, 2005). 
Tissue sections were first mounted on 1% pig skin gelatin from distilled water. Slides 
were then air dried on a slide warmer for 60 minutes at 50 °C. Next, slides were 
immersed in a solution of 1% sodium hydroxide in 80% histological grade ethanol for 5 
minutes. Slides were then rinsed in 70% ethanol for 2 minutes, then distilled water for 2 
minutes, followed by incubation in 0.06% potassium permanganate solution for 10 
minutes. Next, slides were immersed in a 0.0001% FluoroJade C solution of 0.1% acetic 
acid. Slides were then rinsed three times in distilled water for 1 minute per rinse before 
air-drying for 10 minutes on the slide warmer at 50 °C. Slides were then clear with 
xylenes for 1 minute and, before being allowed to dry, coverslipped with DePex (Sigma-
Aldrich, St. Louis, MO, USA) mounting media.  
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In order to verify staining efficacy, one male Sprague-Dawley rat was used as a 
positive control and given a single 1 µg/µl intracerebroventricular (ICV) administration 
of kainic acid (KA) and transcardially perfused 24 hours later. Previous research has 
shown that method of KA treatment produces robust neurodegeneration in hippocampal 
tissue (Nadler, Perry, & Cotman, 1978; Sperk, 1994). During staining of each region of 
interest (ROI), hippocampal tissue from the KA positive control subject was included to 
verify staining continuity across assays. 40 µm sections were then obtained using 
identical tissue processing procedures described above. Photomicrographs were taken 
under epifluorescence microscopy at 488 nm excitation using a Leica DMLB microscope 
equipped with a digital camera that was interfaced to a PC computer. 
Image Analysis 
For GFAP staining, Image analysis was performed using ImageJ  (National 
Institutes of Health, Bethesda, MD, USA) by two independent experiments. Subsequent 
inter-rater reliability was greater than 95%.  Following contrast adjustment, both cell 
counts and percent total area were calculated for the ROIs (CA1 and CA3 of the 
hippocampus; medial PFC) in stained sections (striatal GFAP quantification was not 
possible due to non-specific interference from striosome staining). For neurodegeneration 
staining, no evidence of positive FluoroJade C staining was apparent when assessed by 
two independent experiments blind to groups of animals for ROIs including 
hippocampus, medial PFC, and striatum.  
Experiment 2: Cognitive Task Training 
 After two acclimation days, rats begin both S+/S- reversal learning and delayed-
match-to-position (DMTP) training (see methods below). During initial training, 50 trials 
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were conducted daily for both tasks until all rats met performance criterion (85% correct 
responses for 2 consecutive days). Following acquisition of performance criterion for 
both tasks, rats were placed into DMTP probe tasks or the first reversal for the S+/S- task 
in order to assess baseline cognitive performance before placement into one of three self-
administration groups (see below until experiment 2 IVSA methods). Throughout all 
DMTP and S+/S- reversal procedures, rats were given food for 1 hour a day 30 minutes 
following behavioral procedures to maintain 85% of their free feeding bodyweight. 
Experiment 2: DMTP Apparatus  
 DMTP tasks were conducted in operant chambers (ENV-008; Med Associates, St. 
Albans, VT, USA). All operant chambers were located inside the sound-attenuating 
cubicles equipped with a house light and exhaust fan designed to mask external noise and 
odors, and were interfaced to a personal computer (PC). Chambers were equipped with 
two stainless steel retractable response levers located on one wall with a 4.2 x 5 cm 
sucrose pellet receptacle placed between levers. Each response lever was located 
approximately 7 cm above a stainless steel grid floor. Chocolate sucrose pellets were 
delivered through the food pellet receptacle between the two levers. Prior to beginning 
daily DMTP testing, four drops of orange scented oil extract were placed into the bedding 
located in pans located beneath the grid floor to further aid in testing environment 
discrimination between DMTP from S+/S- tasks.  
Experiment 2: DMTP Training  
For DMTP, rats were placed into the chamber with the house light off and both 
levers retracted, and after an initial 10 sec delay, the house light turned on and the session 
began with the first trial. For each trial, one of the two retractable levers (i.e. the sample 
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lever) would be presented for 10 sec. Presses on the sample lever yielded a chocolate 
flavored sucrose pellet on an FR1 schedule and initiated a 1 sec waiting period where 
both levers were retracted. Failure to press on the sample lever was termed a forfeited 
trial and initiated a 30 sec inter-trial-interval during which both lever were retracted and 
the house light turned off (blackout ITI). After the 1 sec waiting period, both levers were 
ejected.  Presses on the previous sample lever yielded a chocolate pellet reinforcer on an 
FR1 schedule and initiated a 10 sec inter-trial-interval where the house light remained on. 
Presses on the non-sample lever initiated a 30 sec blackout ITI period and no reinforcer 
was given.  Failure to press on either lever during the choice phase after 10 sec was 
recorded as an incorrect response and initiated a 30 sec blackout ITI. Sessions ended after 
50 completed trials or 100 forfeited trials, whichever occurred first.  
Experiment 2: DMTP Probe Tests 
 After meeting criterion on DMTP training tasks, a DMTP probe tasks was 
initiated to assess baseline cognitive performance in all rats.  During probe tasks, the 
initial 10 trials were identical to training trials described above.  Following the initial 10 
trials, four the remaining 40 trials, a series of 4 waiting periods (consisting of 5, 10, 30 
and 60 sec) were presented following presses on the sample lever. These four waiting 
period were presented randomly without replacement ever four trials until all waiting 
periods were introduced in the four trial block (i.e. across 40 trials, 10 four trial block 
were presented). All other task parameters remained identical to DMTP training sessions. 
Following probe tasks, all rats were placed back into DMTP maintenance (identical to 
parameters used during training) training every 48 hours to maintain task performance 
prior to later probe tasks. The second probe test was conducted following 15 or 16 days 
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of 2 hour short access (ShA) self-administration procedures (see methods below) and a 
third reversal test was conducted following 15 or 16 days of 6 hour long access (LgA) 
self-administration procedures (see methods below). 
Experiment 2: S+/S- Training and Reversal Apparatus  
 S+/S- training sessions were conducted in operant chambers (ENV-008; Med 
Associates, St. Albans, VT, USA). All operant chambers were located inside the sound-
attenuating cubicles equipped with a house light and exhaust fan designed to mask 
external noise and odors, and were interfaced to a personal computer (PC). Chambers 
were equipped with two stainless steel non-retractable response levers located on one 
wall with a 4.2 x 5 cm sucrose pellet receptacle placed between levers. Each response 
lever was located approximately 7 cm above a stainless steel grid floor, and positioned 
above each lever was a 2.5-cm diameter white stimulus light. Banana flavored sucrose 
pellets were delivered through the food pellet receptacle between the two levers. Prior to 
beginning daily S+/S- testing, four drops of anise scented oil extract were placed into the 
bedding located in pans located beneath the grid floor to further aid in testing 
environment discrimination between DMTP from S+/S- tasks. 
Experiment 2: S+/S- Training 
 For S+/S- training, rats were placed into the chamber with the house light off and 
both levers ejected. Sessions began when the house light turned on and both stimulus 
lights over the levers turned on. Initially, the right lever was deemed the S+ lever and left 
lever deemed the S- lever. Responses on the right lever yielded a banana flavored sucrose 
pellet reinforcer on an FR1 schedule, initiated a 2 sec tone stimulus and initiated a 2 
second inter-trial interval during which both stimulus lights turned off and additional 
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presses were recorded but produced no programmed consequences.  Responses on the left 
lever yielded no reinforcement but initiated a 5 sec ITI during which both stimulus light 
turned off and presses were recorded but had no programmed consequences.  After the 5 
sec ITI, both stimulus light above the levers were illuminated signaling the beginning of 
the next trial. Sessions ended after 50 completed trials or 2 hours, whichever occurred 
first. 
Experiment 2: S+/S- Reversal Test 
 After meeting criterion on S+/S- training task, a reversal test was initiated to 
assess baseline set shifting performance in all rats. During the reversal task, all task 
parameters remained identical to training with the only change being that the right lever 
now became S- (i.e. trial responses now longer reinforced) and the left lever became S+ 
(i.e. trial responses now reinforced). Following the initial reversal test, the left lever 
remained S+ and right lever S- until the next reversal test was conducted during which 
sessions were conducted every 48 hours, alternating test days with the DMTP 
maintenance testing. The second reversal test was conducted following 15 or 16 days of 2 
hour ShA self-administration procedures (see below) and a third reversal test was 
conducted following 15 or 16 days of 6 hour LgA self-administration procedures (see 
below).  
Experiment 2: Self-administration Apparatus 
 Drug and sucrose self-administration sessions were conducted in operant self-
administration chambers (ENV-008; Med Associates, St. Albans, VT, USA). All self-
administration chambers were located inside the sound-attenuating cubicles equipped 
with a house light and exhaust fan designed to mask external noise and odors, and were 
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interfaced to a personal computer (PC). Chambers were equipped with two nosepokes 
located on one wall with a 4.2 x 5 cm food pellet receptacle placed between levers. Each 
nosepoke was located approximately 6 cm above a stainless steel grid floor and inside 
each nosepoke was a 1 cm diameter white stimulus light. Located near the top of the self- 
administration chambers was a Sonalert speaker that provided an auditory stimulus 
during drug delivery. For drug self-administration, outside each chamber was a syringe 
pump that was interfaced to the computer and delivered the drug solution via a single-
channel liquid swivel mounted atop the chamber via polyethylene tubing. Sucrose pellets 
were delivered through the food pellet receptacle between the two nosepokes. 
Following the initial DMTP probe test and first reversal test, rats were placed into 
three separate groups of eight rats such that baseline performance on the DMTP probe 
was approximately equal across the groups. The three groups were placed into either a 
METH (0.05 mg/kg/infusion; N = 6) or MDPV (0.05 mg/kg/infusion; N = 7) IVSA 
group, or an oral sucrose self-administration group (n = 12).  Rats placed into the METH 
and MDPV IVSA groups underwent surgical procedures (described above) and allowed 
to recovery for five days. Rats in the oral sucrose group received no surgery. Following 
recovery from surgical procedures, self-administration sessions commenced with no 
nosepoke training (i.e. spontaneous acquisition). During all IVSA procedures, the active 
nosepoke was signaled by illumination of the stimulus inside the nosepoke aperture and 
was randomly altered between the right and left nosepoke after each reinforcer delivery. 
During all self-administration sessions, each response on the active nosepoke delivered 
the reinforcer on a fixed-ratio 1 (FR1) schedule of reinforcement. Reinforcer delivery 
was accompanied by concurrent presentation of an auditory stimulus for 2 seconds, 
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followed by a 20-second timeout period, during which the stimulus light inside the 
nosepoke turned off and additional nosepokes were recorded but produced no 
programmed responses. Responses on the inactive nosepoke were recorded but produced 
no programmed responses. As mentioned above, rats were separated into one of three 
reinforcer groups, based upon cognitive performance on the initial DMTP probe test, with 
initially 8 subjects per group. However, two rats from each of the MDPV and METH 
IVSA groups lost patency prior to IVSA procedures and were transferred to the oral 
sucrose self-administration group. The three resulting groups were: an MDPV group 
receiving 0.05 mg/kg per infusion (N=6), a METH group receiving 0.05 mg/kg per 
infusion (N=6), or a sucrose group (N=12) receiving a single 45 mg sucrose pellet per 
reinforcer delivery. Each drug infusion was delivered in a volume of 0.06 ml. MDPV and 
methamphetamine reinforcers were delivered to the vascular access port by polyethylene 
tubing housed in a stainless steel spring tether that was attached to the liquid swivel. 
Sucrose pellets were delivered to the pellet receptacle located between the active and 
inactive nosepokes. Self-administration sessions were conducted 7 consecutive days per 
week, and each session was preceded and followed by an intravenous infusion of 0.1 ml 
Timentin (66.6 mg/ml, in 70 U/ ml heparinized saline) to maintain catheter patency. 
Daily 2 hour ShA self-administration sessions were conducted for 16 days. Next, all rats 
began long access sessions during which the session length was extended to six hours for 
a total of 16 sessions. All other aspects of the self-administration procedures remained the 
same.  
Data and Statistical Analysis  
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 All statistical analyses were conducted using IBM SPSS Statistics version 21 
(Armonk, New York, USA).  All data points represent mean ± SEM. A significance 
criterion of p<0.05 was used for all analyses.  
For experiment 1, the first 16 ShA IVSA sessions were analyzed with a 2 (lever: 
active vs. inactive) X 16 (session: 1 – 16) mixed analysis of variance (ANOVA) for 
MDPV (N = 7), METH (N = 7), and sucrose groups (N=8) separately. Post-hoc t-tests 
were conducted at each session to assess differences between active and inactive lever 
presses. For LgA procedures, total number of reinforcers were analyzed with repeated 
measures ANOVAs with session as repeated measures (sessions 1 – 10) to assess for 
escalation from the first session of LgA for the MDPV, METH, and sucrose groups 
separately. Pairwise comparisons were used to assess for significant differences in total 
reinforcer intake versus LgA session 1. For GFAP, data represents the mean generated by 
total counts and total percent area from 2 – 4 brain slices from both hemispheres (i.e. 
mean of 4 – 8 separate determinations for each subject). Final total counts and percent 
area represent the mean generated by two independent raters showing greater than 95% 
inter-rater-reliability. GFAP cell counts and total percent area of the region of interest 
were analyzed with one-way ANOVAs with group (MDPV, METH, or sucrose: N = 7, 7, 
and 8, respectively) as the between subjects factor. For FluoroJade C neurodegeneration 
staining, one-way ANOVAs with group (MDPV, METH, or sucrose; N = 7,7, and 8, 
respectively) as the between subjects factor were planned, but visual inspection of slices 
revealed no positive cell counts and thus quantitative analyses were not performed (see 
Fig. 25 for representative images).  
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For experiment 2, the first 16 ShA IVSA sessions were analyzed with a 2 
(nosepoke: active vs. inactive) X 16 (session: 1 – 16) mixed analysis of variance 
(ANOVA) for MDPV (N = 6), METH (N = 6), and sucrose groups (N = 12) separately. 
Post-hoc t-tests were conducted at each session to assess differences between active and 
inactive lever presses. For LgA procedures, total number of reinforcers were analyzed 
with repeated measures ANOVAs with session as repeated measures (sessions 1 – 16) to 
assess for escalation from the first session of LgA for the MDPV (N = 6), METH (N = 6), 
and sucrose groups (N = 12) separately. For DMTP probe tests, percent correct responses 
at each waiting interval (1, 5, 10, 30, 60, and total) were analyzed with one-way 
ANOVAs with group (MDPV, METH, or sucrose; N = 6, 6, and 8, respectively) as the 
between subjects factor. Also for DMTP probe tests, total number of completed and 
forfeited trials were also analyzed with one-way ANOVAs with group (MDPV, METH, 
or sucrose) as the between subjects factor and post-hoc Holm-Sidak tests for group 
comparison. For S+/S- reversal tests, percent correct responses and total number of trials 
completed were analyzed with one-way ANOVAs with group (MDPV, METH, or 
sucrose; N = 6, 5, and 11, respectively) serving as the between subjects factor with Holm-
Sidak post-hoc tests used for individual group comparison.  One subject from both the 
METH and sucrose group did not reach acquisition criterion prior to the initial reversal 
test and were not included in any of the S+/S- reversal tests. Finally, bodyweight assessed 
the morning of each of the cognitive testing time points was analyzed with a one-way 
ANOVA with group (MDPV, METH, or sucrose) as the between subjects factor and 
Holm-Sidak post-hoc tests between individual groups.  
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Results 
Experiment 1: Self-administration 
 For MDPV, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive levers) 
X 16 (ShA session) mixed ANOVAs revealed a significant main effect of session 
(F[15,195] = 2.52, p < 0.01), lever (F[1,13] = 18.55, p < 0.001), and session X lever 
interaction (F[15,195] = 2.939, p < 0.001). Post-hoc t-tests revealed that MDPV rats 
successfully discriminated between and active and inactive levers with active lever 
presses greater than inactive lever presses across all sessions, all p’s < 0.05 (Fig. 20a).  
For METH, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive levers) 
X 16 (ShA session) mixed ANOVAs revealed a significant main effect of session 
(F[15,210] = 3.75, p < 0.001), lever (F[1,14] = 13.15, p < 0.01), and session X lever 
interaction (F[15,210] = 2.31, p < 0.01). Post-hoc t-tests revealed that METH rats 
successfully discriminated between and active and inactive levers with active lever 
presses greater than inactive lever presses across all sessions, all p’s < 0.05 (Fig. 20b). 
For sucrose, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive 
levers) X 16 (ShA session) mixed ANOVAs revealed a significant main effect of session 
( [15,210] = 4.80, p < 0.001) lever (F[1,14] = 42.77, p < 0.001), and session X lever 
interaction (F[15,210] = 4.95, p < 0.001). Post-hoc t-tests revealed that sucrose rats 
successfully discriminated between and active and inactive levers with active lever 
presses greater than inactive lever presses across all sessions, all p’s < 0.05 (Fig. 20c).  
Following ShA, rats were placed into LgA session for 10 additional days. 
ANOVAs revealed a significant effect of session in the METH (F[9,54] = 2.09, p< 0.05) 
and MDPV (F [9,54] = 3.05, p< 0.005) groups, but not in sucrose rats (F[9,63 ]= 1.37, p> 
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0.05) (Fig. 21a). Pairwise comparisons revealed a trend toward escalation of intake as 
measured by an increase in the number of reinforcers on LgA session 10 vs LgA session 
1 for the MDPV group, p = 0.052. A trend toward escalation of intake was also found for 
METH LgA session 10 vs LgA session 1 for the METH group, p = 0.061.  Sucrose rats 
did not significantly escalate intake across LgA sessions.   
 For the first two hours of LgA for MDPV, there was a significant main effect of 
session (F[9,54] = 2.86, p < 0.005), but when compared to day 1, pairwise comparisons 
for LgA session 10 only showed a trend towards escalation, p = 0.10. Rats in the METH 
group did not significantly escalate intake in the first two hours (F[9,54] = 1.27, p >0.05). 
Rats in the sucrose groups showed significant changes in reinforcers obtained across the 
first two hours of LgA, but did not escalate from day 1 (F[9,63] = 2.49, p <0.05) (Fig. 
21b).  
Experiment 1: GFAP Total Counts and Percent Total Area 
For the CA1 area, ANOVA did not reveal significant group different for total 
positive cell counts (F[2,19] = 1.13, p > 0.05) (Fig. 22a), or percent total area (F[2,19] = 
1.22, p > 0.05) (Fig. 22b). For the CA3 area, ANOVA did not reveal significant group 
different for total positive cell counts (F[2,19] = 0.03, p > 0.05) (Fig. 23a), or percent 
total area (F[2,19] = 0.67, p > 0.05) (Fig. 23b). For the medial PFC area, ANOVA did not 
reveal significant group differences for total positive cell counts (F[2,19] = 2.12, p > 
0.05) (Fig. 24a), or percent total area (F[2,19] = 2.24, p > 0.05) (Fig. 24b). 
Experiment 1: FluoroJade C Staining 
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 No FluoroJade C staining was observed in the dorsal hippocampus, striatum, or 
medial prefrontal cortex (Fig. 25). Fluorojade C staining was, however, observed in the 
dorsal hippocampus of the rat treated with KA (Fig. 25).  
Experiment 2: Self-administration 
 For MDPV, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive 
nosepokes) X 16 (ShA session) mixed ANOVAs revealed a significant main effect of 
session (F[15,150] = 2.52, p < 0.01), nosepokes (F[1,10] = 8.13, p < 0.05), and session X 
nosepoke interaction (F[15,150] = 2.32, p < 0.001). Post-hoc t-tests revealed that MDPV 
rats successfully discriminated between and active and inactive nosepokes with active 
responses greater than inactive responses for all sessions after ShA session 4, all p’s < 
0.05 (Fig. 26a).  
For METH, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive 
nosepokes) X 16 (ShA session) mixed ANOVAs revealed a significant main effect of 
session (F[15,150] = 2.54, p < 0.01), nosepokes (F[1,10] = 83.13, p < 0.01, and session X 
nosepoke interaction (F[15,150] = 2.32, p < 0.01). Post-hoc t-tests revealed that METH 
rats successfully discriminated between and active and inactive nosepokes with active 
responses greater than inactive responses across all sessions, all p’s < 0.05 (Fig. 26b). 
For sucrose, across 2-hour (ShA) sessions for 16 days, 2 (active vs inactive 
nosepokes) X 16 (ShA session) mixed ANOVAs revealed a significant main effect of 
session (F[15,330] = 5.60, p < 0.001) nosepokes (F[1,22] = 430.66, p < 0.001), and 
session X nosepoke interaction (F[15,330] = 6.40, p < 0.001). Post-hoc t-tests revealed 
that sucrose rats successfully discriminated between and active and inactive nosepokes 
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with active responses greater than inactive responses across all sessions, all p’s < 0.05 
(Fig. 26c).  
Following ShA, rats were placed into LgA sessions for 16 additional days. 
ANOVAs revealed a significant effect of session in the sucrose (F[15,165]= 6.89, p < 
.001) and MDPV (F[15,75] = 2.07, p < 0.05) groups, but not for METH (F[15,75] = 1.25, 
p>.05) (Fig. 26d). For sucrose reinforcers, compared to LgA session 1, LgA sessions 3, 
11, and 13-16 were significantly lower (p’s < 0.05). For MDPV infusions, pairwise 
comparisons did not reveal significant any significant escalation for any LgA session 
compared to LgA session 1.  
Experiment 2: DMTP Probe Tests 
 For percent correct responses on the Pre-IVSA DMTP probe test (Fig. 27a), 
ANOVA revealed a significant main effect of waiting time (F[4,84] = 35.176, p < .001), 
but not treatment group (F[2,21] = 0.433, p > 0.05), or a waiting time X treatment group 
interaction (F[8,84] = 0.399, p > 0.05). Pairwise comparisons revealed performance 
steadily decreased as waiting times increased, within significance occurring between all 
waiting times (p’s < 0.05) with the exception of the 30 and 60 sec waiting time. For total 
forfeited and completed trials (Figs. 28a and b, respectively), ANOVA revealed no 
significant differences between treatment groups (p’s > 0.05).  
 For percent correct responses on the Post-ShA DMTP probe test (Fig. 27b), 
ANOVA revealed a significant main effect of waiting time (F[4,84] = 38.93, p < 0.001), 
but not treatment group (F[2,21] = 0.45, p > 0.05), or a waiting time X treatment group 
interaction (F[8,84] = 0.74, p > 0.05). Pairwise comparisons revealed the following 
differences across waiting times: performance steadily decreased as waiting times 
  143 
increased between the 1 and 5 sec waiting times compared with all waiting times (p’s < 
0.05), (2) no differences were found between 10, 30 and 60 sec waiting times. For total 
forfeited and completed trials (Figs. 28a and b, respectively), ANOVA revealed no 
significant differences between treatment groups (p’s > .05). 
 For percent correct responses on the Post-LgA DMTP probe test (Fig. 27c), 
ANOVA revealed a significant main effect of waiting time (F[4,84] = 33.28, p < 0.001), 
but not treatment group (F[2,21] = 0.38, p > 0.05), or a waiting time X treatment group 
interaction (F[8,84] = 1.23, p > 0.05). Pairwise comparisons revealed the following 
differences across waiting times: (1) performance steadily decreased from the 1 sec 
waiting time for all other waiting times, (2) performance during the 5 sec waiting time 
was significantly better than the 30 and 60 sec waiting time, (3) performance during the 
10 sec waiting time was better than the 60 sec waiting time (p’s < 0.05). No other 
pairwise comparisons were significant. For total completed trials (Fig. 28b), ANOVA 
revealed no significant differences between treatment groups (p’s > 0.05). For forfeited 
trials (Fig. 28a), ANOVA revealed a significant difference in the number of forfeited 
trials (F[2,21] = 9.937, p < 0.001), with Holm-Sidak post-hoc tests showing that sucrose 
rats forfeited significantly more trials than rats in either the MDPV or METH group (p’s 
< 0.05 and 0.01, respectively).  
Experiment 2: S+/S- Reversal Tests 
For percent correct on the Pre-IVSA S+/S- reversal test (Fig. 29), ANOVA 
revealed no significant effect of treatment group (F[2,19] = 1.09, p > 0.05). For percent 
correct on the Post-ShA S+/S- reversal test (Fig. 29), ANOVA revealed no significant 
effect of treatment group (F[2,19] = 0.52, p > 0.05). For percent correct on the Post-LgA 
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S+/S- reversal test (Fig. 29), ANOVA revealed no significant effect of treatment group 
(F[2,19] = 2.97, p > 0.05). Finally, no significant differences in total number of 
completed trials were found across the three S+/S- reversal tests as all subjects in each 
group completed all 50 trials (p’s > 0.05).  
Body weights 
For body weights (Fig. 30), ANOVA did not reveal any significant differences 
between treatment groups for the Pre-IVSA cognitive tests (p’s > 0.05). For the Post-ShA 
test, body weight was significantly different (F[2,21] = 5.10, p < 0.05), with Holm-Sidak 
post-hoc tests revealing a greater body weight in the sucrose group compared to MDPV 
group (p < 0.05). For the Post-LgA test, body weights  were significantly different 
(F[2,21] = 66.492, p < 0.001), with Holm-Sidak post-hoc tests revealing greater body 
weight in the sucrose group compared to MDPV and METH groups (p’s < 0.001).  
 
Discussion 
 The results of the present study revealed that during both ShA and LgA IVSA, 
MDPV produces robust IVSA behavior similar to that of METH, replicating previously 
published findings from both our laboratory (Watterson et al., 2014) and others (Aarde et 
al., 2013). However, as shown in experiment 1, when compared to oral sucrose controls, 
self-administratin of neither MDPV nor METH produced evidence of neurotoxicity in the 
three ROIs assessed (medial PFC, dorsal hippocampus, or striatum). Specifically, no 
evidence of astrogliosis was revealed by changes in GFAP immunoreactivity between the 
three groups , and no evidence of neurodegeneration (as evidenced by a lack of 
FluoroJade C staining) was found in any experimental animals other than a positive 
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control subject injected with KA. In experiment 2, following both 16 days of ShA or LgA 
self-administration procedures, no evidence of working memory deficits or abnormal 
perseveration were revealed from either the DMTP nor S+/S- tasks, respectively, for 
either drug when compared to sucrose controls.  Together, results from this study suggest 
that IVSA of MDPV and METH under the current procedural parameters does not lead to 
neurotoxic or adverse cognitive effects similar to those reported in human users of illicit 
psychostimulants.  
 GFAP is a cytoskeletal intermediate filament protein expressed exclusively in 
astrocytes. GFAP is a validated biomarker of toxicity as damage to both neurons and glial 
cells can elicit astrogliosis that can result from numerous types of toxic insults including 
drugs, chemicals, organic trauma and disease (O’Callaghan & Sriram, 2005; 
O’Callaghan, 1991). Astrogliosis can occur both shortly after insult as a 
neuroimflammatory response or later as glial scarring (Hostenbach, Cambron, 
D’haeseleer, Kooijman, & De Keyser, 2014). For amphetamine-type stimulants, 
increased GFAP activity has become a popular measure of toxicity and has extensively 
been used as a biomarker of CNS damage (O’Callaghan & Miller, 1993, 1994). 
Numerous studies have now shown robust astrogliosis in rodents following exposure to 
METH (Achat-Mendes, Anderson, & Itzhak, 2007; Deng, Ladenheim, Tsao, & Cadet, 
1999; Kuczenski et al., 2007; Zhu, Xu, & Angulo, 2005; Cappon, Pu, & Vorhees, 2000; 
Zhu et al., 2005; Friend & Keefe, 2013; Krasnova et al., 2010), cocaine (Blanco-Calvo et 
al., 2014; Bowers & Kalivas, 2003; Fattore et al., 2002), and the synthetic cathinone 
mephedrone (Martínez-Clemente et al., 2014). Furthermore, these effects have been 
reported in numerous brain regions including the cortex, striatum, and hippocampus (for 
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reviews see (Gonçalves, Baptista, & Silva, 2014; Krasnova & Cadet, 2009). As 
mentioned previously, MDPV is neurochemically most similar to cocaine as a selective 
DAT blocker, but produces much longer lasting effects on striatal extracellular DA and 
similar patterns of IVSA that most closely resembles that of METH (Aarde et al., 2013; 
Baumann, Partilla, Lehner, et al., 2013; Watterson et al., 2014). As such, we predicted 
that IVSA of MDPV and METH would also produce astrogliosis in our ROIs 
(hippocampus, striatum, and medial PFC). Despite the robust self-administration across 
both ShA and LgA, levels of GFAP immunoreactivity in the the hippocampus and medial 
PFC were not significantly different for either drug than rats self-admiinstrering sucrose. 
Striatal GFAP quantification was not possible due to non-specific interference from 
striosome staining.  
While GFAP immunoreactivity in rats self-administering either MDPV or METH 
was not significantly greater from sucrose rats as we had predicted, this is perhaps not 
entirely surprising as the majority of studies previously reporting astrogliosis following 
either cocaine, mephedrone, or METH exposure, have used high-dose experimenter-
administered (non-contingent) treatment regimens of either single large bolus or repeated 
binge-like doses (for reviews see (Krasnova & Cadet, 2009; Gonçalves et al., 2014). 
Indeed, to our knowledge, only a limitied number of published studies have employed 
METH self-administration procedures and subsequently assessed GFAP levels (Schwendt 
et al., 2009; Krasnova et al., 2010; Reichel, Ramsey, Schwendt, McGinty, & See, 2012), 
and no mephedrone self-administration studies assessing GFAP levels have been 
published. In the first of these IVSA METH studies (Schwendt et al., 2009), male Long-
Evans rats  either self-administered METH (0.02 mg/infusion) or received yoked saline 
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for 7 – 10 1-hr sessions, followed by 12-14 days of 6 hr LgA and then approximately 2 
weeks of extinction sessions. Results from this study revealed that despite an escalation 
in METH intake, no resulting increases in GFAP immunoreactivity (as assessed by 
immunoblotting) occurred in the prefrontal cortex, dorsal striatum, or nucleus accumbens 
when compared to saline rats. Furthermore, other common markers of toxicity including 
reductions in immunostaining for tyrosine hydroxylase, NET, or SERT, or 
immunostaining for the microglial activation marker Iba-1, were also not significantly 
different between METH and saline rats in these same regions. Only decreases in DAT 
immunoreactivity in the PFC and striatum were significant. In a second study (Reichel et 
al., 2012), rats received either an experimentally administered binge-dose regimen of 
METH (four 4 mg/kg i.p. injections given every 2 hours) or METH IVSA (0.02 
mg/infusion, 7 days for 1 h/day, followed by 14 days for 6 h/day) followed by 8 days of 
abstinence. In rats receiving the experimenter-administered (non-contingent) binge-dose 
regimen, GFAP striatal immunoreactivity (as assessed by immunoblotting) was increased 
relative to saline controls; however, GFAP levels were not assessed in any other regions. 
Furthermore, TH and DAT were also decreased in striatal tissue. However, in rats 
undergoing IVSA procedures, no significant differences were found in GFAP, TH, or 
DAT immunoreactivity, underscoring that important differences occur following 
experimenter administered vs voluntary self-administration of METH. In the third study 
(Krasnova et al., 2010), rats were placed into either METH IVSA (0.1 mg/kg/infusion) 
procedures or yoked saline control procedures for 15 hours a day for 8 consecutive days. 
After 7 days of abstinence, both striatal and cortical tissue showed robust increases in 
GFAP levels (as assessed by immunoblotting) vs saline controls; furthermore, GFAP 
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immunoreactivity was significantly correlated with total METH intake across the 8 days 
of IVSA in both regions. Increased GFAP immunoreactivity was also accompanied by 
significant decreases in TH and DAT levels in these same regions.  
Thus, in other studies uisng IVSA procedures similar to those in the present study 
with METH and MDPV, effects on GFAP expression in various brain regions is 
inconsistent which are likely the result of the different task or dosing parameters 
employed across these studies. Major disparities between our study and those discussed 
above include differences in METH dose, overall amount of METH intake, tissue assays 
employed (IHC in the present study and immunoblotting in the others), and the length of 
time following IVSA procedures when tissue was harvested (24 hr in the present study vs 
7 – 14 days in the other studies). The most likely explanation for the lack of changes in 
GFAP levels is that the overall amount of METH and MDPV intake was not sufficient to 
induce astrogliosis. In the current study, across both ShA and LgA, MDPV and METH 
rats self-administered approximately 140 and 70 mg/kg, respectively. These totals are 
similar to those reported for two weeks of LgA METH (7-140 mg/kg) in the studies of 
Schwendt et al. (2009) and Reichel et al. (2012) which also reported no effects on GFAP 
levels. In contrast, Krasnova et al., (2010) reported total intake levels between 40-160 
mg/kg over 8 days (15 hr / day) and a significant elevation in GFAP immunoreactivity in 
the striatum and cortex, and these increases in GFAP levels were also positively 
correlated with overall METH intake. Thus, the most likely scenario for the lack of 
effects of MDPV or METH on GFAP immunoreactivity in the present study and others 
mentioned above is an insufficient amount of drug taken in a short enough period of time 
to induce toxicity. 
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Still another explanation for lack of GFAP immunoreactivity could also be related 
to the timecourse of changes in GFAP expression. In the current study, rats were 
sacrificed 24 hours following the last LgA session. In mice, following 1 single injection 
of METH (30 mg/kg, i.p.), GFAP expression is not significantly increased versus saline 
controls at 24 hours post-treatment, but is elevated two days later with peak effects 
occuring at day three (Zhu et al., 2005). In rats, four 10 mg/kg s.c. doses of METH given 
every two hours have been shown to increase striatal GFAP levels at both 48 hour and 32 
day timepoints (Friend & Keefe, 2013) and others have also shown that a single 40 mg/kg 
i.p. dose of METH increases striatal GFAP at 10 days following administration (Cappon, 
Pu, & Vorhees, 2000).  Finally, in rats receiving an escalation binge-dosing regimen of 
METH (10, 15, 15, 20, 20, 25, 30 mg/kg, s.c. over 7 consecutive days) and sacrificed 24 
hours later, no significant differences in GFAP immunoreactivity were found compared 
to saline controls in either the striatum or frontal cortex (Simões et al., 2008). Thus, when 
astrogliosis does occur following psychostimulant exposure, it generally is found in tissue 
harvested at least 2 days following the last drug treatment. It is therefore possible that 
differences in GFAP levels may have emerged had rats been sacrificed at a timepoint 
longer than 24 hours. However, lack of observed changes in GFAP  in the studies by 
Schwendt et al., (2009) and Reichel et al., (2012), in which tissue was collected between 
7-14 days after cessation of drug intake, while others showing that it can last over 30 
days (Friend & Keefe, 2013), argues against this notion.  
Finally, and perhaps most important for the relationship between astrogliosis and 
stimulant addiction, a recent report has suggested that GFAP immunoreactivity is not 
significantly altered in human METH addicts (Kitamura et al., 2010).  In this study, 
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striatal tissue from METH users (N = 12) who died of drug overdose was 
immunohistochemically stained for GFAP. While a positive trend was noted, there was 
no significant increase in GFAP staining when compared to tissue from non-drug using 
control subjects (N = 13). Based on these findings, the authors argued that astrogliosis is 
not likely involved in the transition to the loss of control over drug intake characterizing 
METH addiction. Thus, a likely scenario is that astrogliosis does not typically occur 
following repeated voluntary administration of METH and when it does occur in animals, 
the large bolus doses given are perhaps physiologically irrelevant for addiction.  
Both cupric silver or FluoroJade C staining procedures can detect degenerating 
neurons from a variety of drug, chemical, or organic insults, and stain all degenerating 
regions of neurons including somata, axons, and terminals (Schmued et al., 2005; 
Switzer, 2000). Evidence for neuronal degeneration using these techniques has been 
shown in numerous animal studies followed large non-contingent doses of amphetamines 
in regions such the striatum, hippocampus and various cortical regions (Ares-Santos, 
Granado, Espadas, Martinez-Murillo, & Moratalla, 2014; Bowyer & Ali, 2006; 
Commins, 1987; Eisch, Schmued, & Marshall, 1998; Jensen & Olin, 1993; Kuroda, 
Ornthanalai, Kato, & Murphy, 2010; Ricaurte, Guillery, & Seiden, 1982; Schmued, 2003; 
also see  reviews by (Cadet et al., 2003; Krasnova & Cadet, 2009). To our knowledge, 
there have been no published studies showing neuronal degeneration with cupric silver or 
FluoroJade C staining following self-administration of any psychostimulant, but has been 
demonstrated to occur in the granule cell layer of the hippocampus of alcohol dependent 
rats following self-administration (Richardson, Chan, & Crawford, 2009).  Cell death has 
also been demonstrated by immunostaining for  activated caspase-3 (AC-3), a marker of 
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apoptotic activity (AC-3), following ShA and LgA METH IVSA (Mandyam et al., 2008; 
Recinto et al., 2012). However, a number of psychostimulant self-administration studies 
have been published in which neuronal degeneration has been inferred by reductions in 
DAT, TH, or SERT staining (for example see (Kousik, Carvey, & Napier, 2014) as 
decreases in these proteins often occur comcomittantly with neuronal degeneration 
(Marshall & O’Dell, 2012). Furthermore, a number of prominent human imaging studies 
have also inferred neurodegeneration from decreased DAT binding and gray matter 
volumes (Chang, Alicata, Ernst, & Volkow, 2007). However, a note of caution must be 
urged in making the inference of neuronal degeneration from reductions in these other 
markers. For example, some studies have shown that reductions in these aforementioned 
proteins due to amphetamine exposure can occur at timepoints earlier than the emergence 
of positive cupric silver or FluoroJade C staining (Ares-Santos et al., 2014; Baumann, 
Wang, & Rothman, 2007) or other overt signs associated with terminal degeneration such 
as loss of VMAT immunoreactivity (Moszczynska et al., 2004; Wilson et al., 1996). 
Thus, while these various markers typically co-occur, it has been argued that reductions 
in transporters or rate-limiting enzymes such as TH can reflect earlier adaptive processes 
(e.g. simple downregulation of protein expression) which do not ncessarily reflectactive 
degenerative processes (Volkow, Chang, Wang, Fowler, Franceschi, et al., 2001; 
Volkow, Chang, Wang, Fowler, Leonido-Yee, et al., 2001). 
In addition to amphetamines, studies using either cupric silver or FluoroJade C 
staining techniques following cocaine exposure have generally failed to produce evidence 
of neuronal degeneration in striatum or hippocampus, although patterns of degeneration 
in the lateral habenula and occasional, but seemingly random, cortical pyramidal cells 
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were found (Ellison, 1992; Goodman & Sloviter, 1993). In the study by Goodman and 
Slovier (1993), cocaine injections (40 mg/kg) were given daily for 3 months, producing 
seizures in many of the animals.  Like the present study, a positive control animal 
injected with KA did produce evidence of hippocampus neuronal degeneration. However, 
despite 3 months of high level cocaine exposure and seizures, no evidence of cupric 
silver staining was shown. The reason for numerous accounts of amphetamine related 
neuronal degeneration and lack of robust effects in cocaine is not entirely clear, but it has 
been argued that differential effects at DAT (cocaine being a blocker, with amphetamines 
being monoamine releasers) leads to greater continued DA release by amphetamines 
which translates into greater toxicity (Ellison, 1992). As MDPV acts primarily as a DAT 
blocker, and not a monoamine releaser, this is one possible explanation for the lack of 
effects in FluoroJade C staining in MDPV rats in the present study.  Still, lack of 
FluoroJade C staining with METH in the current study may be related to other factors as 
evidenced by other METH IVSA studies.  
As mentioned above, in METH IVSA studies, neurodegeneration has generally 
been inferred from the aforementioned markers. In the METH IVSA study by Schwendt 
et al. (2009) discussed earlier (7-10 1-hr sessions + 12-14 6 hr sessions + 2 weeks of 
extinction), decreases in DAT levels in the PFC and striatum were revealed, but levels of 
TH, NET or SERT were not significantly different saline rats in these same regions. As a 
result, the authors argued that decreased DAT occuring in the absence of these other 
markers likely signified DAT terminal related neuroadaptation and not overt terminal 
degeneration (Schwendt et al., 2009).  Moreover, in the aforementioned study by Reichel 
et al., (2012), rats receiving the experimenter-administered (non-contingent) binge-dose 
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regimen (four 4 mg/kg i.p. injections given every 2 hours), but not METH IVSA (7 1 hr 
sessions +, 14 6 hr sessions + 8 days of abstinence), showed decreases in TH and DAT 
levles in striatal tissue. Together, these results suggest that IVSA procedures similar to 
those here do not allow for a sufficient amount of intake to result in neurodegenerative 
changes. Alternatively, in the aforementioned by Krasnova et al. (2010), METH IVSA 
(0.1 mg/kg/infusion; 8 15-hr sessions + 7 days of abstinence) did produce significant 
decreases in TH and DAT levels in striatal and cortical tissue. Finally, in a METH IVSA 
study (Mandyam, Wee, Eisch, Richardson, & Koob, 2007) in which rats receiving either 
ShA, intermittent ShA (2 days a week), or LgA to METH (0.05 mg/kg/infusion) for 49 
days (42 days of LgA), but no abstinence period, a substantial increase in the number of 
dying cells (pyknotic cells) was found in the medial PFC for all three IVSA groups when 
compared to drug-naïve controls receiving no behavioral testing. These data suggest that 
standard ShA and LgA procedures, using the same dose of METH used in the present 
study (0.05 mg/kg/infusion) can lead to neurodegenerative effects in the medial PFC 
without a withdrawal period, but only after 49 days of continuous access. Together, these 
studies suggest that lack of sufficient exposure most likely explains the null effects of the 
current study.  However, in a recently published study (Kousik et al., 2014), METH 
IVSA (0.1 mg/kg/infusion) for only 3 hours a day for 14 sessions produced decreases in 
striatal and accumbal TH levels, but only when rats were sacrified at least 14-56 days 
later. Subjects sacrificed 24 hours after IVSA procedures showed no decreases in TH 
staining. Moreover, TH staining was also decreased in the VTA and substantia nigra, but 
only at 28-56 day timepoints. Furthermore, reduced Fluorogold (a retrograde tracer) 
staining of these DAergic pathways was also observed, suggesting that METH-induced 
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terminal field neurodegeneration (striatum / accumbens) caused neurodegenerative 
effects in VTA/substantia nigra in a retrograde manner.  Thus, these authors argue that 
METH IVSA can induce DAergic-related neurodegenerative effects, even after limited 
exposure, but only after much longer abstinence periods.  
Given these collective findings and the lack of degeneration found in our study, it 
is most likely that our IVSA procedures failed to produce overt signs of 
neurodegeneration as a result of (1) insufficient  accesstime to acquire a sufficient 
amount of drug (either METH or MDPV) or (2) lack of protracted withdrawal 
procedures. Indeed, Krasnova et al. (2012) argue that traditional IVSA procedures similar 
to those of the present study likely do not mimic the large quantity and binge-like 
METH-taking seen in humans and recommend that animal models aiming to replicate 
human METH use employ longer access (i.e. 15 hours instead of standard 2 or 6 hr) 
procedures. Moreover, Kousik et al. (2014) also recommend sufficiently long withdrawal 
periods to fully capture METH-induced neurodegeneration. Thus, LgA METH IVSA 
does appear to cause neurodegenerative effects when the number of sessions is much 
higher than those in the present study even without withdrawal. However, as discussed 
with Kousik et al., (2014), lower exposure levels can lead to pathological effects, but only 
after long abstinence periods. Thus, neurotoxicity only appears to manifest without 
withdrawal after sufficiently long IVSA access, or without large amounts of exposure 
only after a sufficiently long withdrawal period..  
With regards to cognitive functioning, numerous studies have reported that long-
term abuse of psychostimulants such as amphetamines or cocaine in humans can lead to 
adverse cognitive effects in domains such as information processing speed, motor skills, 
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attention, decision-making, planning, set shifting, working memory, long-term memory, 
and others (for reviews see (Nordahl, Salo, & Leamon, 2003; Scott et al., 2007). In the 
current study, results of cognitive tests revealed no deficits following either METH or 
MDPV self-administration for either of the two domains of cognitive functioning tested 
(working memory with the DMTP task and set shifting with the S+/S- reversal learning 
task).  While puzzling, several possibilities likely explain these null results.  
Research shows that performance on the DMTP and other working memory tests 
is dependent on both hippocampal and medial PFC functioning as lesions and/or 
pharmacological blockade impaired performance (Aggleton, Keith, & Rawlins, 1992; S. 
Dunnett, Wareham, & Torres, 1990). Set switching, as assessed in various discrimination 
reversal learning tasks and the Wisconsin Card Sorting Task, is also dependent on both 
hippocampal and medial PFC functioning, specifically the ILC/PLC regions in rodents) 
(Izquierdo & Jentsch, 2012). Thus, successful performance on these tasks is dependent 
upon functioning in the same regions showing no overt signs of  neurodegeneration in 
Experiment 1 under nearly identical IVSA procedures. Given the lack of astrogliosis or 
neurodegenerative effects from Experiment 1, most likely as a result of insufficient 
access / intake of either MDPV or METH or lack of a sufficiently long withdrawal 
period, the most parsimonious explanation for lack of cognitive effects in Experiment 2 is 
also insufficient access / intake of both drugs.  Indeed, of the few IVSA studies published 
assessing cognitive deficits with similar procedures, adverse effects are typically seen 
following much longer treatment regimens combined with long withdrawal periods.  
For example, in a study by George et al., (2008), rats were placed into either 1 hr 
ShA or 6 hr LgA cocaine (0.5 mg/kg) IVSA procedures for a minimum of 85 sessions. 
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Escalated intake was found in the LgA, but not ShA, rats across the 85 IVSA sessions. 
Three to fifteen days following IVSA procedures, rats were tested in two hippocampal 
dependent tasks, the spontaneous alternation Y-maze task (day 3 of abstinence) and the 
delayed-nonmatching-to-sample (DMTS) t-maze task (day 15-17 of abstinence). On the 
DMTS task, LgA rats performed significantly worse than ShA rats, with the magnitude of 
cocaine escalation negatively correlating with performance (i.e. as cocaine intake 
increase, DMTS performance decreased). Furthermore, working memory impairments 
were also correlated with an overall decrease in medial PFC neurons when tissue was 
collected 2 months after IVSA, suggesting working memory impairments were related to 
the neurodegenerative effects of cocaine after a long withdrawal period. On the 
spontaneous alternation task, no differences were noted between ShA or LgA rats. In a 
recently published study (Recinto et al., 2012), METH IVSA procedures were paired 
with the same cognitive tests describe above (George, Mandyam, Wee, & Koob, 2008). 
Here, rats were placed into either ShA, intermittent ShA (1 hr/day 2 days, Monday and 
Thursday, a week) or LgA METH (0.05 mg/kg) IVSA procedures for 22 days. As shown 
previously by this same group, rats in the LgA group displayed significant escalation of 
METH intake across sessinos (Mandyam et al., 2008, 2007). Three to fifteen days 
following IVSA procedures, rats were tested in the spontaneous alternation Y-maze task 
(day 3 of abstinence) and the delayed-nonmatching-to-sample t-maze task (days 15-17 of 
abstinence). Here, LgA rats were significantly worse than either ShA, intermittent ShA, 
or drug-naïve controls rats on both tasks. Interestingly, drug-naïve controls were impaired 
relative to the intermittent ShA group for both tasks, highlighting that voluntary METH 
consumption under certain conditions can actually improve performance. Indeed, 
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improved performance across a number of cognitive domains has been shown in humans 
following acute or intermittent METH exposure (for review see Hart, Marvin, Silver, & 
Smith, 2012). Finally, LgA also lead to significant increases in the apoptotic marker AC-
3 and decreases in neurogenesis in the hippocampal dentate gyrus, whereas the 
intermittant ShA group has increased neurogenesis, suggesting that neurodegenerative 
processes likely contributed to impaired working memory performance. In another 
METH (0.02 mg/infusion) IVSA study, rats underwent 10 days of 1 or 2 hr ShA, 
followed by 14 days of either 1, 2, or 6 hr LgA. After 10 days of extinction training, rats 
were tested on a hippocampal dependent (Cohen & Stackman Jr, 2014) novel object 
recognition test (object exploration task) (Rogers, De Santis, & See, 2008). LgA METH 
rats displayed impaired recognition memory compared to saline controls. In a follow-up 
study by the same group under similar IVSA procedures (7 1 hr ShA +14 6 hr LgA 
sessions vs. yoked saline controls and escalation of METH intake across LgA), novel 
object recognition memory was again impaired following 7 days of abstinence (Reichel et 
al., 2012).  
Thus, while it is difficult to pinpoint why cognitive deficits were not found in our 
study, the most likely reasons are insufficient access / intake of either METH or MDPV 
or assessment of cognitive effects concurrently with IVSA procedures instead of during 
protracted withdrawal.  In each of the studies discussed above, LgA lead to signficant 
escalation of intake, an effect not seen in Experiment 2 of the present study. Furthermore, 
in each of the above studies, cognitive effects were assessed during protracted withdrawal 
at least 3 days following cessation of IVSA procedures. Thus, it is possible that cognitive 
effects may have emerged had they been assessed perhaps starting 3 days after IVSA 
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experiments. In our study, rats were assessed only during the acute withdrawal phase 
(each morning prior to IVSA) which may not have been a sufficient to detect declines in 
cognitive performance. Still another possibility is that sucrose rats were less motivated to 
perform the cognitive tests on the final LgA DMTP test as they had significantly more 
forfeited trials and significantly greater body weights. These effects were not seen during 
the prior two DMTP tests and suggest that, perhaps being less motivated compared to 
MDPV or METH rats, their performance was artificially decreased and masked potential 
performance differences. However, lack of differences in percent correct responding 
across all three DMTP tests for any group argues against this possibility. Finally, another 
possibility is that, while many studies in human abusers of illicit psychostimulant have 
reported cognitive impairments, the evidence is often inconsistent. Indeed, a number of 
recent reviews have shown that most published studies have revealed little to only 
moderate impairments in neuropsychological and cognitive functioning in 
psychostimulants abusers (Hart et al., 2012; Scott et al., 2007; Wood et al., 2014).  
In conclusion, the overall lack of toxic or adverse cognitive effects in the present 
study largely suggest that standard IVSA models comprised of ShA (1 – 2 hours) + LgA 
(6 hour) that do not incorporate either a large number of sessions  or protracted 
withdrawal periods do not lead to toxic or adverse cognitive effects reported in human 
psychostimulant abusers. While these traditional IVSA procedures appear sufficient to 
establish reinforcing properties of psychostimulants, and perhaps model to the emergence 
of loss of control and/or tolerance seen in addiction (Ahmed & Koob, 1998; Kitamura et 
al., 2006), the overall picture that emerges is that they do not fully capitulate many of the 
resulting adverse toxic effects reported in human METH or cocaine addicts. Thus, future 
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IVSA experiments assessing toxic or cognitive deficits should, at the very least, employ 
longer within-session acquisition periods (such as the 15 hr/day procedures used in 
Krasnova et al., (2012) or even newer 96 hr access used elsewhere (Cornett & Goeders, 
2013), more total LgA sessions (22-85) seen in George et al., (2008), Mandyam et al., 
(2012), or Recinto et al., (2012)), along with protracted withdrawal (at least 3 days after 
IVSA). Finally, the lack of neurotoxicity seen in these traditional IVSA models, but 
overabundance of effects seen following non-contingent large dose treatment regimens, 
suggests that these latter approaches use doses that are physiologically irrelevant to 
addiction and may only model potential neurotoxic effects related to accidental overdose.  
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CHAPTER 9 
GENERAL DISCUSSION 
The abuse of illicit psychostimulants such as METH, cocaine, MDMA, and newer 
designer cathinones continues to be a major public health issues around the world.  In the 
latest World Drug Reports, approximately 80 million people used either cocaine or an 
amphetamine-type stimulant (ATS) at least once in the previous calendar year (UNODC, 
2014). In the United States, epidemiological data suggests that despite abuse already 
existing at epidemic levels, total ATS use, of which METH is the most popular, continues 
to increase (Maxwell & Brecht, 2011; UNODC, 2014). METH use also continues to grow 
in parts of the Middle East, Eastern Europe, Oceania, Asia, and Southeast Asia. In recent 
years, synthetic cathinones also emerged as “legal” stimulants, further compounding 
problems associated with stimulant abuse. As a result, legislative actions by many 
countries have banned the use of many of these new drugs. However, while these bans 
have had the desired effect of decreasing availability certain synthetic cathinones, drug 
manufacturers have responded by producing new analogues often as dangerous as the 
drugs they were designed to replace. This has led to a legislative cat and mouse game, 
where newer generations of synthetic cathinones continue to emerge to elude authorities 
(Cohen, 2014). Indeed, when synthetic cathinones emerged in 2009, only a handful of 
synthetic cathinone were available on drug markets with MDPV, mephedrone and 
methylone comprising 98% of these in the United States (D. E. A. United States 
Department of Justice, 2011c). As of last count, over 40+ synthetic cathinones have been 
discovered on international markets (Glennon, 2014), most of which have yet to be 
assessed in any type of scientific study. Thus, it is clear that global stimulant abuse has 
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grown and continued research regarding the abuse liability, toxicity, and therapeutic 
intervention for stimulant addiction is desperately needed. The studies in this dissertation 
have focused on these goals and collectively have generated of novel findings that have 
made significant impacts on the studies of stimulant addiction, highlight knowledge gaps 
where future research is needed, and suggest changes in rodent IVSA models to better 
model stimulant addiction in the future.  
In chapter 2, we assessed the ability of the mGluR5 NAM fenobam to attenuate 
reinstatement to METH-seeking following ShA IVSA procedures.  Fenobam was chosen 
as it has been shown to be well tolerated in humans (Berry-Kravis et al., 2009). The 
mGluR5 receptor has become a target of tremendous interest for stimulant addiction as 
previous work had revealed that reinforcing and locomotor effects of cocaine were absent 
in mGluR5 knockout mice, and preclinical studies with other mGluR5 NAMs had shown 
positive effects in attenuating cocaine-seeking (for example see (Kumaresan et al., 2009). 
Our results showed that fenobam had the effect of decreasing METH-seeking after both 
METH-prime and cue-prime reinstatement procedures. However, decreased responding 
for food and sucrose during cue-primed procedures suggested non-specific effects that 
would limit clinical adoption.  Furthermore, other laboratories reported similar effects of 
mGluR5 NAMs on sucrose-seeking during cocaine studies (Keck et al., 2013). Despite 
these non-specific effects and discontinued studies with fenobam, attenuated METH 
reinstatement justifies continued assessment of mGluR5 as a potential therapeutic target. 
Indeed both newer fenobam analogues (Gichinga et al., 2011) and mGluR5 NAMs are 
being developed, with a recent study showing that MPEP analogue MFZ 10-7 inhibits 
cocaine self-administration and cocaine-seeking behavior in reinstatement procedures 
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with less overall non-specific effects on sucrose intake (Keck et al., 2014). Thus, while 
interest in the drug fenobam has decreased in recent years, subsequent studies with newer 
mGluR5 ligands have renewed interest in this target.  
In chapter 3, we review the literature regarding the use of AMPA PAMs as 
potential cue-exposure therapy adjuncts for stimulant addiction. We also present data 
from two novel AMPA PAMs, CX1739 and CX1837. Our interest in these drugs was 
motivated by positive reports of the AMPA PAM (4-[2-(phenylsulfonylamino)ethylthio]-
2,6-difluorophenoxyacetamide; PEPA) and its ability to facilitate extinction following 
cocaine IVSA and subsequently decrease cocaine reinstatement (LaLumiere et al., 2010, 
2012) as well as facilitated motor recovery from an animal model of stroke with both of 
these compounds (Clarkson et al., 2011).  While both of these drugs proved capable of 
facilitating extinction following METH IVSA procedures, decreased extinction 
responding did not translate into attenuated cue-primed reinstatement of METH-seeking. 
As with fenobam, these disappointing results prompted us to discontinue testing these 
compounds. Nonetheless, facilitated effects during extinction procedures and the 
development of newer AMPA PAMs showing promise in numerous other 
neuropsychiatric disorders (Lynch, 2006) point to the need for further research in this 
area.  
In chapters 4 and 5, we showed for the first time that MDPV and methylone, two 
of the most popular synthetic cathinones to initially emerge as “legal highs” on 
international markets, possess similar to greater reinforcing (IVSA) and rewarding 
(ICSS) effects as compared to METH and MDMA, the two illicit psychostimulants they 
were designed to mimic, respectively. Since publishing these initial studies, MDPV IVSA 
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has been replicated by us (chapter 8) and others (Aarde et al., 2013; Fantegrossi et al., 
2013). Furthermore, others have shown MDPV facilitation of ICSS (Bonano et al., 2014; 
De Felice et al., 2013), locomotor stimulant effects (Baumann, Partilla, Lehner, et al., 
2013; Fantegrossi et al., 2013; Glennon, 2014; Marusich et al., 2014), and full 
discrimination for cocaine, methamphetamine and MDMA (Fantegrossi et al., 2013; 
Gatch et al., 2013; Glennon, 2014).  Furthermore, as shown in chapter 7, repeated 
intermittent treatment with MDPV produces both behavioral sensitization and cross-
sensitization with METH, corroborating in vitro data showing common neurological 
targets (DAT and NET) and human data suggesting that a history of amphetamine abuse 
increases the sympathomimetic and neurotoxic effects with subsequent MDPV use 
(Spiller et al., 2011). Thus, based on our initial IVSA and ICSS studies, we predicted that 
subsequent work would reveal METH-like stimulant effects, high abuse addictive 
liability in humans, and continued MDPV abuse after legislative bans.  Each of these 
predictions appears to have come true, as subsequent animal studies have revealed 
METH-like behavioral effects (see above), human case reports of MDPV addiction 
(Sadeg et al., 2014), and findings that MDPV is still being abused despite its now 
Schedule I status (NMS Labs, 2014). With regards to methylone, our IVSA experiments 
revealed greater reinforcing effects compared to MDMA, but also did not produce 
escalated intake suggesting a lower abuse potential than MDPV or METH. Thus, based 
upon our IVSA and ICSS results, we predicted subjective effects and episodic abuse 
patterns in humans most akin to MDMA. Interestingly, subsequent drug discrimination 
work has shown full substitution for both cocaine and METH (Gatch et al., 2013) and 
ICSS studies using a different methods revealed greater facilitated ICSS effects that those 
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shown in our study (Bonano et al., 2014). Furthermore, recent studies have also 
demonstrated MDMA-like depletion of serotonin and serotonin metabolites in rats 
following experimenter-administered binge-treatment regimens (den Hollander et al., 
2013). Together, these animal studies suggest a methylone addiction potential similar to 
greater than that of MDMA. To our knowledge, no reports of methylone dependence 
have been reported in humans, but the most recent published data on use patterns 
suggests that methylone continues to be used despite its now Schedule I status (NMS 
Labs, 2014).  
In chapter 6, our ICSS results for α-PVP and 4-MEC suggest that these newer 
second generation synthetic cathinones, which largely emerged as MDPV and methylone 
alternatives following their classification as Schedule I substances, produce similar 
rewarding effects and thus likely have a similar degree of addiction potential as METH 
and MDMA, respectively.  Indeed, our data shows that α-PVP, while about half as potent 
as MDPV in reducing ICSS thresholds, was equipotent with METH. These results 
demonstrated for the first time rewarding effects for either of these drugs. Additional 
research has determined that α-PVP is a potent catecholamine transporter blocker similar 
to MDPV and produces robust locomotor stimulant properties (Marusich et al., 2014). 
While early data suggests high abuse liability, reinforcing effects in IVSA experiments 
have yet to be published and no reports of α-PVP addiction in humans has been reported. 
For 4-MEC, recent work has shown that this drug produces locomotor stimulant effects 
and fully substitutes for METH in drug discrimination assays(Gatch, Rutledge, & Forster, 
2014), suggestive of a relatively high addiction potential and corroborating our ICSS 
findings. Thus, while our ICSS data predicts similar abuse liability of these drugs as 
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compared to first generation synthetic cathinones, only a handful of animal studies have 
been published, and additional studies are needed before definitive predictions regarding 
addiction potential in humans can be made. 
Despite an abundance of data showing neurotoxic or adverse cognitive effects in 
humans and animals following chronic METH exposure, and the acute toxic effects of 
MDPV reported in humans, neither IVSA of METH nor MDPV produced evidence of 
neurotoxicity or cognitive deficits as shown in chapter 8. While these results were 
surprising, when viewed in light of the published literature, the overall lack of toxic or 
adverse cognitive effects in the present study largely suggest that standard IVSA models 
that even incorporate a sufficient LgA (10-16 sessions) procedures that lead to escalation 
of drug intake, do not lead to toxic or adverse cognitive effects reported in human 
psychostimulant abusers. Instead, evidence from the literature collectively suggests that 
escalation of intake alone is not sufficient, but needs to be combined with a longer 
duration of exposure (i.e. 22-85 sessions) and/or protracted withdrawal periods (i.e. at 
least 3 days following IVSA procedures) in order to produce toxic or adverse cognitive 
effects. Thus, while it is possible that voluntary MDPV intake simply does not produce 
the toxic effects, our lack of effects for METH when others have reported neurotoxic and 
adverse cognitive effects in rats following IVSA suggest that our IVSA parameters in 
chapter 8 were not optimal for producing these effects.  Interestingly, review papers 
discussing the relationship between escalation with LgA and resulting toxic or cognitive 
deficits do not explicitly discuss the importance of duration of drug exposure or inclusion 
of withdrawal periods, but instead focus entirely on escalation itself (Ahmed, 2010, 
2012). Thus, it is recommended that future studies employ more non-traditional IVSA 
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procedures consisting of either much longer within-session times (e.g. 15 hr or 96 hr 
binge regimens), more total sessions (22-85) if standard 6-hr LgA is used, and/or 
protracted withdrawal periods (at least 3 days).  
In conclusion, assessment of the abuse liability and toxicity of synthetic 
cathinones is still in its infancy, and there are still no pharmacological treatments for 
addiction to any stimulant. With specific regards to synthetic cathinones, several 
questions remain. 1) Will the predictions of high addiction potential from animal models 
be corroborated with an epidemic of synthetic cathinone addiction, or will abuse of 
synthetic cathinones become only a minor class of abuse substances? Thus far, while a 
recent case report of MDPV addiction has emerged, most reports of compulsive synthetic 
cathinone use have been anecdotal. 2) What other neurotransmitter systems are involved 
in the rewarding, reinforcing, or psychological effects of these drugs? There is substantial 
evidence for contribution of non-monoaminergic transmitters such as acetylcholine, 
glutamate, and neuropeptides in psychostimulant reward and reinforcement. 3) Do any of 
these substances have potential as pharmacotherapeutics for disorders such as depression, 
ADHD, narcolepsy, or perhaps even as agonist-replacement therapies for traditional illicit 
stimulants such as METH or cocaine? Indeed, the drug buproprion is a FDA approved 
synthetic cathinone for both depression and smoking cessation, has relatively low abuse 
liability, and has shown some efficacy in clinical trials for cocaine addiction (Rush & 
Stoops, 2012). It is likely that among the multitude of potential synthetic cathinones, 
some of these will possess favorable neurochemical profiles for pharmaceutical 
development.  4) While numerous case reports have detailed immediate adverse effects 
and intoxication with synthetic cathinones, what are the long term neurotoxic or adverse 
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cognitive effects of acute or chronic use of these drugs? 5) Will newer synthetic 
cathinones continue to flood drug markets as replacements after governmental bans, and 
if so, how should policy-makers adjust their strategy to limit such effects? While the 
current legislative strategies have improved some outcomes such as decreasing use of 
those drugs specifically banned, they have also motivated drug manufacturers to market 
newer, and sometimes more dangerous, drugs of which we possess even less 
understanding.  
With regards to addiction to more traditional illicit stimulants such as METH or 
cocaine, there is still a great deal of work needed to develop more effective interventions. 
While numerous compounds have demonstrated efficacy in animal models, the dismal 
translation into approved medications suggests that significant improvements are needed 
for better drug development and screening at the preclinical level. Perhaps with such 
improvements, more effective treatment interventions will be developed and reduce the 
impact that these devastating drugs can have on individuals and society.  
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 Table 1. Inactive lever presses per 2 hr session during extinction and reinstatement 
procedures 
Data are presented as mean ± 
2 days of extinction training pri
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SEM. Extinction (Ext) data represent the average of the last 
or to the first reinstatement test.  
 
 Table 2. Slopes, ED50 values, and maximum ICSS threshold reductions.
Slope values represent the means for the descending linear slope of log
doses. ED50 values represent the mean dose leading to 50% maximal response with 
upper 95% confidence limits (UL) and lower 95% confidence limit (LL). Maximal 
response values represent the mean maximum intracranial self
threshold reduction (independent of dose) ± 95% confidence intervals. Results reported 
for methylenedioxypyrovalerone (MDPV) and methylone were obtained from previous 
publications (Watterson et al., 2012, 2014).
 
 
 
 
 
 
 203 
  
-transformed 
-stimulation (ICSS) 
 
 
  204 
 
 
  205 
Figure 1. Effects of fenobam on the reinstatement of METH-seeking by acute METH 
administration or METH-associated cues. Effects of fenobam on the reinstatement of 
METH-seeking induced by (a) acute administration of METH (0.5 mg/kg i.p.,) or (b) 
METH-associated cues. SA values represent the average of the last 2 days of METH self-
administration. Extinction (Ext) values represent the average of the last 2 days of 
extinction training prior to the first reinstatement test. *p<0.05 vs. vehicle treatment, 
#p<0.05 vs. SA. Data are presented as mean ± SEM.  
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Figure 2. Effects of fenobam on the reinstatement of a sucrose- and food-seeking induced 
associated by cues. (a) Effects of fenobam on the reinstatement of a sucrose-seeking by 
sucrose-associated cues and (b) food-seeking induced by food-associated cues. SAvalues 
represent the average of the last 2 days of sucrose or food self-administration. Extinction 
(Ext) values represent the average of the last 2 days of extinction training prior to the first 
reinstatement test. *p<0.05 vs. vehicle treatment, #p<0.05 vs. SA. Data are presented as 
mean ± SEM 
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Figure 3. Effects of vehicle or fenobam (10 mg/kg) on locomotor behavior. Data are 
presented as mean ± SEM and represent the average number of full turns (open bars and 
left y-axis) or quarter turns (shaded bars and right y-axis) during 90 min locomotor test 
sessions. 
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Figure 4. Effects of AMPA PAMs on extinction. Male Sprague-Dawley rats were placed 
into 2 h daily methamphetamine IVSA-administration sessions for 10 days.Presses on an 
active lever produced methamphetamine infusions (0.05 mg/kg/infusion) on an FR1 
schedule of reinforcement with a simultaneous 2 s light-tone stimulus complex. 
Following stable acquisition of methamphetamine IVSA, rats were placed into daily 2 h 
extinction sessions for 10 days during which active-lever presses no longer produced 
drug infusions or presentation of the stimulus complex. Twenty min prior to being placed 
into each extinction session, rats received intraperitoneal (i.p.) administration of either 
vehicle (Veh, 30% w/v 2-hydroxypropyl-β-cyclodextrin), CX1837 0.1 mg/kg (N = 6) 
CX1837 1 mg/kg (N = 12) CX1739 0.1 mg/kg (N = 7), 1 mg/kg (N = 7), or 10 mg/kg (N 
= 9). Vehicle treated rats (N = 20) were used for comparison for both CX1739 and 
CX1837. Data points represent the mean percent change (± SEM) from self-
administration (mean of the final 2 days of self-administration procedures) for active 
lever presses. For CX1837, a mixed ANOVA analysis revealed a significant main effect 
of extinction session  (F[9,306] = 5.78, p < 0.001), a significant extinction session x dose 
interaction (F[18, 306] = 2.77, p < 0.001), but no main effect of dose (F[2,34] = 1.32, p > 
0.05). Post-hoc analyses revealed a significant reduction in responding on extinction day 
one by the 1 mg/kg dose of CX1837 versus vehicle (F[2,34] = 4.86, p < 0.05). No other 
measures were significantly different. For CX1739, a significant main effect of extinction 
session (F[9,351] = 15.180, p < 0.001), a significant extinction session X dose interaction 
(F[27,351] = 1.94, p < 0.004), but not a significant main effect of dose (F[3,39] = 2.60 p 
> 0.05). Post-hoc analyses revealed a significant reduction in responding on extinction 
day one by the 10 mg/kg dose of CX1739 vs. vehicle (F[3,39] = 5.476, p < 0.003). No 
  212 
other measures were significantly different. All experimental procedures were conducted 
with the approval of the Institutional Animal Care and Use Committee at Arizona State 
University and according to the Guide for Care and Use of Laboratory Animals as 
adopted by the National Institutes of Health (NIH).  
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Figure 5. Effects of AMPA PAMs on reinstatement. Following extinction sessions, rats 
were placed into cue-primed reinstatement procedures to assess the retention of 
extinction learning. Data points represent the mean percent change (±SEM) from self-
administration (mean of the final 2 days of self-administration procedures) for active 
lever presses. A one-way ANOVA did not reveal significant differences between vehicle 
or any CX1837 doses (0.1 or 1 mg/kg, i.p.) (F[3,39] = 0.161, p = 0.922), nor any 
significant differences between vehicle and of the doses of CX1739 tested (0.1, 1, or 10 
mg/kg, i.p.)(F[2,35] = 0.294, p = 0.747). 
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Figure 6. MDPV IVSA in ShA. Intravenous self-administration (IVSA) of 3,4-
methylenedioxypyrovalerone (MDPV). Data presented are active and inactive lever 
presses across the first 10 days of IVSA procedures for the (a) 0.05, (b) 0.1 and (c) 0.2 
mg/kg per infusion groups (n = 9 for each group). *P < 0.05 between active and inactive 
lever presses. (d) Total number of infusions during 2-hour daily access session across the 
first 10 days of IVSA and for each dose of MDPV tested. 
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Figure 7.MDPV IVSA during progressive ratio responding. Total number of infusions 
earned during progressive ratio (PR) responding for the 0.05, 0.1 and 0.2 mg/kg per 
infusion doses of 3,4-methylenedioxypyrovalerone (MDPV) (n = 9 for each group) as 
well as a separate group of rats self-administering methamphetamine at a dose of 0.05 
mg/kg per infusion (n = 9). The total number of infusions earned during the PR session is 
plotted along the left y-axis. As a reference, the total number of active lever presses 
completed during the test is plotted along the right y-axis. *P < 0.05 versus the 0.05 
mg/kg dose of MDPV. #P < 0.05 versus the 0.1 mg/kg dose of MDPV.  
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Figure 8. MDPV IVSA during LgA. Total number of infusions obtained during short 
access (ShA), long access (LgA) and the first 2 hours of LgA sessions across the final 10 
days of intravenous self-administration (IVSA) procedures for the (a) 0.05, (b) 0.1 and (c) 
0.2 mg/kg per infusion doses of 3,4- methylenedioxypyrovalerone groups (n = 5 for each 
LgA group), as well as rats self-administering methamphetamine at a dose of 0.05 mg/kg 
per infusion (d, n = 9). *P < 0.05 for sessions in which the number of total infusions 
obtained during LgA was significantly greater than total infusions obtained during ShA. 
#P < 0.05 for total number of infusions obtained during LgA sessions versus day 1 of 
LgA.+P < 0.05 for total number of infusions obtained during the first 2 hours of LgA 
sessions versus day 1 of LgA (first 2 hours).  
 
 
 
 
 
 
 
 
  221 
 
 
 
 
 
 
 
 
  222 
Figure 9. MDPV ICSS. Effects of vehicle and 3,4-methylenedioxypyrovalerone (MDPV) 
(0.1, 0.5, 1 and 2 mg/kg, i.p.) on thresholds for intracranial self-stimulation (ICSS) (n = 
5). *P < 0.05 versus vehicle. 
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Figure 10. Methylone IVSA during ShA. Intravenous self-administration (IVSA) of 
methylone. Data presented are active and inactive lever presses across the first 21 days of 
IVSA sessions for the (a) 0.05 (b) 0.1 (c) 0.2 and (d) 0.5 mg/kg/infusion groups (n = 12 
for 0.05 and 0.5 mg/kg/infusion groups; n = 11 for the 0.1 and 0.2 mg/kg/infusion 
groups). *p<0.05 between active and inactive lever presses. 
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Figure 11. Infusions of methylone across ShA. (a) Total number of infusions obtained 
during the first 21 days of 2 hr daily access sessions for each dose of methylone tested 
(n=12 for 0.05 and 0.5 mg/kg/infusion groups; n = 11 for the 0.1 and 0.2 mg/kg/infusion 
groups). (b) Percent of animals at or above criterion (10 active lever presses per session) 
for each experimental session. 
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Figure 12. Infusions during PR and LgA methylone IVSA. Total number of infusions 
earned during progressive ratio (PR) tests following 21 days of ShA sessions (ShA PR) 
and 10 days of LgA sessions (LgA PR) for the 0.05, 0.1, 0.2, and 0.5 mg/kg/infusion 
groups (n = 12 for 0.05 and 0.5 mg/kg/infusion groups; n = 11 for the 0.1 and 0.2 
mg/kg/infusion groups). *p<0.05 compared to the 0.05, 0.1, and 0.2 mg/kg/infusion dose 
groups. (b) Total number of infusions obtained during the 10 days of LgA IVSA sessions 
for each dose of methylone tested (n=10 for 0.05 and 0.5 mg/kg/infusion groups; n = 11 
for the 0.1 and 0.2 mg/kg/infusion groups). 
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Figure 13.Methylone ICSS. Effects of saline vehicle and methylone (0.1, 0.5, 1, 3, 5, and 
10 mg/kg, i.p.) on intracranial self-stimulation (ICSS) current-intensity thresholds (n=4). 
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Figure 14. Chemical structures of psychostimulants. Chemical structures of the 
traditional psychostimulants methamphetamine  (METH) and 
methylenedioxymethamphetamine (MDMA) first-generation synthetic cathinones 
methylenedioxypyrovalerone (MDPV) and methylone, and second-generation synthetic 
cathinones α‐pyrrolidinopentiophenone (α-PVP) and 4-methyl-N-ethcathinone (4-MEC). 
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Figure 15. α-PVP, 4-MEC, and METH ICSS.  Effects of the second-generation synthetic 
cathinone (A) 4-methyl-N-ethcathinone (4-MEC) (1, 3, 10, 30, mg/kg), (B) 
α‐pyrrolidinopentiophenone (α-PVP) (0.1, 0.3, 1, and 3 mg/kg), and the traditional 
psychostimulant (C) methamphetamine hydrochloride (METH) (0.1, 0.3, 1, and 3 mg/kg) 
on intracranial self-stimulation (ICSS) thresholds. Data represent mean ± 95% confidence 
interval and are expressed as a percent change in ICSS thresholds relative to the previous 
baseline session. N = 5, 5, and 4 in A, B, and C, respectively. *Symbols represent P < .05 
vs. saline. In C, the confidence interval upper limit (no shown) for the 3-mg/kg dose = 
153.87. 
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Figure 16. 24 hr MDPV sensitization. Effects of five repeated MDPV administrations 
separated by 24 hrs on locomotion and MDPV behavioral sensitization. For experiment 
1A (A), 1 mg/kg MDPV (filled squares)(N=8) or saline vehicle (open circles)(N=8) were 
administered via the intraperitoneal route across five treatment sessions separated by 24 
hr intervals. For experiment 1B (B), 5 mg/kg MDPV (filled squares)(N=8) or saline 
vehicle (open circles)(N=5) were administered via the intraperitoneal route across five 
treatment sessions separated by 24 hr intervals. Across the five treatment sessions, 
animals receiving 1 mg/kg MDPV (experiment 1A) or 5 mg/kg MDPV (experiment 1B) 
displayed more quarter turns compared to rats receiving saline vehicle (p’s <0.05). For 
experiment 1A sensitization tests using 0.5 mg/kg MDPV, there were no differences in 
quarter turns between rats with a history of 1 mg/kg MDPV vs saline vehicle. For 
experiment 1B sensitization tests, there was a significantly greater number of quarter 
turns in rats with a history of saline vs 5 mg/kg MDPV (p<0.05). 
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Figure 17. 48 hr MDPV sensitization. Effects of five repeated MDPV administrations 
separated by 48 hrs on locomotion and MDPV behavioral sensitization. For experiment 2, 
1 mg/kg MDPV (filled squares)(N=10) or saline vehicle (open circles)(N=8) was 
administered via the intraperitoneal route across five treatment sessions separated by 48 
hr intervals. Across the five treatment sessions (A), animals receiving 1 mg/kg MDPV 
displayed more quarter turns compared to rats receiving saline vehicle (p<0.05). For 
saline sensitization tests (B), there were no differences in quarter turns between rats with 
a history of 1 mg/kg MDPV vs saline vehicle. For sensitization tests using 0.5 mg/kg 
MDPV (B), there was a significantly greater number of quarter turns in rats with a history 
of 1 mg/kg MDPV vs saline vehicle (* p<0.05). 
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Figure 18. 48 hr METH-MDPV cross-sensitization. Effects of five repeated METH 
administration separated by 48 hrs on locomotion and MDPV cross-sensitization. For 
experiment 3, 1 mg/kg METH (filled squares)(N=16) or saline vehicle (open 
circles)(N=16) was administered via the intraperitoneal route across five treatment 
sessions separated by 48 hr intervals. Across the five treatment sessions (A), animals 
receiving 1 mg/kg METH displayed more quarter turns compared to rats receiving saline 
vehicle (p<0.05). For saline sensitization tests (B), there were no differences in quarter 
turns between rats with a history of 1 mg/kg METH vs saline vehicle. For sensitization 
tests using 0.5 mg/kg MDPV (B), there also were no differences in quarter turns between 
rats with a history of 1 mg/kg METH vs saline vehicle. 
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Figure 19. 48 hr MDPV-METH cross-sensitization. Effects of five repeated MDPV 
administrations separated by 48 hrs on locomotion and MDPV-METH cross-
sensitization. For experiment 4, 1 mg/kg MDPV (filled squares)(N=6), 5 mg/kg MDPV 
(filled triangles)(N=10), or saline vehicle (open circles)(N=8) was administered via the 
intraperitoneal route across five treatment sessions separated by 48 hr intervals. Across 
the five treatment sessions (A), animals receiving 1 mg/kg MDPV and 5 mg/kg MDPV 
displayed more quarter turns compared to rats receiving saline vehicle (p<0.05). For 
saline sensitization tests (B), there were no differences in quarter turns between rats with 
a history of 1 mg/kg MDPV, 5 mg/kg MDPV or saline vehicle. For sensitization tests 
using 0.5 mg/kg METH (B), there was a significantly greater number of quarter turns in 
rats with a history of 1 mg/kg MDPV vs saline vehicle (* p<0.05). 
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Figure 20: Self-administration of MDPV, METH, and sucrose for Experiment 1. Data 
presented are active and inactive lever presses across the first 16 days of ShA of IVSA 
procedures for (a) MDPV (0.05 mg/kg per infusion, N = 7) (b) METH (0.05 mg/kg per 
infusion, N = 7) (c) sucrose (45 mg pellets, N = 8). All groups displayed successful lever 
discrimination across all ShA trials. (D) Data represent the total number of reinforcers 
received for each reinforcer group. 
 
 
 
 
 
 
 
 
 
 
 
  245 
Reinforcers Across LgA Sessions
LgA
1
LgA
2
LgA
3
LgA
4
LgA
5
LgA
6
LgA
7
LgA
8
LgA
9
LgA
10
# 
Re
in
fo
rc
e
rs
 
Re
ce
ive
d
0
50
100
150
200
250
300
Sucrose Pellets 
METH Infusions 
MDPV Infusions 
Reinforcers Across LgA Sessions (First 2 hours)
LgA
1
LgA
2
LgA
3
LgA
4
LgA
5
LgA
6
LgA
7
LgA
8
LgA
9
LgA
10
# 
Re
in
fo
rc
e
rs
 
Re
ce
ive
d
0
20
40
60
80
100
120
140
Sucrose Pellets 
METH Infusions 
MDPV Infusions 
A
B
*
#
 
  246 
Figure 21: Reinforcers obtained during LgA IVSA procedures in Experiment 1. (A) Total 
number of reinforcers obtained in experiment 1 across long (LgA) sessions for each 
reinforcer group.  Rats in the MDPV and METH group showed a trend toward escalation 
on LgA session 10 vs. LgA session 1 (p’s = 0.052 and 0.061, respectively). (B) Total 
number of reinforcers obtained in experiment 1 across the first 2 hours of LgA sessions 
for each reinforcer group.  No escalation of intake was noted for any of the groups. 
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Figure 22: GFAP staining in the CA1 region of the hippocampus. (A) Total number of 
GFAP positive cells and (B) total percentage of the CA1 region of the dorsal 
hippocampus with positive GFAP staining in rats that self-administered MDPV (N=7), 
METH (N=7), or sucrose (N=8). (C) Representative 10X magnification photograph of the 
CA1 region.  
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Figure 23: GFAP staining in the CA3 region of the hippocampus.  (A)Total number of 
GFAP positive cells and (B) total percentage of the CA3 region of the dorsal 
hippocampus with positive GFAP staining in rats that self-administered MDPV (N=7), 
METH (N=7), or sucrose (N=8). Representative 10X magnification photograph of the 
CA3 region. 
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Figure 24: GFAP staining in the mPFC. (A) Total number of GFAP positive cells and 
(B) total percentage of the mPFC with positive GFAP staining in rats that self-
administered MDPV (N=7), METH (N=7), or sucrose (N=8).  Representative 10X 
magnification photograph of the mPFC. 
 
 
 
 
 
 
 
 
 
 
 
 
  253 
 
 
 
 
 
 
 
 
 
 
  254 
Figure 25. Results of FluoroJade C neurodegeneration staining. (A,B) FluoroJade C 
staining across the entire dorsal hippocampus (A) and at 10X magnification in the CA3 
region (B) in a rat injected intracerebroventrically with 1 µg/µl KA. (C) Representative 
image of the mPFC region of a rat that underwent MDPV self-administration. (D) 
Representative FluoroJade C staining (10X magnification) of the ILC/PLC from the same 
subject under fluorescence. (E) Representative image of the hippocampus in a rat that 
underwent METH self-administration. (F) Representative FluoroJade C staining  (10X 
magnification) of CA3 region in the same rat under fluorescence). (G) Representative 
image of the striatum of a rat that underwent MDPV self-adminitration. (H) 
Representative FluoroJade C staining (10X magnification) of the dorsal striatum of the 
same subject under fluorescence. 
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Figure 26: Self-administration of MDPV, METH, and sucrose for Experiment 2. Data 
presented are active and inactive nosepokes across the first 16 days of ShA of IVSA 
procedures for (a) MDPV (0.05 mg/kg per infusion, N = 6) (b) METH (0.05 mg/kg per 
infusion, N = 6) and (c) sucrose (45 mg pellets, N = 12). All groups displayed successful 
lever discrimination during ShA sessions. (D) Total number of reinforcers obtained in 
experiment 2 across long (LgA) sessions for each reinforcer group. No escalation of 
intake occurred acoss LgA sessions for any group of rats.  
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Figure 27. Results from DMTP probe tests. Data represent percent correct responses 
across all five waiting times (1, 5, 10, 30, and 60) and total percent correct across all 
trials (total) during DMTP tests in groups of rats that underwent self-administration of 
MDPV (N=6), METH (N=6), or sucrose (N = 12). (A) Percent correct in rats prior to 
self-administration procedures (Pre-IVSA DMTP test). (B) Percent correct in rats 
following 15 or 16 days of ShA self-administration procedures (Post-ShA DMTP test). 
(C) Percent correct in rats following 15 or 16 days of LgA self-administration procedures 
(Post-LgA DMTP test).  
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Figure 28: Total forfeited and completed DMTP probe trials. (A) Total number of 
forfeited DMTP test trials in groups of rats that underwent self-administration of MDPV 
(N=6), METH (N=6), or sucrose (N = 12) prior to testing procedures (Pre-IVSA), 
following 15 or 16 days of ShA self-administration procedures (Post-ShA), or following 
15 or 16 days of LgA self-administration procedures (Post-LgA). (B) Total number of 
completed DMTP test trials (maximum 50) in groups of rats that underwent self-
administration of MDPV, METH, or sucrose prior to self-administration procedures (Pre-
IVSA), following 15 or 16 days of ShA (Post-ShA), or following 15 or 16 days of LgA 
(Post-LgA). 
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Figure 29: Performance on S+/S- reversal tests. Data represent percent correct responses 
during S+/S- reversal tests in groups of rats that underwent self-administration of MDPV 
(N=6), METH (N=5), or sucrose (N = 11). (A) Percent correct in rats prior to self-
administration procedures (Pre-IVSA), following 15 or 16 days of ShA  (Post-ShA). or 
following 15 or 16 days of LgA  (Post-LgA).  
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Figure 30. Body weights. Body weight (g) in groups of rats that underwent self-
administration of MDPV, METH, or sucrose. Weights were recorded the morning of 
initial cognitive tests (Pre-IVSA), the morning of cognitive tests following 15 or 16 days 
of ShA (Post-ShA), or the morning of cognitive tests following 15 or 16 days of LgA 
(Post-LgA). 
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